Index_NN
Page_NN
Page_NN
Accounting_GER
policies_NN
89_CD
Independent_NN
Auditors_NN
report_VPRT [PUBV]
83_CD
Accounting_GER
presentation_NOMZ
55,89_CD
Intellectual_NN
property_NN
25,157_CD
Achieve_NN
commercial_NN
and_CC
operational_JJ
excellence_NN
06,14_CD
Interest_NN
rate_NN
risk_NN
management_NOMZ
70_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
119_CD
Internal_NN
control_NN
framework_NN
33_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
32_CD
Inventories_NN
105_CD
Assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
106_CD
Investments_NOMZ
in_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
104_CD
Associates_NN
and_CC
joint_JJ
ventures_NN
97,104_CD
Investor_NN
information_NOMZ
171_CD
Be_VPRT [BEMA]
the_DT
best_JJ
place_NN
for_PIN
the_DT
best_JJ
people_NN
to_TO
do_VB [PROD]
their_TPP3
best_JJ
work_NN
06,16_CD
Legal_NN
proceedings_GER
157-164_CD
Board_NN
28,30_CD
Movements_NOMZ
in_PIN
equity_NOMZ
67,117_CD
Build_VPRT
the_DT
best_JJ
product_NN
pipeline_NN
in_PIN
the_DT
industry_NN
06,07-13_CD
Net_JJ
debt_NN
67,114_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
106_CD
New_NN
accounting_GER
policies_NN
and_CC
future_JJ
requirements_NOMZ
92_CD
Combined_NN
Code_NN
35,82_CD
Non-Executive_NN
Director_NN
terms_NN
,_,
conditions_NOMZ
and_PHC
fees_NN
44_CD
Commitments_NOMZ
67,122_CD
Non-Executive_JJ
Directors_NN
remuneration_VPRT
46,47_CD
Committee_NN
reports_NN
34,35,37-54_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
89-170_CD
Community_NOMZ
investment_NOMZ
18-19_CD
Operating_GER
and_CC
financial_JJ
review_NN
and_PHC
prospects_NN
55-80_CD
Consolidated_NN
balance_NN
sheet_NN
85_CD
Operating_GER
profit_NN
95,96_CD
Consolidated_NN
cash_NN
ow_NN
statement_NOMZ
86_CD
Other_JJ
intangible_JJ
assets_NN
103,104_CD
Consolidated_NN
income_NN
statement_NOMZ
84_CD
Other_JJ
investments_NOMZ
105_CD
Consolidated_NN
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
88_CD
Other_JJ
non-current_JJ
assets_NN
105_CD
Consumer_NN
Healthcare_NN
09,14,17,23,24,78_CD
Other_JJ
non-current_JJ
liabilities_NOMZ
113_CD
Contact_NN
details_NN
185_CD
Other_JJ
operating_GER
income_NN
78,95_CD
Contingent_NN
liabilities_NOMZ
67,68,114_CD
Other_JJ
provisions_NN
113_CD
Corporate_JJ
Executive_NN
Team_NN
29_CD
Outlook_NN
and_CC
risk_VB
factors_NN
71-74_CD
Corporate_JJ
governance_NN
27-36_CD
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
67,107-112_CD
Corporate_JJ
responsibility_NOMZ
06,18,183_CD
Pharmaceutical_NN
turnover_NN
57-61_CD
Critical_JJ
accounting_GER
policies_NN
64_CD
Presentation_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
89_CD
Description_NOMZ
of_PIN
business_NOMZ
05-26_CD
Principal_NN
Group_NN
companies_NN
147-149_CD
Dialogue_NN
with_PIN
shareholders_NN
31_CD
Products_NN
and_PHC
competition_NOMZ
20-23_CD
Directors_NN
and_CC
Senior_JJ
Management_NOMZ
remuneration_NOMZ
44-54_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
66,101-102_CD
Directors_NN
interests_NN
48_CD
Quarterly_JJ
trend_NN
172-177_CD
Directors_NN
interests_NN
in_PIN
contracts_NN
54_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
135-146_CD
Directors_NN
statements_NOMZ
of_PIN
responsibility_NOMZ
82,165_CD
Regulatory_NN
environment_NOMZ
24-26_CD
Dividends_NN
63,100,182_CD
Related_VBN
party_NN
transactions_NOMZ
118_CD
Earnings_GER
per_PIN
share_NN
100_CD
Remuneration_NOMZ
Report_NN
37-54_CD
Employee_NN
costs_NN
96_CD
Report_NN
of_PIN
the_DT
Directors_NN
04-80_CD
Employee_NN
share_NN
schemes_NN
132-134_CD
Responsibility_NOMZ
for_PIN
environment_NOMZ
,_,
health_NN
and_PHC
safety_NN
26_CD
Exchange_NN
rates_NN
92,180_CD
Risk_NN
factors_NN
71-74_CD
Executive_NN
Director_NN
terms_NN
,_,
conditions_NOMZ
and_PHC
remuneration_NOMZ
42,43_CD
Segment_NOMZ
information_NOMZ
93-95_CD
Finance_NN
costs_NN
56,63,97_CD
Share_NN
capital_NN
and_PHC
share_NN
premium_NN
116_CD
Finance_NN
income_NN
63,97_CD
Share_NN
options_NOMZ
49-51_CD
,132_CD
-134_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
123-131_CD
Shareholder_NN
information_NOMZ
182-186_CD
Financial_NN
position_NOMZ
and_PHC
resources_NN
66-70_CD
Strategy_NN
06_CD
Financial_NN
record_NN
172-181_CD
Taxation_NOMZ
63,97-99_CD
Financial_NN
statements_NOMZ
81-170_CD
Taxation_NOMZ
information_NOMZ
for_PIN
shareholders_NN
186_CD
Financial_NN
summary_NN
04_CD
Total_JJ
Equity_NOMZ
67_CD
Financial_NN
trends_NN
and_PHC
ratios_NN
56_CD
Trade_NN
and_CC
other_JJ
payables_NN
66,106_CD
Five_CD
year_NN
record_NN
178-181_CD
Trade_NN
and_CC
other_JJ
receivables_NN
66,106_CD
Foreign_NN
exchange_NN
risk_NN
management_NOMZ
70,123_CD
Trademarks_NN
05,26_CD
Global_JJ
manufacturing_GER
and_PHC
supply_NN
17_CD
Transition_NOMZ
to_PIN
IFRS_NN
150-156_CD
Glossary_NN
of_PIN
terms_NN
187_CD
Treasury_NN
policies_NN
69,70_CD
Goodwill_NN
102_CD
US_FPP1
law_NN
and_PHC
regulation_NOMZ
36_CD
Governance_NN
and_PHC
policy_NN
30_CD
World_NN
economy_NN
57_CD
IFRS_NN
adjustments_NOMZ
150_CD
World_NN
market_NN
pharmaceuticals_NN
57_CD
Improve_NN
access_NN
to_PIN
medicines_NN
15_CD
Incentive_NN
plans_NN
51,52_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
188_CD
INVESTOR_NN
INFORMATION_NOMZ
Corporate_NN
Website_NN
brochure_NN
About_IN
us_FPP1
Meeting_VBG
global_JJ
challenges_NN
Our_FPP1
products_NN
Commitment_NOMZ
to_PIN
innovation_NOMZ
Your_SPP2
health_NN
Access_NN
to_PIN
medicines_NN
Responsibility_NOMZ
Therapy_NN
areas_NN
In_PIN
the_DT
community_NOMZ
Our_FPP1
mission_NN
Research_NN
&_CC
Development_NOMZ
A_NN
better_RB
future_JJ
What_WP
would_PRMD
Investors_NN
Media_NN
center_NN
you_SPP2
like_VPRT
to_TO
know_VB [PRIV]
Careers_NN
about_IN
GSK_NN
?_.
com_NN
Corporate_JJ
Annual_JJ
responsibility_NOMZ
review_NN
report_NN
Access_NN
to_PIN
medicines_NN
An_DT
interview_NN
with_PIN
Research_NN
and_PHC
innovation_NOMZ
the_DT
Chairman_NN
and_PHC
CEO_NN
Ethical_JJ
conduct_NN
Focus_NN
on_PIN
the_DT
patient_JJ
Employees_NN
The_DT
year_NN
of_PIN
the_DT
vaccine_NN
Annual_JJ
Human_JJ
rights_NN
Growing_VBG [WZPRES]
brands_NN
report_NN
Environment_NOMZ
Powering_GER
performance_NN
Community_NOMZ
investment_NOMZ
Performance_NN
highlights_VPRT
Business_NOMZ
operating_VBG [WZPRES]
review_NN
Summary_NN
remuneration_NOMZ
report_NN
An_DT
interview_NN
with_PIN
Corporate_JJ
governance_NN
the_DT
Chairman_NN
and_PHC
CEO_NN
Summary_NN
financial_JJ
statements_NOMZ
Financial_JJ
summary_NN
Shareholder_NN
information_NOMZ
Description_NOMZ
of_PIN
business_NOMZ
Chairman_NN
and_PHC
CEOs_NN
Corporate_JJ
governance_NN
closing_VBG [WZPRES]
letter_NN
Remuneration_NOMZ
report_NN
Operating_GER
and_CC
financial_JJ
review_NN
and_PHC
prospects_NN
Financial_JJ
statements_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
Investor_NN
information_NOMZ
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
Head_NN
Office_NN
and_PHC
Registered_NN
Office_NN
GlaxoSmithKline_NN
plc_NN
980_CD
Great_NN
West_NN
Road_NN
Designed_VBN [WZPAST]
by_PIN
CGI_NN
London_NN
._.
Brentford_NN
,_,
Middlesex_NN
TW8_NN
9GS_NN
Printed_NN
by_PIN
The_DT
Midas_NN
Press_NN
in_PIN
the_DT
UK_NN
._.
The_DT
paper_NN
used_VBN [WZPAST]
in_PIN
the_DT
United_NN
Kingdom_NN
production_NOMZ
of_PIN
this_DEMO
document_NOMZ
is_VPRT [PASS]
made_VBN
from_PIN
pulps_NN
harvested_VBD
Tel_NN
:_:
44_CD
0_CD
20 8047 5000_CD
from_PIN
sustainable_JJ
forests_NN
,_,
also_RB
using_VBG
sawmill_NN
residues_NN
and_PHC
www_NN
._.
Annual_JJ
Review_NN
2005_CD
human_JJ
being_VBG
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
01_CD
An_DT
interview_NN
with_PIN
Sir_NN
Christopher_NN
Gent_NN
,_,
Chairman_NN
,_,
and_ANDC
JP_NN
Garnier_NN
,_,
Chief_NN
Executive_NN
officer_NN
05_CD
Tachi_NN
Yamada_NN
,_,
Chairman_NN
,_,
Research_NN
&_CC
Development_NOMZ
,_,
Pharmaceuticals_NN
06_CD
Jean_NN
Stphenne_NN
,_,
President_NN
and_PHC
General_NN
Manager_NN
,_,
GSK_NN
Biologicals_NN
08_CD
John_NN
Clarke_NN
,_,
President_NN
,_,
Consumer_NN
Healthcare_NN
11_CD
David_NN
Stout_NN
,_,
President_NN
,_,
Pharmaceutical_NN
Operations_NOMZ
14_CD
Performance_NN
highlights_VPRT
15_CD
Business_NOMZ
operating_GER
review_NN
18_CD
The_NN
Board_NN
19_CD
The_DT
Corporate_JJ
Executive_NN
Team_NN
20_CD
Summary_NN
remuneration_NOMZ
report_NN
23_CD
Corporate_NN
governance_NN
24_CD
Responsibility_NOMZ
statements_NOMZ
25_CD
Summary_NN
financial_JJ
statements_NOMZ
26_CD
Summary_NN
information_NOMZ
under_IN
US_FPP1
GAAP_NN
27_CD
Shareholder_NN
information_NOMZ
29_CD
Chairman_NN
and_PHC
CEOs_NN
closing_VBG [WZPRES]
letter_NN
JP_NN
Garnier_NN
left_VBD
and_CC
Sir_NN
Christopher_NN
Gent_NN
right_JJ
Discovering_VBG [PRIV]
important_JJ
medicines_NN
,_,
eradicating_VBG
diseases_NN
,_,
improving_VBG [PRESP]
the_DT
quality_NOMZ
of_PIN
peoples_NN
lives_NN
and_CC
making_VBG
medicines_NN
available_JJ
to_PIN
a_DT
greater_JJ
number_NN
of_PIN
people_NN
._.
This_DEMP
is_VPRT
what_WP
we_FPP1
do_VPRT [PROD]
and_ANDC
what_WP
we_FPP1
do_VPRT [PROD]
matters_NN
to_PIN
people_NN
._.
JP_NN
Garnier_NN
,_,
Chief_NN
Executive_NN
officer_NN
An_DT
interview_NN
with_PIN
Sir_NN
Christopher_NN
Gent_NN
,_,
Chairman_NN
and_PHC
JP_NN
Garnier_NN
,_,
Chief_NN
Executive_NN
officer_NN
2005_CD
:_:
a_DT
year_NN
of_PIN
success_NN
and_PHC
progress_NN
Thanks_NN
to_PIN
the_DT
efforts_NN
of_PIN
our_FPP1
employees_NN
around_PLACE
the_DT
companys_NN
pipeline_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
largest_JJ
and_CC
most_EMPH
world_NN
,_,
2005_CD
was_VBD [BEMA]
a_DT
very_AMP
successful_JJ
year_NN
for_PIN
GSK_NN
,_,
says_VPRT [PUBV]
promising_JJ
in_PIN
the_DT
industry_NN
,_,
with_PIN
149_CD
projects_NN
in_PIN
clinical_JJ
JP_NN
Garnier_NN
,_,
Chief_NN
Executive_NN
officer_NN
._.
Not_XX0
only_DWNT
was_VBD [BEMA]
it_PIT
development_NOMZ
as_IN
at_PIN
the_DT
end_NN
of_PIN
February_NN
2006_CD
,_,
our_FPP1
best_JJ
year_NN
ever_RB
from_PIN
a_DT
financial_JJ
standpoint_NN
,_,
we_FPP1
also_RB
including_VBG
95_CD
new_JJ
chemical_NN
entities_NOMZ
NCEs_NN
,_,
29_CD
product_NN
made_VBN
substantial_JJ
progress_NN
with_PIN
our_FPP1
pipeline_NN
of_PIN
line_NN
extensions_NN
PLEs_NN
and_CC
25_CD
vaccines_NN
._.
innovative_JJ
new_JJ
medicines_NN
and_PHC
vaccines_NN
._.
In_PIN
2006_CD
,_,
we_FPP1
anticipate_VPRT [PRIV]
further_RB
good_JJ
news_NN
on_PIN
GSKs_NN
GSK_NN
delivered_VBD
an_DT
excellent_JJ
financial_JJ
performance_NN
in_PIN
late-stage_JJ
pipeline_NN
,_,
which_WDT [SERE]
is_VPRT
developing_VBG
at_PIN
a_DT
fast_JJ
pace_NN
._.
Turnover_NN
of_PIN
21.7_CD
billion_CD
grew_VBD
by_PIN
7_CD
%_NN
at_PIN
Eight_CD
major_JJ
new_JJ
assets_NN
are_VPRT [PASS]
scheduled_VBN
to_TO
enter_VB
phase_NN
constant_JJ
exchange_NN
rates_NN
CER_NN
._.
Earnings_GER
per_PIN
share_NN
EPS_NN
III_NN
in_PIN
2006_CD
,_,
doubling_VBG [PRESP]
our_FPP1
late-stage_JJ
pipeline_NN
,_,
says_VPRT [PUBV]
JP_NN
._.
were_VBD [BEMA]
82.6_CD
p_NN
,_,
with_PIN
growth_NN
of_PIN
18_CD
%_NN
at_PIN
CER_NN
,_,
putting_VBG
GSK_NN
in_PIN
the_DT
top_JJ
tier_NN
of_PIN
global_JJ
pharmaceutical_JJ
companies_NN
in_PIN
The_DT
pharmaceutical_JJ
industry_NN
is_VPRT
making_VBG
a_DT
terms_NN
of_PIN
performance_NN
._.
positive_JJ
improvement_NOMZ
to_PIN
peoples_NN
lives_NN
._.
It_PIT
These_DEMO
gures_NN
confirm_VPRT [PUBV]
the_DT
excellent_JJ
growth_NN
of_PIN
our_FPP1
key_NN
has_VPRT
a_DT
noble_JJ
purpose_NN
._.
It_PIT
develops_VPRT
medicines_NN
products_NN
and_CC
the_DT
efficiency_NN
of_PIN
our_FPP1
global_JJ
operations_NOMZ
,_,
says_VPRT [PUBV]
JP_NN
._.
and_ANDC
vaccines_NN
that_TSUB
save_VPRT
lives_NN
and_CC
make_VB
people_NN
feel_VB [PRIV]
better_JJ
._.
GSKs_NN
performance_NN
was_VBD [BYPA]
driven_VBN
by_PIN
sales_NN
of_PIN
key_JJ
pharmaceutical_JJ
products_NN
._.
Sales_NN
of_PIN
Seretide_NN
Advair_NN
,_,
Sir_NN
Christopher_NN
Gent_NN
,_,
Chairman_NN
Avandia_NN
,_,
Coreg_NN
,_,
Lamictal_NN
and_PHC
Valtrex_NN
all_QUAN
continued_VBD
their_TPP3
impressive_JJ
growth_NN
,_,
says_VPRT [PUBV]
JP_NN
._.
We_FPP1
also_RB
saw_VBD [PRIV]
good_JJ
Year_NN
of_PIN
the_DT
vaccine_NN
performance_NN
from_PIN
a_DT
number_NN
of_PIN
newer_JJ
products_NN
,_,
2005_CD
was_VBD [BEMA]
a_DT
landmark_NN
year_NN
for_PIN
GSKs_NN
vaccines_NN
including_VBG [WZPRES]
Avodart_NN
for_PIN
enlarging_VBG
prostate_NN
,_,
Boniva_NN
business_NOMZ
._.
Sales_NN
increased_VBN [WZPAST]
by_PIN
15_CD
%_NN
and_CC
the_DT
company_NN
Bonviva_NN
for_PIN
osteoporosis_NN
and_PHC
Requip_NN
for_PIN
Restless_NN
Legs_NN
made_VBD
a_DT
number_NN
of_PIN
significant_JJ
strategic_JJ
acquisitions_NOMZ
._.
Syndrome_NN
,_,
which_WDT [SERE]
all_QUAN
show_VPRT [PRIV]
great_JJ
promise_NN
for_PIN
the_DT
The_DT
acquisition_NOMZ
of_PIN
ID_NN
Biomedical_NN
was_VBD [BEMA]
an_DT
important_JJ
future_NN
,_,
both_DT
for_PIN
patients_NN
and_PHC
GSK_NN
._.
move_NN
for_PIN
GSK_NN
,_,
says_VPRT [PUBV]
JP_NN
,_,
which_WDT [SERE]
strengthened_VBD
our_FPP1
Looking_VBG
into_PIN
2006_CD
,_,
the_DT
strong_JJ
growth_NN
seen_VBN [PRIV] [WZPAST]
from_PIN
key_JJ
position_NOMZ
in_PIN
the_DT
global_JJ
u_NN
vaccine_NN
market_NN
,_,
and_ANDC
products_NN
and_CC
from_PIN
our_FPP1
vaccines_NN
business_NOMZ
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
increased_VBN
our_FPP1
ability_NOMZ
to_TO
prepare_VB
for_PIN
and_CC
respond_VB
to_PIN
a_DT
continue_VB
and_CC
we_FPP1
anticipate_VPRT [PRIV]
an_DT
EPS_NN
growth_NN
of_PIN
around_PLACE
potential_JJ
u_NN
pandemic_NN
._.
We_FPP1
also_RB
acquired_VBD
a_DT
plant_NN
in_PIN
Marietta_NN
,_,
Pennsylvania_NN
Pipeline_NN
progress_NN
which_WDT [WHSUB]
will_PRMD
give_VB
us_FPP1
access_NN
to_PIN
tissue_NN
culture_NN
technology_NN
GSK_NN
continues_VPRT
to_TO
meet_VB
the_DT
challenge_NN
of_PIN
increasing_VBG
in_PIN
our_FPP1
vaccine_NN
manufacturing_GER
._.
The_DT
acquisition_NOMZ
of_PIN
Corixa_NN
Research_NN
&_CC
Development_NOMZ
R&D_NN
productivity_NOMZ
to_TO
discover_VB [PRIV]
gives_VPRT
us_FPP1
valuable_JJ
adjuvant_JJ
technology_NN
,_,
enabling_VBG [PRESP]
us_FPP1
to_PIN
new_JJ
medicines_NN
faster_RB
and_PHC
more_EMPH
economically_RB
._.
The_DT
boost_NN
human_JJ
immune_JJ
response_NN
to_PIN
our_FPP1
vaccines_NN
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
01_CD
Private_JJ
sector_NN
expertise_NN
is_VPRT [BEMA]
critical_PRED
for_PIN
making_VBG
rapid_JJ
progress_NN
._.
In_CONJ
particular_NULL
,_,
I_FPP1
would_PRMD
like_VB
to_TO
thank_VB
GSK_NN
for_PIN
its_PIT
commitment_NOMZ
to_PIN
R&D_NN
on_PIN
malaria_NN
and_CC
on_PIN
other_JJ
neglected_VBN
diseases_NN
._.
It_PIT
would_PRMD
make_VB
a_DT
huge_JJ
difference_NN
if_COND
more_EMPH
companies_NN
followed_VBD
GSKs_NN
example_NN
._.
Bill_NN
Gates_NN
Bill_NN
&_CC
Melinda_NN
Gates_NN
Foundation_NOMZ
,_,
October_NN
2005_CD
3,000_CD
Each_QUAN
day_NN
,_,
malaria_NN
causes_VPRT
the_DT
death_NN
of_PIN
about_IN
3,000_CD
people_NN
in_PIN
sub-Saharan_JJ
Africa_NN
._.
Most_EMPH
of_PIN
them_TPP3
are_VPRT
children_NN
._.
GSK_NN
is_VPRT
working_VBG
in_PIN
publicprivate_NN
partnerships_NN
to_TO
create_VB
safe_JJ
and_PHC
effective_JJ
vaccines_NN
and_PHC
treatments_NOMZ
against_PIN
malaria_NN
._.
com_NN
On_PIN
this_DEMO
page_NN
you_SPP2
will_PRMD
nd_VB
:_:
Access_NN
to_PIN
medicines_NN
:_:
Reaching_VBG [PRESP]
out_PIN
to_PIN
patients_NN
:_:
Humanitarian_JJ
response_NN
:_:
JP_NN
in_PIN
Africa_NN
GSK_NN
also_RB
made_VBD
good_JJ
progress_NN
on_PIN
its_PIT
pipeline_NN
of_PIN
new_JJ
Islands_NN
of_PIN
hope_NN
vaccines_NN
._.
We_FPP1
expect_VPRT [PRIV]
five_CD
major_JJ
vaccine_NN
launches_NN
in_PIN
In_PIN
late_TIME
2005_CD
,_,
JP_NN
visited_VBD
Ghana_NN
and_PHC
South_NN
Africa_NN
to_TO
see_VB [PRIV]
the_DT
next_JJ
five_CD
years_NN
,_,
says_VPRT [PUBV]
JP_NN
._.
Perhaps_RB
most_EMPH
exciting_JJ
is_VPRT [BEMA]
some_QUAN
of_PIN
GSKs_NN
community_NOMZ
activities_NOMZ
._.
In_PIN
Ghana_NN
,_,
he_TPP3
heard_VBD [PRIV]
Cervarix_NN
for_PIN
cervical_JJ
cancer_NN
,_,
which_WDT [SERE]
we_FPP1
expect_VPRT [PRIV]
to_TO
le_FW
for_PIN
how_RB
villagers_NN
cope_VB
with_PIN
lymphatic_JJ
lariasis_NN
LF_NN
or_CC
elephantiasis_NN
._.
LF_NN
is_VPRT [BEMA]
a_DT
disease_NN
that_TOBJ
the_DT
company_NN
,_,
working_VBG
approval_NN
in_PIN
Europe_NN
in_PIN
March_NN
2006_CD
and_CC
in_PIN
the_DT
USA_NN
by_PIN
with_PIN
the_DT
World_NN
Health_NN
Organization_NOMZ
,_,
is_VPRT
striving_VBG
to_TO
eradicate_VB
the_DT
end_NN
of_PIN
the_DT
year_NN
._.
This_DEMO
LF_NN
program_NN
has_VPRT [PEAS]
reached_VBN
its_PIT
target_NN
in_PIN
Ghana_NN
of_PIN
treating_VBG
all_QUAN
ten_CD
million_CD
people_NN
at_PIN
risk_NN
from_PIN
the_DT
Improving_GER
access_NN
to_PIN
medicines_NN
disease_NN
._.
In_PIN
South_NN
Africa_NN
,_,
JP_NN
saw_VBD [PRIV]
the_DT
impact_NN
of_PIN
HIV_NN
AIDS_NN
GSK_NN
continues_VPRT
to_TO
seek_VB
new_JJ
ways_NN
of_PIN
improving_VBG
access_NN
and_CC
the_DT
work_NN
of_PIN
volunteers_NN
in_PIN
a_DT
GSK-supported_JJ
clinic_NN
to_PIN
its_PIT
medicines_NN
for_PIN
people_NN
who_WP [WHSUB]
need_VPRT
them_TPP3
,_,
but_CC
are_VPRT [BEMA]
north_PLACE
of_PIN
Johannesburg_NN
._.
least_JJ
able_JJ
to_TO
obtain_VB
them_TPP3
._.
This_DEMO
challenge_NN
is_VPRT [BEMA]
particularly_RB
It_PIT
was_VBD [BEMA]
shocking_PRED
and_PHC
humbling_PRED
,_,
yet_RB
even_RB
in_PIN
this_DEMO
sea_NN
of_PIN
acute_JJ
in_PIN
the_DT
developing_VBG
world_NN
,_,
where_RB
GSK_NN
has_VPRT [PEAS]
been_VBN
distress_NN
there_EX
are_VPRT
islands_NN
of_PIN
hope_NN
._.
I_FPP1
was_VBD [BYPA]
inspired_VBN
by_PIN
the_DT
offering_GER
many_QUAN
of_PIN
its_PIT
medicines_NN
and_PHC
vaccines_NN
at_PIN
not-forpeople_NN
who_WP [WHSUB]
have_VPRT [PEAS]
dedicated_VBN
their_TPP3
lives_NN
to_TO
working_VBG
in_PIN
these_DEMO
profit_NN
prices_NN
for_PIN
some_QUAN
years_NN
._.
I_FPP1
was_VBD [BEMA]
able_PRED
to_PIN
witness_NOMZ
the_DT
realities_NOMZ
of_PIN
Africa_NN
and_PHC
whats_NN
really_EMPH
important_JJ
there_RB
,_,
says_VPRT [PUBV]
JP_NN
._.
I_FPP1
am_VPRT [BEMA]
proud_PRED
of_PIN
the_DT
However_CONJ
,_,
addressing_VBG [PRESP]
this_DEMO
challenge_NN
is_VPRT
something_QUPR
GSK_NN
role_NN
that_TOBJ
GSK_NN
is_VPRT
playing_VBG
._.
I_FPP1
am_VPRT [BEMA]
grateful_PRED
to_TO
have_VB [PEAS]
experienced_VBN
can_POMD
not_XX0
do_VB
alone_RB
._.
The_DT
work_NN
of_PIN
GSK_NN
with_PIN
organizations_NOMZ
these_DEMO
things_NN
and_CC
,_,
crucially_RB
,_,
to_TO
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
do_VB [PROD]
such_JJ
as_IN
the_DT
Bill_NN
&_CC
Melinda_NN
Gates_NN
Foundation_NOMZ
highlights_VPRT
something_QUPR
about_IN
it_PIT
._.
My_FPP1
determination_NOMZ
to_TO
do_VB [SPAU]
more_EMPH
has_VPRT
the_DT
benets_NN
of_PIN
public-private_JJ
partnerships_NN
._.
provide_VB
a_DT
way_NN
for_PIN
companies_NN
such_JJ
as_IN
GSK_NN
and_CC
the_DT
private_JJ
sector_NN
to_TO
work_VB
together_RB
._.
Typically_RB
,_,
GSK_NN
provides_VPRT
the_DT
R&D_NN
,_,
technology_NN
,_,
manufacturing_GER
and_PHC
distribution_NOMZ
expertise_NN
,_,
while_OSUB
other_JJ
partners_NN
and_PHC
governments_NOMZ
help_VPRT
fund_VB
the_DT
development_NOMZ
and_PHC
delivery_NN
costs_NN
._.
Public-private_JJ
partnerships_NN
use_VPRT
the_DT
respective_JJ
strengths_NN
of_PIN
the_DT
partners_NN
and_CC
bring_VB
out_PIN
the_DT
best_JJ
of_PIN
each_QUAN
._.
Most_EMPH
importantly_RB
,_,
it_PIT
is_VPRT [BEMA]
a_DT
model_NN
that_TSUB
works_VPRT
._.
In_PIN
2005_CD
,_,
GSK_NN
entered_VBD
three_CD
groundbreaking_VBG
publicprivate_NN
partnerships_NN
to_TO
develop_VB
vaccines_NN
against_PIN
the_DT
biggest_JJ
causes_NN
of_PIN
death_NN
in_PIN
the_DT
developing_VBG
world_NN
today_TIME
AIDS_NN
,_,
malaria_NN
and_PHC
tuberculosis_NN
._.
The_DT
year_NN
saw_VBD [PRIV]
a_DT
number_NN
of_PIN
natural_JJ
disasters_NN
,_,
including_VBG
Reaching_VBG
out_PIN
to_PIN
patients_NN
the_DT
Asian_JJ
tsunami_NN
,_,
the_DT
Guatemalan_NN
hurricane_NN
,_,
the_DT
In_PIN
2005_CD
,_,
GSK_NN
introduced_VBD
and_PHC
strengthened_VBD
a_DT
number_NN
New_NN
Orleans_NN
oods_NN
and_CC
the_DT
earthquake_NN
that_TSUB
struck_VBD
of_PIN
initiatives_NN
aimed_VBN [WZPAST]
at_PIN
improving_VBG
patients_NN
understanding_VBG [PRIV] [WZPRES]
parts_NN
of_PIN
India_NN
and_PHC
Pakistan_NN
._.
GSK_NN
was_VBD [BEMA]
quick_PRED
to_TO
respond_VB
of_PIN
GSKs_NN
medicines_NN
,_,
and_ANDC
programs_NN
to_TO
help_VB
gain_VB
access_NN
to_TO
help_VB
victims_NN
of_PIN
these_DEMO
tragedies_NN
._.
These_DEMO
initiatives_NN
include_VPRT
GSKs_NN
pioneering_JJ
our_FPP1
employees_NN
for_PIN
their_TPP3
response_NN
to_PIN
these_DEMO
crises_NN
._.
It_PIT
Clinical_JJ
Trial_NN
Register_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
expanded_VBN
to_TO
contain_VB
makes_NN
me_FPP1
proud_JJ
to_TO
lead_VB
an_DT
organization_NOMZ
with_PIN
such_JJ
2,125_CD
summaries_NN
of_PIN
clinical_JJ
trials_NN
by_PIN
the_DT
end_NN
of_PIN
2005_CD
._.
committed_JJ
and_PHC
compassionate_JJ
people_NN
,_,
who_WP
can_POMD
respond_VB
so_RB
effectively_RB
to_TO
help_VB
people_NN
in_PIN
real_JJ
need_NN
,_,
In_PIN
the_DT
USA_NN
,_,
GSK_NN
is_VPRT
placing_VBG
more_EMPH
emphasis_NN
on_PIN
says_VPRT [PUBV]
JP_NN
._.
education_NOMZ
and_CC
the_DT
patient_NN
in_PIN
direct-to-consumer_NN
advertising_GER
,_,
and_ANDC
providing_VBG
people_NN
with_PIN
advice_NN
on_PIN
GSKs_NN
For_PIN
these_DEMO
disasters_NN
alone_RB
,_,
GSK_NN
contributed_VBD
more_EMPH
than_PIN
programs_NN
and_CC
the_DT
industrys_NN
Partnerships_NN
for_PIN
3_CD
million_CD
in_PIN
cash_NN
and_CC
donated_VBD
medicines_NN
and_PHC
vaccines_NN
Prescriptions_NOMZ
Assistance_NN
which_WDT [WHSUB]
help_VPRT
people_NN
gain_VB
access_NN
valued_VBN [WZPAST]
at_PIN
over_IN
14_CD
million_CD
towards_PIN
the_DT
relief_NN
efforts_NN
._.
to_PIN
the_DT
medicines_NN
they_TPP3
need_VPRT
._.
The_DT
tragedies_NN
during_PIN
the_DT
year_NN
brought_VBD
home_NN
to_PIN
me_FPP1
Through_PIN
these_DEMP
and_CC
other_JJ
initiatives_NN
,_,
we_FPP1
are_VPRT
seeking_VBG
the_DT
extent_NN
to_PIN
which_WDT [PIRE]
the_DT
pharmaceutical_JJ
industry_NN
is_VPRT
to_TO
differentiate_VB
GSK_NN
as_IN
a_DT
company_NN
nding_VBG [WZPRES]
solutions_NOMZ
making_VBG [WZPRES]
a_DT
positive_JJ
improvement_NOMZ
to_PIN
peoples_NN
lives_NN
,_,
says_VPRT [PUBV]
to_PIN
the_DT
healthcare_NN
challenges_VPRT
that_DEMO
society_NN
faces_NN
._.
It_PIT
develops_VPRT
I_FPP1
believe_VPRT [PRIV] [THATD]
we_FPP1
are_VPRT [BEMA]
well_RB
on_PIN
the_DT
way_NN
to_TO
achieving_VBG
that_DEMP
,_,
medicines_NN
and_PHC
vaccines_NN
that_TSUB
save_VPRT
lives_NN
and_CC
make_VB
says_VPRT [PUBV]
Sir_NN
Christopher_NN
Gent_NN
,_,
Chairman_NN
._.
A_DT
broader_JJ
contribution_NOMZ
GSK_NN
's_POS
global_JJ
community_NOMZ
investment_NOMZ
activities_NOMZ
in_PIN
2005_CD
were_VBD [PASS]
valued_VBN
at_PIN
380_CD
million_CD
,_,
equivalent_JJ
to_PIN
5.6_CD
%_NN
of_PIN
Group_NN
profit_NN
before_IN
tax_NN
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
03_CD
For_PIN
our_FPP1
work_NN
at_PIN
GSK_NN
,_,
we_FPP1
149_CD
GSK_NN
had_VBD
149_CD
projects_NN
in_PIN
seek_VPRT
greater_JJ
insight_NN
into_PIN
the_DT
clinic_NN
at_PIN
the_DT
end_NN
of_PIN
February_NN
2006_CD
._.
This_DEMP
included_VBD
95_CD
new_JJ
chemical_NN
the_DT
needs_NN
of_PIN
patients_NN
entities_NOMZ
NCEs_NN
,_,
an_DT
increase_NN
of_PIN
70_CD
%_NN
over_IN
2001_CD
._.
and_ANDC
to_TO
apply_VB
these_DEMO
insights_NN
in_PIN
R&D_NN
to_PIN
Moncef_NN
Slaoui_NN
pictured_VBD
right_RB
,_,
will_PRMD
succeed_VB
Tachi_NN
create_VB
better_JJ
medicines_NN
._.
Yamada_NN
left_VBD
as_IN
head_NN
of_PIN
R&D_NN
in_PIN
June_NN
2006_CD
._.
Tachi_NN
Yamada_NN
,_,
Chairman_NN
,_,
Research_NN
&_CC
Development_NOMZ
,_,
Pharmaceuticals_NN
On_PIN
this_DEMO
page_NN
you_SPP2
will_PRMD
nd_VB
:_:
Patient_NN
insight_NN
:_:
Partnerships_NN
:_:
Maturing_VBG
pipeline_NN
:_:
Confronting_VBG
cancer_NN
Tachi_NN
Yamada_NN
,_,
Chairman_NN
,_,
Research_NN
&_CC
Development_NOMZ
,_,
Pharmaceuticals_NN
Focus_NN
on_PIN
the_DT
patient_JJ
Applying_VBG
insights_NN
in_PIN
R&D_NN
for_PIN
the_DT
creation_NOMZ
of_PIN
better_JJ
medicines_NN
Tachi_NN
Yamada_NN
was_VBD [BEMA]
a_DT
physician_NN
and_PHC
teacher_NN
of_PIN
physicians_NN
Confronting_VBG [WZPRES]
cancer_NN
before_IN
he_TPP3
joined_VBD
GSK_NN
to_TO
work_VB
with_PIN
scientists_NN
and_CC
other_JJ
Cancer_NN
remains_VPRT
an_DT
area_NN
of_PIN
substantial_JJ
unmet_JJ
medical_JJ
need_NN
._.
He_TPP3
retains_VPRT
a_DT
passion_NN
for_PIN
helping_VBG
Our_FPP1
strategy_NN
is_VPRT [PASS]
focused_VBN
on_PIN
meeting_GER
all_QUAN
aspects_NN
of_PIN
a_DT
cancer_NN
improve_VB
the_DT
quality_NOMZ
of_PIN
life_NN
for_PIN
patients_NN
and_CC
his_TPP3
patients_NN
treatment_NOMZ
,_,
says_VPRT [PUBV]
Tachi_NN
._.
GSK_NN
is_VPRT
building_VBG
on_PIN
its_PIT
existing_VBG
oncology_JJ
portfolio_NN
to_PIN
good_JJ
effect_NN
._.
We_FPP1
now_TIME
have_VPRT
experience_NN
as_IN
a_DT
physician_NN
has_VPRT [PEAS]
inuenced_VBN
his_TPP3
work_NN
as_IN
an_DT
oncology_JJ
pipeline_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
strongest_JJ
and_CC
head_NN
of_PIN
R&D_NN
for_PIN
GSK_NN
._.
most_EMPH
promising_JJ
in_PIN
our_FPP1
industry_NN
._.
In_PIN
November_NN
2005_CD
,_,
investors_NN
and_CC
financial_JJ
analysts_NN
were_VBD [PASS]
updated_VBN
on_PIN
this_DEMO
In_PIN
the_DT
hospital_NN
wards_NN
,_,
I_FPP1
would_PRMD [SPAU]
sometimes_RB
place_VB
a_DT
rapidly_RB
expanding_VBG
pipeline_NN
._.
In_PIN
2006_CD
,_,
GSK_NN
expects_VPRT [PRIV]
four_CD
new_JJ
photograph_NN
of_PIN
the_DT
patient_NN
above_PLACE
their_TPP3
bed_NN
,_,
says_VPRT [PUBV]
Tachi_NN
._.
oncology_JJ
medicines_NN
to_TO
be_VB [BEMA]
in_PIN
final-stage_JJ
clinical_JJ
trials_NN
Tykerb_NN
The_DT
picture_NN
showed_VBD [PRIV]
them_TPP3
when_RB
they_TPP3
were_VBD [BEMA]
active_PRED
and_CC
lapatinib_NN
for_PIN
breast_NN
cancer_NN
,_,
eltrombopag_NN
for_PIN
patients_NN
with_PIN
healthy_JJ
,_,
and_ANDC
I_FPP1
would_PRMD [SPAU]
then_RB
challenge_VB
my_FPP1
staff_NN
to_TO
work_VB
low_JJ
platelet_NN
count_NN
,_,
casopitant_NN
to_TO
help_VB
patients_NN
overcome_VB
towards_PIN
the_DT
goal_NN
of_PIN
helping_VBG
the_DT
patient_NN
back_RB
to_TO
being_VBG [BEMA]
the_DT
side-effects_NN
of_PIN
chemotherapy_JJ
and_CC
pazopanib_NN
for_PIN
like_IN
the_DT
person_NN
in_PIN
the_DT
picture_NN
._.
I_FPP1
would_PRMD
urge_VB [SUAV]
them_TPP3
to_PIN
prevention_NOMZ
of_PIN
tumor_NN
growth_NN
._.
focus_NN
on_PIN
the_DT
patient_NN
and_CC
their_TPP3
needs_NN
._.
Today_TIME
,_,
it_PIT
is_VPRT [BEMA]
the_DT
same_JJ
approach_NN
for_PIN
our_FPP1
work_NN
at_PIN
GSK_NN
,_,
where_RB
we_FPP1
seek_VPRT
greater_JJ
insight_NN
into_PIN
the_DT
needs_NN
of_PIN
patients_NN
and_CC
to_TO
apply_VB
these_DEMO
insights_NN
in_PIN
R&D_NN
to_TO
create_VB
better_JJ
medicines_NN
._.
GSK_NN
projects_NN
in_PIN
clinical_JJ
development_NOMZ
As_IN
at_PIN
February_NN
2006_CD
149_CD
11_CD
118_CD
38_CD
%_NN
of_PIN
pipeline_NN
46_CD
Late_TIME
stage_NN
12_CD
26_CD
%_NN
of_PIN
growth_NN
pipeline_NN
19_CD
38_CD
25_CD
41_CD
29_CD
25 21 2001 2005_CD
New_NN
Chemical_NN
Entities_NOMZ
NCEs_NN
NCEs_NN
Phase_NN
I_FPP1
Phase_NN
III_NN
registration_NOMZ
Product_NN
Line_NN
Extensions_NN
NCEs_NN
Phase_NN
II_NN
Vaccines_NN
registration_NOMZ
,_,
46_CD
NCEs_NN
and_CC
9_CD
vaccines_NN
were_VBD [BEMA]
in_PIN
phase_NN
II_NN
and_CC
38_CD
NCEs_NN
and_CC
7_CD
vaccines_NN
were_VBD [BEMA]
in_PIN
phase_NN
I._NN
This_DEMP
is_VPRT [BEMA]
an_DT
increase_NN
of_PIN
70_CD
%_NN
over_IN
the_DT
number_NN
of_PIN
NCEs_NN
that_TOBJ
GSK_NN
Tachi_NN
and_CC
his_TPP3
teams_NN
also_RB
talk_VPRT
to_PIN
doctors_NN
and_CC
other_JJ
had_VBD
at_PIN
the_DT
end_NN
of_PIN
2001_CD
._.
healthcare_NN
experts_NN
to_TO
gather_VB [PRIV]
information_NOMZ
that_TSUB
will_PRMD
help_VB
shape_VB
the_DT
direction_NOMZ
and_PHC
priorities_NOMZ
of_PIN
the_DT
complex_JJ
R&D_NN
process_NN
that_TSUB
leads_VPRT
to_PIN
innovative_JJ
medicines_NN
of_PIN
There_EX
has_VPRT [PEAS]
been_VBN
a_DT
marked_JJ
increase_NN
in_PIN
the_DT
value_NN
._.
Through_PIN
a_DT
range_NN
of_PIN
partnerships_NN
,_,
the_DT
company_NN
size_NN
of_PIN
our_FPP1
NCE_NN
portfolio_NN
and_CC
an_DT
increasing_VBG
has_VPRT
access_NN
to_PIN
the_DT
talent_NN
,_,
ideas_NN
and_PHC
assets_NN
beyond_IN
the_DT
maturity_NOMZ
of_PIN
the_DT
pipeline_NN
._.
boundaries_NN
of_PIN
its_PIT
own_JJ
R&D_NN
organization_NOMZ
._.
In_PIN
2005_CD
,_,
GSK_NN
set_VBD
up_RP
a_DT
new_JJ
internal_JJ
management_NOMZ
team_NN
to_PIN
Seven_CD
product_NN
lings_NN
are_VPRT [PASS]
planned_VBN
for_PIN
2006_CD
,_,
including_VBG
deliver_VB
more_EMPH
compounds_NN
through_PIN
partnerships_NN
with_PIN
two_CD
vaccines_NN
Cervarix_NN
for_PIN
cervical_JJ
cancer_NN
and_CC
a_DT
biotechnology_NN
companies_NN
,_,
small_JJ
and_PHC
mid-sized_JJ
potential_JJ
H5N1_NN
pandemic_NN
u_NN
vaccine_NN
see_VPRT [PRIV]
pages_NN
6_CD
pharmaceutical_JJ
companies_NN
and_CC
academic_JJ
institutions_NOMZ
._.
and_ANDC
8_CD
,_,
Allermist_NN
for_PIN
allergic_JJ
rhinitis_NN
,_,
eltrombopag_NN
for_PIN
A_DT
maturing_VBG
pipeline_NN
patients_NN
with_PIN
low_JJ
platelet_NN
count_NN
,_,
Tykerb_NN
for_PIN
breast_NN
The_DT
strength_NN
of_PIN
GSKs_NN
work_VPRT
on_PIN
medicines_NN
and_PHC
vaccines_NN
cancer_NN
,_,
mepolizumab_NN
for_PIN
hypereosinophilic_JJ
syndrome_NN
of_PIN
the_DT
future_NN
can_POMD
be_VB [PASS]
seen_VBN [PRIV]
in_PIN
the_DT
product_NN
development_NOMZ
and_CC
Lamictal_JJ
XR_NN
,_,
a_DT
once-daily_JJ
formulation_NOMZ
for_PIN
epilepsy_NN
._.
pipeline_NN
,_,
one_CD
that_DEMP
is_VPRT
growing_VBG
and_PHC
maturing_VBG
._.
At_PIN
the_DT
end_NN
of_PIN
February_NN
2006_CD
,_,
the_DT
company_NN
had_VBD
149_CD
projects_NN
in_PIN
GSK_NN
also_RB
expects_VPRT [PRIV]
eight_CD
major_JJ
new_JJ
assets_NN
to_TO
enter_VB
the_DT
clinic_NN
including_VBG [WZPRES]
95_CD
new_JJ
chemical_NN
entities_NOMZ
NCEs_NN
,_,
25_CD
phase_NN
III_NN
development_NOMZ
during_PIN
2006_CD
,_,
signicantly_RB
vaccines_NN
and_CC
29_CD
product_NN
line_NN
extensions_NN
PLEs_NN
._.
Of_PIN
expanding_VBG
the_DT
late-stage_JJ
pipeline_NN
._.
In_CONJ
addition_NULL
to_PIN
the_DT
these_DEMP
,_,
11_CD
NCEs_NN
and_CC
9_CD
vaccines_NN
were_VBD [BEMA]
in_PIN
phase_NN
III_NN
oncology_NN
products_NN
,_,
casopitant_NN
and_PHC
pazopanib_NN
see_VPRT [PRIV]
GSK_NN
Annual_JJ
Review_NN
2005_CD
05_CD
On_PIN
this_DEMO
page_NN
you_SPP2
will_PRMD
nd_VB
:_:
Delivering_VBG
medicines_NN
of_PIN
value_NN
:_:
Vaccines_NN
performance_NN
:_:
Vaccines_NN
pipeline_NN
:_:
Vaccines_NN
investment_NOMZ
Confronting_VBG [WZPRES]
cancer_NN
page_NN
5_CD
,_,
GSK_NN
expects_VPRT [PRIV] [THATD]
new_JJ
assets_NN
Delivering_VBG [WZPRES]
medicines_NN
of_PIN
value_NN
for_PIN
Alzheimers_NN
disease_NN
,_,
HIV_NN
,_,
meningitis_NN
,_,
lupus_NN
and_PHC
GSK_NN
has_VPRT
one_CD
of_PIN
the_DT
most_EMPH
promising_JJ
pipelines_NN
in_PIN
the_DT
diabetes_NN
to_TO
enter_VB
phase_NN
III_NN
development_NOMZ
._.
Our_FPP1
challenge_NN
,_,
going_VBG [PRESP]
forward_RB
,_,
is_VPRT
to_TO
deliver_VB
to_PIN
patients_NN
the_DT
many_QUAN
medicines_NN
we_FPP1
have_VPRT
in_PIN
There_EX
has_VPRT [PEAS]
been_VBN
a_DT
marked_JJ
increase_NN
in_PIN
the_DT
size_NN
of_PIN
our_FPP1
development_NOMZ
,_,
whilst_OSUB
continuing_VBG
to_TO
grow_VB
the_DT
NCE_NN
portfolio_NN
and_CC
an_DT
increasing_JJ
maturity_NOMZ
of_PIN
the_DT
pipeline_NN
,_,
says_VPRT [PUBV]
Moncef_NN
Slaoui_NN
,_,
who_WP
will_PRMD
succeed_VB
pipeline_NN
._.
All_QUAN
this_DEMP
indicates_VPRT [PRIV]
that_THVC
the_DT
way_NN
we_FPP1
structure_VPRT
Tachi_NN
as_IN
Chairman_NN
,_,
R&D_NN
,_,
in_PIN
June_NN
2006_CD
._.
Along_IN
with_PIN
R&D_NN
is_VPRT
paying_VBG
off_PIN [STPR]
,_,
says_VPRT [PUBV]
Tachi_NN
,_,
who_WP
is_VPRT
retiring_VBG
from_PIN
GSK_NN
my_FPP1
colleagues_NN
in_PIN
R&D_NN
,_,
we_FPP1
are_VPRT
embracing_VBG
this_DEMO
in_PIN
June_NN
2006_CD
to_TO
take_VB
up_RP
a_DT
new_JJ
role_NN
as_IN
Executive_NN
challenge_NN
and_CC
we_FPP1
fully_AMP
expect_VPRT [PRIV]
to_TO
be_VB [BEMA]
able_PRED
to_TO
deliver_VB
Director_NN
of_PIN
the_DT
Global_NN
Health_NN
Program_NN
for_PIN
the_DT
Bill_NN
&_CC
medicines_NN
of_PIN
great_JJ
value_NN
for_PIN
patients_NN
and_CC
for_PIN
GSK_NN
in_PIN
Melinda_NN
Gates_NN
Foundation_NOMZ
._.
Jean_NN
Stphenne_NN
,_,
President_NN
and_PHC
General_NN
Manager_NN
,_,
GSK_NN
Biologicals_NN
The_DT
year_NN
of_PIN
the_DT
vaccine_NN
Strong_JJ
growth_NN
and_CC
a_DT
promising_JJ
pipeline_NN
GSK_NN
is_VPRT [BEMA]
a_DT
world-leading_JJ
supplier_NN
of_PIN
vaccines_NN
._.
Our_FPP1
an_DT
improved_VBN
inuenza_NN
vaccine_NN
for_PIN
older_JJ
people_NN
:_:
and_ANDC
vaccines_NN
business_NOMZ
had_VBD
one_CD
of_PIN
its_PIT
best_JJ
years_NN
,_,
with_PIN
sales_NN
vaccine_NN
combinations_NOMZ
against_PIN
meningitis_NN
._.
growing_VBG [PRESP]
by_PIN
15_CD
%_NN
to_PIN
1.4_CD
billion_CD
,_,
says_VPRT [PUBV]
Jean_NN
Stphenne_NN
,_,
We_FPP1
know_VPRT [PRIV]
more_EMPH
about_IN
the_DT
bodys_NN
immune_JJ
system_NN
and_PHC
President_NN
and_PHC
General_NN
Manager_NN
of_PIN
GSK_NN
Biologicals_NN
,_,
the_DT
how_RB
it_PIT
works_VPRT
than_PIN
ever_RB
before_RB
,_,
which_WDT [SERE]
enables_VPRT
us_FPP1
to_PIN
companys_NN
vaccines_NN
business_NOMZ
._.
This_DEMO
growth_NN
was_VBD [BYPA]
led_VBN
by_PIN
produce_NN
safer_JJ
,_,
stronger_JJ
and_CC
more_EMPH
targeted_JJ
vaccines_NN
,_,
Infanrix_NN
and_CC
helped_VBN
by_PIN
the_DT
launches_NN
of_PIN
Boostrix_NN
and_CC
says_VPRT [PUBV]
Jean_NN
._.
Our_FPP1
pipeline_NN
of_PIN
vaccines_NN
promises_VPRT [PUBV]
real_JJ
opporFluarix_NN
in_PIN
the_DT
USA_NN
._.
This_DEMP
,_,
together_RB
with_PIN
a_DT
strong_JJ
product_NN
tunities_NOMZ
to_TO
improve_VB
the_DT
quality_NOMZ
of_PIN
health_NN
worldwide_NN
._.
pipeline_NN
,_,
gives_VPRT
us_FPP1
confidence_NN
in_PIN
the_DT
future_JJ
prospects_NN
for_PIN
our_FPP1
business_NOMZ
._.
Vaccines_NN
investment_NOMZ
In_PIN
2005_CD
,_,
GSK_NN
made_VBD
a_DT
number_NN
of_PIN
moves_NN
to_TO
be_VB [BEMA]
a_DT
major_JJ
Vaccines_NN
pipeline_NN
force_NN
in_PIN
vaccines_NN
against_PIN
inuenza_NN
,_,
the_DT
subject_NN
of_PIN
With_PIN
60_CD
years_NN
experience_NN
,_,
the_DT
company_NN
continues_VPRT
to_TO
heightened_VBN
global_JJ
concern_NN
during_PIN
the_DT
year_NN
._.
The_DT
build_VPRT
a_DT
very_AMP
productive_JJ
R&D_NN
pipeline_NN
and_CC
,_,
in_PIN
the_DT
next_JJ
company_NN
invested_VBD
over_IN
1_CD
billion_CD
to_TO
expand_VB
its_PIT
u_JJ
five_CD
years_NN
,_,
expects_VPRT [PRIV]
five_CD
major_JJ
new_JJ
vaccines_NN
to_TO
be_VB
vaccine_NN
manufacturing_GER
capabilities_NOMZ
._.
One_CD
of_PIN
these_DEMP
is_VPRT
Cervarix_NN
,_,
for_PIN
the_DT
prevention_NOMZ
than_PIN
doubling_VBG
u_JJ
vaccine_NN
production_NOMZ
capacity_NOMZ
at_PIN
its_PIT
of_PIN
human_JJ
papilloma_NN
virus_NN
HPV_NN
,_,
which_WDT [SERE]
causes_VPRT
cervical_JJ
Dresden_NN
site_NN
to_PIN
80_CD
million_CD
doses_NN
a_DT
year_NN
by_PIN
2008_CD
._.
GSK_NN
cancer_NN
a_DT
disease_NN
second_JJ
only_DWNT
to_PIN
breast_NN
cancer_NN
in_PIN
the_DT
also_RB
acquired_VBN
the_DT
Canadian_JJ
vaccine_NN
manufacturer_NN
ID_NN
list_NN
of_PIN
most_EMPH
common_JJ
cancers_NN
affecting_VBG [WZPRES]
women_NN
._.
Global_JJ
clinical_JJ
trials_NN
have_VPRT [PEAS]
shown_VBN [PRIV]
that_THVC
Cervarix_NN
provides_VPRT
Annual_JJ
epidemic_JJ
excellent_JJ
efcacy_NN
against_PIN
HPV16_NN
and_PHC
HPV18_NN
,_,
which_WDT [SERE]
A_DT
seasonal_JJ
epidemic_NN
,_,
inuenza_NN
is_VPRT [BEMA]
a_DT
significant_JJ
economic_JJ
are_VPRT [BEMA]
responsible_PRED
for_PIN
over_IN
70_CD
%_NN
of_PIN
cervical_JJ
cancers_NN
._.
burden_NN
through_PIN
hospital_NN
and_CC
other_JJ
healthcare_NN
costs_NN
as_RB
well_RB
as_IN
lost_VBN
productivity_NOMZ
._.
The_DT
World_NN
Health_NN
Organization_NOMZ
says_VPRT [PUBV]
an_DT
estimated_VBN [PRIV]
5-15_CD
%_NN
of_PIN
the_DT
global_JJ
population_NOMZ
is_VPRT [PASS]
affected_VBN
with_PIN
Our_FPP1
pipeline_NN
of_PIN
vaccines_NN
promises_VPRT [PUBV]
real_EMPH
upper_JJ
respiratory_JJ
tract_NN
infections_NOMZ
each_QUAN
year_NN
._.
Although_CONC
difopportunities_NOMZ
to_TO
improve_VB
the_DT
quality_NOMZ
cult_NN
to_TO
assess_VB
,_,
annual_JJ
u_NN
epidemics_NN
are_VPRT [PASS]
thought_VBN [PRIV]
to_TO
result_VB
in_PIN
250,000-500_CD
,000_CD
deaths_NN
every_QUAN
year_NN
around_PLACE
the_DT
world_NN
._.
Cervarix_NN
is_VPRT [BEMA]
a_DT
genuine_JJ
breakthrough_NN
in_PIN
womens_NN
healthcare_NN
._.
It_PIT
meets_VPRT
a_DT
clear_JJ
medical_JJ
need_NN
and_CC
the_DT
sheer_JJ
volume_NN
of_PIN
women_NN
who_WP [WHSUB]
will_PRMD
benefit_VB
gives_VPRT
it_PIT
great_JJ
potential_JJ
,_,
says_VPRT [PUBV]
Jean_NN
._.
Cervarix_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
submitted_VBN [PUBV]
for_PIN
European_NN
Union_NN
approval_NN
in_PIN
March_NN
2006_CD
and_CC
in_PIN
the_DT
USA_NN
before_IN
the_DT
end_NN
of_PIN
the_DT
year_NN
._.
The_DT
other_JJ
major_JJ
new_JJ
products_NN
expected_VBN [PRIV] [WZPAST]
in_PIN
the_DT
next_JJ
five_CD
years_NN
will_PRMD
be_VB
Rotarix_NN
,_,
for_PIN
rotavirus_NN
gastroenteritis_NN
already_RB
launched_VBN
in_PIN
a_DT
number_NN
of_PIN
countries_NN
in_PIN
Latin_NN
America_NN
,_,
Africa_NN
and_PHC
Asia_NN
,_,
with_PIN
launch_NN
in_PIN
Europe_NN
expected_VBN [PRIV] [WZPAST]
in_PIN
the_DT
first_JJ
half_NN
of_PIN
2006_CD
:_:
Streptorix_NN
,_,
for_PIN
pneumococcal_JJ
disease_NN
:_:
GSK_NN
Annual_JJ
Review_NN
2005_CD
06_CD
With_PIN
vaccines_NN
,_,
25_CD
GSK_NN
had_VBD
25_CD
vaccines_NN
in_PIN
the_DT
greatest_JJ
successes_NN
are_VPRT [BEMA]
clinical_JJ
development_NOMZ
at_PIN
the_DT
end_NN
of_PIN
2005_CD
,_,
with_PIN
five_CD
major_JJ
vaccine_NN
launches_NN
those_DEMO
we_FPP1
do_VPRT
not_XX0
know_VB [PRIV]
about_IN
anticipated_VBN [PRIV]
in_PIN
the_DT
next_JJ
five_CD
years_NN
._.
the_DT
people_NN
who_WP [WHSUB]
have_VPRT [PEAS]
not_XX0
suffered_VBN
or_CC
died_VBN
Egg-based_JJ
vaccines_NN
are_VPRT [PASS]
produced_VBN
at_PIN
Dresden_NN
,_,
Germany_NN
pictured_VBD
,_,
from_PIN
vaccine-preventable_JJ
diseases_NN
._.
where_RB
GSK_NN
is_VPRT [BEMA]
more_EMPH
than_PIN
doubling_VBG
u_JJ
vaccine_NN
Jean_NN
Stphenne_NN
,_,
President_NN
and_PHC
General_NN
Manager_NN
,_,
GSK_NN
Biologicals_NN
production_NOMZ
capacity_NOMZ
._.
On_PIN
this_DEMO
page_NN
you_SPP2
will_PRMD
nd_VB
:_:
Preparing_VBG [PRESP]
for_PIN
a_DT
u_JJ
pandemic_NN
:_:
Consumer_NN
Healthcare_NN
business_NOMZ
model_NN
:_:
Growth_NN
opportunity_NOMZ
:_:
Beating_GER
tobacco_NN
Biomedical_NN
and_CC
a_DT
vaccines_NN
production_NOMZ
facility_NOMZ
in_PIN
Preparing_VBG
for_PIN
a_DT
u_JJ
pandemic_JJ
Marietta_NN
,_,
Pennsylvania_NN
,_,
which_WDT [SERE]
will_PRMD
focus_VB
on_PIN
the_DT
GSK_NN
is_VPRT [PASS]
committed_VBN
to_TO
doing_VBG [PROD]
everything_QUPR
it_PIT
can_POMD
to_PIN
development_NOMZ
and_PHC
production_NOMZ
of_PIN
tissue_NN
culture_NN
support_NN
governments_NOMZ
and_PHC
health_NN
authorities_NOMZ
around_PLACE
technology_NN
that_TSUB
will_PRMD
be_VB [PASS]
used_VBN
for_PIN
seasonal_JJ
and_PHC
pandemic_JJ
the_DT
world_NN
in_PIN
planning_VBG
responses_NN
to_PIN
a_DT
possible_JJ
global_JJ
u_NN
vaccines_NN
._.
The_DT
company_NN
also_RB
purchased_VBD
Corixa_NN
in_PIN
the_DT
inuenza_NN
pandemic_NN
._.
The_DT
company_NN
is_VPRT
developing_VBG
a_DT
USA_NN
,_,
a_DT
developer_NN
of_PIN
adjuvants_NN
,_,
which_WDT [SERE]
are_VPRT
agents_NN
that_DEMO
prototype_NN
H5N1_CD
pandemic_JJ
vaccine_NN
,_,
and_ANDC
clinical_JJ
trials_NN
boost_VPRT
human_JJ
immune_JJ
response_NN
to_PIN
vaccine_NN
antigens_NN
._.
testing_GER
this_DEMO
vaccine_NN
against_PIN
the_DT
H5N1_NN
u_NN
strain_NN
are_VPRT
taking_VBG
place_NN
in_PIN
2006_CD
._.
This_DEMO
prototype_NN
uses_VPRT
an_DT
innovative_JJ
With_PIN
approval_NN
in_PIN
2005_CD
by_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
adjuvant_JJ
which_WDT
may_POMD
allow_VB [SUAV]
lower_JJ
amounts_NN
of_PIN
antigen_NN
Administration_NOMZ
FDA_NN
,_,
Fluarix_NN
became_VBD
the_DT
first_JJ
to_TO
be_VB [PASS]
used_VBN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
essential_PRED
for_PIN
manufacturing_VBG
a_DT
large_JJ
biological_JJ
product_NN
to_TO
be_VB [PASS]
reviewed_VBN
under_IN
accelerated_VBN
number_NN
of_PIN
doses_NN
in_PIN
the_DT
event_NN
of_PIN
a_DT
pandemic_NN
._.
The_DT
shortage_NN
of_PIN
u_JJ
vaccine_NN
in_PIN
also_RB
invested_VBN
to_TO [SPIN]
signicantly_RB
increase_VB
production_NOMZ
the_DT
USA_NN
in_PIN
2004_CD
was_VBD [BEMA]
a_DT
reminder_NN
of_PIN
the_DT
importance_NN
of_PIN
capacity_NOMZ
of_PIN
GSKs_NN
antiviral_JJ
Relenza_NN
to_TO
help_VB
meet_VB
vaccines_NN
in_PIN
healthcare_NN
,_,
says_VPRT [PUBV]
Jean_NN
._.
We_FPP1
worked_VBD
quickly_RB
increased_VBN
global_JJ
demand_NN
._.
Work_NN
is_VPRT
going_VBG
on_PIN
across_PLACE
with_PIN
US_FPP1
government_NOMZ
ofcials_NN
to_TO
make_VB
Fluarix_NN
available_JJ
GSK_NN
to_TO
anticipate_VB [PRIV]
and_PHC
address_VB
all_QUAN
aspects_NN
of_PIN
a_DT
potential_JJ
and_CC
increase_VB
supply_NN
at_PIN
a_DT
critical_JJ
time_NN
._.
John_NN
Clarke_NN
,_,
President_NN
,_,
Consumer_NN
Healthcare_NN
Growing_VBG [WZPRES]
brands_NN
Product_NN
innovation_NOMZ
aligned_VBN [WZPAST]
to_PIN
consumers_NN
needs_VPRT
Aquafresh_NN
and_PHC
Sensodyne_NN
toothpaste_NN
,_,
Nicorette_NN
and_CC
to_TO
be_VB [PASS]
launched_VBN
in_PIN
2006_CD
,_,
accompanied_VBN [PASTP]
by_PIN
a_DT
consumer_NN
NicoDerm_NN
smoking_GER
cessation_NOMZ
products_NN
,_,
and_ANDC
Ribena_NN
education_NOMZ
program_NN
._.
Like_IN
stopping_VBG
smoking_GER
,_,
weight_NN
and_PHC
Lucozade_NN
drinks_NN
are_VPRT [BEMA]
among_PIN
the_DT
products_NN
that_DEMO
loss_NN
requires_VPRT [SUAV]
a_DT
change_NN
in_PIN
behavior_NN
._.
Often_RB
,_,
though_CONC
,_,
make_VB
GSK_NN
Consumer_NN
Healthcare_NN
a_DT
leading_VBG
physicians_NN
dont_NN
have_VPRT
the_DT
training_GER
or_CC
the_DT
time_NN
to_TO
help_VB
manufacturer_NN
and_PHC
marketer_NN
of_PIN
consumer_NN
brands_NN
._.
patients_NN
change_VPRT
their_TPP3
behavior_NN
,_,
says_VPRT [PUBV]
John_NN
._.
The_DT
new_JJ
Consumer_NN
Healthcare_NN
sales_NN
in_PIN
2005_CD
were_VBD [BEMA]
3_CD
billion_CD
,_,
an_DT
OTC_NN
product_NN
will_PRMD
not_XX0
be_VB [BEMA]
a_DT
get-slim-quick_JJ
pill_NN
._.
Proper_JJ
increase_NN
of_PIN
2_CD
%_NN
over_IN
2004_CD
._.
diet_NN
and_CC
appropriate_JJ
exercise_NN
will_PRMD [SPAU]
still_RB
be_VB
part_NN
of_PIN
the_DT
overall_JJ
weight_NN
loss_NN
program_NN
and_CC
our_FPP1
education_NOMZ
Redening_VBG [WZPRES]
the_DT
business_NOMZ
model_NN
efforts_NN
will_PRMD
be_VB [BEMA]
a_DT
major_JJ
component_NN
in_PIN
supporting_VBG
this_DEMP
._.
Like_IN
others_NN
in_PIN
the_DT
consumer_NN
healthcare_NN
industry_NN
,_,
GSK_NN
operates_VPRT
in_PIN
a_DT
competitive_JJ
and_CC
changing_VBG
environment_NOMZ
._.
Beating_GER
tobacco_NN
Consumers_NN
are_VPRT
demanding_VBG [SUAV]
better_JJ
quality_NOMZ
,_,
better_JJ
value_NN
Since_OSUB
GSK_NN
Consumer_NN
Healthcares_NN
pioneering_JJ
switch_NN
of_PIN
and_CC
improved_VBD
performance_NN
,_,
while_OSUB
retailers_NN
have_VPRT
Nicorette_JJ
nicotine_NN
gum_NN
in_PIN
the_DT
USA_NN
in_PIN
1996_CD
,_,
the_DT
company_NN
has_VPRT [PEAS]
consolidated_VBN
and_PHC
strengthened_VBD
their_TPP3
negotiating_GER
innovated_VBD
to_TO
expand_VB
its_PIT
portfolio_NN
,_,
adding_VBG [PUBV] [PRESP]
a_DT
patch_NN
and_CC
more_EMPH
recently_TIME
a_DT
lozenge_NN
._.
This_DEMP
has_VPRT [PEAS]
broadened_VBN
appeal_NN
and_PHC
power_NN
,_,
says_VPRT [PUBV]
John_NN
Clarke_NN
,_,
who_WP
succeeded_VBD
Jack_NN
Ziegler_NN
successfully_RB
helped_VBD
over_IN
five_CD
million_CD
smokers_NN
escape_VPRT
their_TPP3
as_IN
President_NN
,_,
Consumer_NN
Healthcare_NN
,_,
in_PIN
February_NN
2006_CD
._.
tobacco_NN
dependence_NN
worldwide_NN
._.
As_IN
tobacco_NN
kills_VPRT
many_QUAN
users_NN
,_,
To_TO
conduct_VB
business_NOMZ
more_EMPH
effectively_RB
in_PIN
this_DEMO
these_DEMO
Consumer_NN
Healthcare_NN
products_NN
really_EMPH
do_EMPH
save_VB
lives_NN
._.
environment_NOMZ
,_,
Consumer_NN
Healthcare_NN
has_VPRT [PEAS]
redened_VBN
its_PIT
While_OSUB
GSK_NN
is_VPRT
doing_VBG [PROD]
good_JJ
things_NN
for_PIN
public_JJ
health_NN
,_,
the_DT
business_NOMZ
strategy_NN
and_PHC
operating_GER
model_NN
to_TO
deliver_VB
faster_JJ
opportunities_NOMZ
for_PIN
these_DEMO
nicotine_JJ
replacement_NOMZ
therapy_NN
NRT_NN
sales_NN
growth_NN
._.
We_FPP1
expect_VPRT [PRIV]
to_TO
achieve_VB
this_DEMO
growth_NN
brands_NN
NiQuitin_NN
,_,
Nicabate_NN
,_,
Commit_NN
,_,
NicoDerm_NN
CQ_NN
and_PHC
Nicorette_NN
continue_VPRT
to_TO
expand_VB
as_IN
countries_NN
implement_VPRT
through_PIN
a_DT
vigorous_JJ
focus_NN
on_PIN
delivering_VBG
new_JJ
product_NN
smoke-free_JJ
legislation_NOMZ
._.
developments_NOMZ
that_TSUB
are_VPRT [SPAU] [PASS]
tightly_RB
aligned_VBN
with_PIN
consumer_NN
needs_NN
,_,
says_VPRT [PUBV]
John_NN
._.
The_DT
new_JJ
structure_NN
brings_VPRT
together_RB
our_FPP1
R&D_NN
,_,
marketing_GER
and_CC
commercial_JJ
operating_VBG
units_NN
and_CC
gives_VPRT
us_FPP1
greater_JJ
focus_NN
,_,
alignment_NOMZ
and_PHC
simplicity_NOMZ
._.
Growth_NN
opportunity_NOMZ
Consumer_NN
Healthcare_NN
has_VPRT
a_DT
particularly_RB
exciting_JJ
new_JJ
growth_NN
opportunity_NOMZ
for_PIN
the_DT
business_NOMZ
with_PIN
Alli_NN
orlistat_NN
,_,
an_DT
over-the-counter_JJ
OTC_NN
weight_NN
loss_NN
medicine_NN
._.
In_PIN
January_NN
2006_CD
,_,
a_DT
FDA_NN
Advisory_NN
Committee_NN
recommended_VBD [SUAV]
that_THVC
Alli_NN
be_VB [PASS]
approved_VBN
for_PIN
OTC_NN
use_NN
in_PIN
the_DT
USA_NN
._.
If_COND
approved_VBN
,_,
Alli_NN
will_PRMD
be_VB [BEMA]
the_DT
only_DWNT
FDA-approved_JJ
weightloss_NN
medicine_NN
available_JJ
over-the-counter_JJ
and_CC
is_VPRT [PASS]
expected_VBN [PRIV]
GSK_NN
Annual_JJ
Review_NN
2005_CD
08_CD
23_CD
million_CD
Millions_NN
of_PIN
people_NN
use_VPRT
and_CC
23_CD
million_CD
bottles_NN
of_PIN
Lucozade_NN
Sport_NN
Hydro_NN
Active_NN
were_VBD [PASS]
sold_VBN
in_PIN
2005_CD
._.
trust_NN
our_FPP1
Consumer_NN
Healthcare_NN
The_DT
most_EMPH
recent_JJ
innovation_NOMZ
for_PIN
Lucozade_NN
,_,
products_NN
every_QUAN
day_NN
._.
Hydro_NN
Active_NN
has_VPRT [PEAS]
been_VBN [SPAU] [PASS]
specially_RB
formulated_VBN
to_PIN
We_FPP1
are_VPRT [PASS]
focused_VBN
on_PIN
delivering_VBG
even_RB
better_JJ
help_NN
replace_VB
the_DT
salts_NN
and_PHC
uids_NN
you_SPP2
lose_VPRT
during_PIN
exercise_NN
,_,
keeping_VBG [PRESP]
you_SPP2
products_NN
that_TSUB
give_VPRT
consumers_NN
what_WP
they_TPP3
need_VPRT
._.
better_RB
hydrated_VBN
than_PIN
water_NN
alone_RB
._.
John_NN
Clarke_NN
,_,
President_NN
,_,
Consumer_NN
Healthcare_NN
I_FPP1
was_VBD [BEMA]
really_EMPH
surprised_PRED
21_CD
million_CD
when_RB
the_DT
doctor_NN
told_VBD
me_FPP1
I_FPP1
had_VBD
diabetes_NN
._.
Nearly_DWNT
21_CD
million_CD
Americans_NN
have_VPRT
diabetes_NN
,_,
Within_PIN
a_DT
few_QUAN
weeks_NN
of_PIN
almost_DWNT
one-third_NN
of_PIN
whom_WP [PIRE]
are_VPRT [BEMA]
undiagnosed_PRED
._.
The_DT
incidence_NN
of_PIN
the_DT
disease_NN
starting_VBG [WZPRES]
Avandia_NN
my_FPP1
blood_NN
sugar_NN
has_VPRT [PEAS]
risen_VBN
14_CD
%_NN
in_PIN
the_DT
past_JJ
two_CD
years_NN
._.
levels_NN
returned_VBD
to_PIN
normal_JJ
Maggie_NN
Lopez_NN
pictured_VBD
nds_VPRT
that_DEMO
Avandia_NN
helps_VPRT
her_TPP3
to_TO
lead_VB
the_DT
sort_NN
of_PIN
life_NN
and_CC
I_FPP1
soon_TIME
had_VBD
my_FPP1
energy_NN
back_RB
._.
Maggie_NN
Lopez_NN
,_,
Daytona_NN
Beach_NN
,_,
Florida_NN
,_,
USA_NN
On_PIN
this_DEMO
page_NN
you_SPP2
will_PRMD
nd_VB
:_:
Pharma_NN
key_JJ
growth_NN
drivers_NN
:_:
New_NN
products_NN
:_:
Improving_GER
osteoporosis_NN
treatments_NOMZ
David_NN
Stout_NN
,_,
President_NN
,_,
Pharmaceutical_NN
Operations_NOMZ
Powering_GER
performance_NN
Driving_VBG [WZPRES]
growth_NN
through_PIN
people_NN
and_PHC
products_NN
Our_FPP1
performance_NN
in_PIN
2005_CD
was_VBD [BEMA]
undoubtedly_RB
due_PRED
to_TO
published_VBN
that_DEMP
reinforced_VBD
the_DT
use_NN
of_PIN
Lamictal_NN
as_IN
first-line_JJ
the_DT
contributions_NOMZ
from_PIN
all_QUAN
our_FPP1
staff_NN
around_PLACE
the_DT
world_NN
,_,
maintenance_NN
treatment_NOMZ
for_PIN
bi-polar_JJ
disorder_NN
where_RB
the_DT
and_CC
they_TPP3
deserve_VPRT
congratulations_NOMZ
on_PIN
the_DT
years_NN
licence_NN
allows_VPRT [SUAV]
,_,
and_ANDC
GSK_NN
led_VBD
once-daily_RB
Coreg_NN
CR_NN
with_PIN
achievements_NOMZ
._.
Their_TPP3
enthusiasm_NN
and_PHC
passion_NN
about_IN
the_DT
FDA_NN
towards_PIN
the_DT
end_NN
of_PIN
2005_CD
._.
helping_VBG
to_TO
improve_VB
healthcare_NN
is_VPRT [BEMA]
clear_PRED
,_,
says_VPRT [PUBV]
David_NN
New_NN
products_NN
Stout_NN
,_,
President_NN
,_,
Pharmaceutical_NN
Operations_NOMZ
._.
New_JJ
products_NN
also_RB
started_VBD
to_TO
deliver_VB
significant_JJ
sales_NN
._.
Key_NN
growth_NN
drivers_NN
Avodart_NN
for_PIN
enlarging_VBG
prostate_NN
,_,
for_CONJ
example_NULL
,_,
GSK_NN
pharmaceutical_JJ
sales_NN
in_PIN
2005_CD
were_VBD [BEMA]
18.7_CD
billion_CD
,_,
performed_VBN [PASTP]
well_RB
and_CC
accounted_VBD
for_PIN
over_IN
40_CD
%_NN
of_PIN
new_JJ
an_DT
increase_NN
of_PIN
8_CD
%_NN
over_IN
2004_CD
,_,
led_VBN [PASTP]
by_PIN
the_DT
companys_NN
prescription_NOMZ
sales_NN
in_PIN
its_PIT
class_NN
in_PIN
the_DT
USA_NN
._.
This_DEMP
was_VBD [BEMA]
key_JJ
pharmaceutical_JJ
growth_NN
drivers_NN
and_PHC
vaccines_NN
see_VPRT [PRIV]
exceptionally_RB
fast_JJ
growth_NN
and_PHC
Avodart_NN
will_PRMD
be_VB [BEMA]
an_DT
page_NN
6_CD
._.
Our_FPP1
biggest-selling_JJ
product_NN
,_,
Seretide_NN
Advair_NN
,_,
exciting_JJ
product_NN
for_PIN
us_FPP1
,_,
says_VPRT [PUBV]
David_NN
._.
had_VBD
another_DT
strong_JJ
year_NN
and_CC
continued_VBD
to_TO
gain_VB
market_NN
share_NN
across_PLACE
all_QUAN
regions_NN
,_,
driven_VBN [PASTP]
by_PIN
its_PIT
efcacy_NN
in_PIN
treating_VBG
Avandia_NN
Avandamet_NN
goes_VPRT
from_PIN
strength_NN
these_DEMO
debilitating_GER
conditions_NOMZ
,_,
says_VPRT [PUBV]
David_NN
._.
We_FPP1
believe_VPRT [PRIV] [THATD]
physicians_NN
accept_VB [PRIV]
market_NN
share_NN
by_PIN
value_NN
in_PIN
the_DT
anti-asthma_NN
and_PHC
COPD_NN
and_CC
like_IN
it_PIT
,_,
and_ANDC
increasingly_RB
use_VB
it_PIT
as_IN
a_DT
therapy_NN
class_NN
of_PIN
27_CD
%_NN
in_PIN
Europe_NN
and_CC
33_CD
%_NN
in_PIN
the_DT
USA_NN
,_,
first-line_JJ
treatment_NOMZ
for_PIN
many_QUAN
patients_NN
an_DT
increase_NN
of_PIN
two_CD
percentage_NN
points_NN
in_PIN
both_DT
cases_NN
compared_VBN [WZPAST]
with_PIN
2004_CD
._.
where_RB
the_DT
licence_NN
allows_VPRT [SUAV]
._.
Osteoporosis_NN
,_,
a_DT
disease_NN
in_PIN
which_WDT [PIRE]
bones_NN
become_VPRT
brittle_JJ
Market_NN
share_NN
by_PIN
value_NN
and_CC
more_EMPH
likely_JJ
to_TO
break_VB
,_,
affects_VPRT
an_DT
estimated_VBN [PRIV]
75_CD
Seretide_NN
Advair_NN
Avandia_NN
Avandamet_NN
40_CD
%_NN
million_CD
people_NN
in_PIN
the_DT
USA_NN
,_,
Europe_NN
and_PHC
Japan_NN
._.
An_DT
35_CD
33_CD
31_CD
estimated_VBD [PRIV]
one_CD
in_PIN
three_CD
women_NN
will_PRMD
sustain_VB
an_DT
29_CD
30_CD
%_NN
27_CD
25_CD
osteoporosis-related_JJ
fracture_NN
in_PIN
their_TPP3
lifetime_NN
._.
Boniva_NN
Bonviva_NN
,_,
developed_VBD
with_PIN
Roche_NN
,_,
was_VBD [PASS]
launched_VBN
20_CD
%_NN
14_CD
in_PIN
the_DT
USA_NN
in_PIN
April_NN
2005_CD
,_,
and_ANDC
in_PIN
several_QUAN
countries_NN
in_PIN
11_CD
10_CD
%_NN
Improving_GER
treatments_NOMZ
Bisphosphonate_NN
treatments_NOMZ
for_PIN
osteoporosis_NN
involve_VPRT
taking_VBG
Europe_NN
USA_NN
Europe_NN
USA_NN
a_DT
tablet_NN
with_PIN
a_DT
full_JJ
glass_NN
of_PIN
water_NN
first_JJ
thing_NN
in_PIN
the_DT
morning_GER
,_,
September_NN
2004_CD
September_NN
2005_CD
then_RB
remaining_VBG
upright_JJ
and_CC
delaying_VBG
eating_NN
or_CC
drinking_GER
for_PIN
30-60_CD
minutes_NN
._.
With_PIN
Boniva_NN
Bonviva_NN
,_,
women_NN
have_VPRT
to_PIN
Sales_NN
of_PIN
diabetes_NN
treatments_NOMZ
were_VBD [BEMA]
also_RB
strong_PRED
._.
Diabetes_NN
follow_VB
this_DEMO
dosing_NN
routine_JJ
just_EMPH
once_TIME
a_DT
month_NN
,_,
instead_CONJ
of_NULL
affects_VPRT
more_EMPH
than_PIN
190_CD
million_CD
people_NN
worldwide_JJ
._.
GSK_NN
four_CD
times_NN
as_IN
required_VBN [SUAV]
with_PIN
weekly_JJ
bisphosphonate_NN
treatments_NOMZ
._.
Data_NN
have_VPRT [PEAS]
shown_VBN [PRIV]
that_THVC
two_CD
out_PIN
of_PIN
three_CD
women_NN
launched_VBD
Avandia_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
type_NN
2_CD
diabetes_NN
preferred_VBN [SUAV]
the_DT
once-monthly_JJ
dosing_NN
of_PIN
Boniva_NN
Bonviva_NN
over_IN
in_PIN
1999_CD
and_CC
a_DT
combination_NOMZ
product_NN
,_,
Avandamet_NN
,_,
for_PIN
a_DT
once-weekly_JJ
treatment_NOMZ
,_,
nding_VBG [PRESP]
it_PIT
more_EMPH
convenient_JJ
._.
Avandia_NN
Avandamet_NN
new_JJ
injectable_JJ
form_NN
of_PIN
Boniva_NN
was_VBD [PASS]
approved_VBN
for_PIN
use_NN
in_PIN
the_DT
goes_VPRT
from_PIN
strength_NN
to_PIN
strength_NN
._.
We_FPP1
believe_VPRT [PRIV]
physicians_NN
USA_NN
in_PIN
January_NN
2006_CD
._.
This_DEMO
quarterly_JJ
treatment_NOMZ
may_POMD
bring_VB
accept_VB [PRIV]
and_PHC
like_VB
it_PIT
,_,
and_ANDC
increasingly_RB
use_VB
it_PIT
as_IN
a_DT
first-line_JJ
the_DT
benets_NN
of_PIN
Boniva_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
postmenopausal_JJ
treatment_NOMZ
for_PIN
many_QUAN
patients_NN
where_RB
the_DT
licence_NN
allows_VPRT [SUAV]
,_,
osteoporosis_NN
to_TO
even_RB
more_EMPH
women_NN
._.
The_DT
product_NN
group_NN
was_VBD [PASS]
expanded_VBN
further_RB
in_PIN
February_NN
2006_CD
with_PIN
the_DT
launch_NN
in_PIN
the_DT
USA_NN
of_PIN
a_DT
xeddose_JJ
combination_NOMZ
treatment_NOMZ
,_,
Avandaryl_NN
,_,
which_WDT [SERE]
combines_VPRT
Avandia_NN
with_PIN
a_DT
sulfonylurea_NN
._.
In_PIN
2005_CD
,_,
Avandia_NN
Avandamet_NN
achieved_VBD
a_DT
market_NN
share_NN
by_PIN
value_NN
in_PIN
oral_JJ
anti-diabetics_NN
of_PIN
14_CD
%_NN
in_PIN
Europe_NN
and_CC
35_CD
%_NN
in_PIN
the_DT
USA_NN
,_,
up_RB
3_CD
and_CC
6_CD
percentage_NN
points_NN
respectively_RB
._.
Other_JJ
growth_NN
drivers_NN
included_VBD
Lamictal_NN
,_,
Valtrex_NN
and_PHC
Coreg_NN
,_,
which_WDT [SERE]
did_VBD
well_RB
in_PIN
their_TPP3
respective_JJ
markets_NN
of_PIN
bipolar_NN
disorder_NN
and_PHC
epilepsy_NN
,_,
herpes_NN
and_PHC
heart_NN
disease_NN
,_,
delivering_VBG [PRESP]
a_DT
total_NN
of_PIN
over_IN
2.1_CD
billion_CD
in_PIN
sales_NN
,_,
up_RB
25_CD
%_NN
over_IN
2004_CD
._.
During_PIN
the_DT
year_NN
new_JJ
guidelines_NN
were_VBD
GSK_NN
Annual_JJ
Review_NN
2005_CD
11_CD
On_PIN
this_DEMO
page_NN
you_SPP2
will_PRMD
nd_VB
:_:
Commercial_NN
and_CC
operational_JJ
excellence_NN
:_:
Maintaining_VBG [PUBV]
high_JJ
standards_NN
:_:
Seretide_NN
Advair_NN
patient_JJ
prole_NN
Europe_NN
in_PIN
September_NN
2005_CD
,_,
as_IN
the_DT
first_JJ
ever_RB
oral_JJ
communication_NOMZ
from_PIN
senior_JJ
management_NOMZ
to_PIN
treatment_NOMZ
administered_VBN
as_IN
one_CD
tablet_NN
once-a-month_JJ
employees_NN
on_PIN
areas_NN
where_RB
policy_NN
is_VPRT
changing_VBG
or_CC
there_EX
for_PIN
postmenopausal_JJ
osteoporosis_NN
._.
Since_OSUB
its_PIT
launch_NN
,_,
are_VPRT
concerns_NN
about_IN
compliance_NN
:_:
global_JJ
induction_NOMZ
Boniva_NN
has_VPRT [PEAS]
achieved_VBN
10_CD
%_NN
share_NN
of_PIN
new_JJ
prescriptions_NOMZ
courses_NN
that_TSUB
include_VPRT
training_GER
on_PIN
the_DT
GSK_NN
Code_NN
of_PIN
in_PIN
the_DT
oral_JJ
bisphosphonate_NN
market_NN
in_PIN
the_DT
USA_NN
._.
The_DT
Conduct_NN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
new_JJ
employees_NN
understand_VPRT [PRIV]
the_DT
injectable_JJ
form_NN
of_PIN
Boniva_NN
Bonviva_NN
was_VBD [PASS]
approved_VBN
for_PIN
importance_NN
of_PIN
ethical_JJ
conduct_NN
from_PIN
their_TPP3
first_JJ
day_NN
:_:
and_ANDC
use_VB
in_PIN
the_DT
USA_NN
,_,
and_ANDC
recommended_VBD [SUAV]
for_PIN
approval_NN
in_PIN
an_DT
annual_JJ
certication_NOMZ
process_NN
which_WDT [WHSUB]
extends_VPRT
to_PIN
all_QUAN
Europe_NN
in_PIN
January_NN
2006_CD
._.
It_PIT
is_VPRT [BEMA]
the_DT
first_JJ
intravenous_JJ
senior_JJ
managers_NN
globally_RB
and_CC
all_QUAN
middle_JJ
managers_NN
in_PIN
bisphosphonate_NN
to_TO
be_VB [PASS]
approved_VBN
for_PIN
the_DT
treatment_NOMZ
of_PIN
the_DT
UK_NN
and_PHC
USA_NN
._.
We_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
ensuring_VBG [SUAV] [PRIV]
our_FPP1
business_NOMZ
practices_NN
Another_DT
launch_NN
in_PIN
the_DT
USA_NN
in_PIN
2005_CD
was_VBD
Requip_NN
for_PIN
meet_VPRT
high_JJ
standards_NN
and_CC
that_THVC
our_FPP1
employees_NN
behave_VPRT
Restless_JJ
Legs_NN
Syndrome_NN
RLS_NN
,_,
a_DT
chronic_NN
and_CC
disruptive_JJ
ethically_RB
and_PHC
honestly_RB
._.
We_FPP1
strive_VPRT
to_TO
operate_VB
to_PIN
high_JJ
condition_NOMZ
characterised_VBN [WZPAST]
by_PIN
an_DT
urge_NN
to_TO
move_VB [SUAV]
the_DT
legs_NN
,_,
ethical_JJ
standards_NN
,_,
act_NN
responsibly_RB
and_CC
comply_VB
with_PIN
the_DT
particularly_RB
at_PIN
night_NN
._.
The_DT
condition_NOMZ
is_VPRT [BEMA]
common_PRED
,_,
underlaw_NN
._.
This_DEMP
is_VPRT [BEMA]
vital_PRED
because_CAUS
of_PIN
the_DT
simple_JJ
fact_NN
that_TOBJ
GSK_NN
diagnosed_VBD
and_CC
can_POMD
have_VB
a_DT
significant_JJ
effect_NN
on_PIN
sleep_NN
products_NN
are_VPRT [BEMA]
important_PRED
to_PIN
the_DT
health_NN
of_PIN
people_NN
around_PLACE
and_CC
daily_JJ
activities_NOMZ
._.
Since_OSUB
it_PIT
was_VBD [PASS]
launched_VBN
for_PIN
RLS_NN
in_PIN
the_DT
the_DT
world_NN
,_,
says_VPRT [PUBV]
David_NN
._.
USA_NN
,_,
the_DT
volume_NN
of_PIN
new_JJ
prescriptions_NOMZ
for_PIN
Requip_NN
has_VPRT [PEAS]
quadrupled_VBN
,_,
with_PIN
sales_NN
of_PIN
156_CD
million_CD
,_,
up_RB
34_CD
%_NN
._.
On_PIN
top_NN
of_PIN
the_DT
world_NN
Approval_NN
in_PIN
Europe_NN
for_PIN
Requip_NN
Adartrel_NN
as_IN
a_DT
treatment_NOMZ
In_PIN
2005_CD
,_,
Mogens_NN
Jensen_NN
ran_VBD
and_PHC
cycled_VBD
7,000_CD
miles_NN
from_PIN
for_PIN
RLS_NN
is_VPRT [PASS]
expected_VBN [PRIV]
in_PIN
the_DT
first_JJ
half_NN
of_PIN
2006_CD
._.
his_TPP3
home_NN
in_PIN
Denmark_NN
to_PIN
a_DT
base_NN
camp_NN
in_PIN
Tibet_NN
as_IN
a_DT
warm_JJ
up_RP
for_PIN
his_TPP3
bid_NN
to_TO
become_VB
the_DT
first_JJ
asthmatic_JJ
to_TO
climb_VB
Commercial_JJ
and_PHC
operational_JJ
excellence_NN
Mount_NN
Everest_NN
._.
Although_CONC
he_TPP3
was_VBD [BEMA]
not_XX0
successful_JJ
frostbite_NN
GSK_NN
continued_VBD
to_TO
make_VB
good_JJ
progress_NN
towards_PIN
forced_VBN
Mogens_NN
to_TO
abandon_VB
his_TPP3
climb_NN
not_XX0
far_PLACE
from_PIN
the_DT
commercial_JJ
and_PHC
operational_JJ
excellence_NN
to_TO
improve_VB
summit_NN
his_TPP3
effort_NN
displayed_VBD
a_DT
formidable_JJ
strength_NN
of_PIN
character_NN
and_CC
physical_JJ
tness_NOMZ
undiminished_VBN [WZPAST]
by_PIN
disease_NN
._.
underlying_VBG
performance_NN
,_,
with_PIN
tight_JJ
cost_NN
control_NN
Diagnosed_VBN [WZPAST]
with_PIN
asthma_NN
in_PIN
1998_CD
,_,
Mogens_NN
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
underpinning_JJ
operations_NOMZ
._.
Through_PIN
the_DT
companys_NN
not_XX0
to_TO
allow_VB [SUAV]
it_PIT
to_TO
control_VB
his_TPP3
life_NN
and_CC
stop_VB
his_TPP3
sporting_VBG
Worldwide_NN
Sales_NN
Force_NN
Excellence_NN
initiative_NN
,_,
sales_NN
activities_NOMZ
._.
After_IN
trying_VBG
different_JJ
medications_NOMZ
,_,
he_TPP3
found_VBD [PRIV] [THATD]
representatives_NN
are_VPRT [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
strengthen_VB
the_DT
Seretide_NN
very_AMP
effective_JJ
in_PIN
controlling_VBG
his_TPP3
symptoms_NN
._.
With_PIN
product_NN
knowledge_NN
of_PIN
physicians_NN
so_IN
they_TPP3
can_POMD
deliver_VB
the_DT
help_NN
of_PIN
Seretide_NN
,_,
I_FPP1
have_VPRT [PEAS]
taken_VBN
control_NN
of_PIN
my_FPP1
asthma_NN
patient-specic_JJ
treatment_NOMZ
options_NOMZ
more_EMPH
efficiently_RB
and_CC
and_CC
not_XX0
allowed_VBN [SUAV]
my_FPP1
asthma_NN
to_TO
control_VB
me_FPP1
,_,
he_TPP3
says_VPRT [PUBV]
._.
We_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
ensuring_VBG [SUAV] [PRIV]
our_FPP1
business_NOMZ
practices_NN
meet_VPRT
high_JJ
standards_NN
and_CC
that_THVC
our_FPP1
employees_NN
behave_VPRT
ethically_RB
and_PHC
honestly_RB
._.
In_PIN
manufacturing_GER
and_PHC
supply_NN
,_,
GSK_NN
introduced_VBD
the_DT
Vision_NN
Factory_NN
initiative_NN
which_WDT [WHSUB]
is_VPRT
identifying_VBG
improvements_NOMZ
in_PIN
productivity_NOMZ
and_PHC
cost_NN
reduction_NOMZ
._.
We_FPP1
started_VBD
the_DT
year_NN
with_PIN
some_QUAN
manufacturing_GER
problems_NN
that_TSUB
stopped_VBD
production_NOMZ
of_PIN
two_CD
medicines_NN
at_PIN
our_FPP1
Cidra_NN
plant_NN
in_PIN
Puerto_NN
Rico_NN
._.
Our_FPP1
people_NN
are_VPRT
working_VBG
with_PIN
the_DT
FDA_NN
to_TO
implement_VB
solutions_NOMZ
and_CC
minimize_VB
the_DT
interruption_NOMZ
to_TO
supply_VB
,_,
says_VPRT [PUBV]
David_NN
._.
The_DT
learning_GER
from_PIN
this_DEMP
,_,
combined_VBN [PASTP]
with_PIN
the_DT
Vision_NN
Factory_NN
initiative_NN
,_,
will_PRMD
increase_VB
the_DT
operational_JJ
excellence_NN
of_PIN
our_FPP1
manufacturing_GER
operations_NOMZ
in_PIN
the_DT
future_NN
,_,
ensuring_VBG [SUAV] [PRIV]
product_NN
quality_NOMZ
and_PHC
patient_NN
safety_NN
are_VPRT [BEMA]
paramount_PRED
._.
Maintaining_VBG [PUBV]
high_JJ
standards_NN
GSK_NN
audits_NN
its_PIT
operations_NOMZ
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
relevant_JJ
standards_NN
expected_VBN [PRIV]
,_,
such_JJ
as_IN
those_DEMO
in_PIN
marketing_GER
practices_NN
,_,
are_VPRT [PASS]
reached_VBN
or_CC
exceeded_VBN
._.
GSK_NN
has_VPRT
in_PIN
place_NN
a_DT
number_NN
of_PIN
mechanisms_NN
to_TO
support_VB
compliance_NN
with_PIN
policies_NN
and_PHC
procedures_NN
._.
These_DEMP
include_VPRT
direct_JJ
GSK_NN
Annual_JJ
Review_NN
2005_CD
13_CD
2005_CD
performance_NN
highlights_VPRT
82.6_CD
p_NN
4.7_CD
bn_NN
earnings_GER
per_PIN
share_NN
free_JJ
cash_NN
ow_NN
18_CD
%_NN
CER_NN
growth_NN
in_PIN
2005_CD
increase_NN
of_PIN
26_CD
%_NN
over_IN
2004_CD
25_CD
95_CD
vaccines_NN
in_PIN
clinical_JJ
development_NOMZ
NCEs_NN
in_PIN
clinical_JJ
development_NOMZ
at_PIN
the_DT
end_NN
of_PIN
2005_CD
at_PIN
the_DT
end_NN
of_PIN
2005_CD
with_PIN
five_CD
major_JJ
vaccine_NN
launches_NN
70_CD
%_NN
increase_NN
over_IN
2001_CD
anticipated_VBN [PRIV]
in_PIN
the_DT
next_JJ
five_CD
years_NN
35_CD
%_NN
27_CD
%_NN
market_NN
share_NN
by_PIN
value_NN
of_PIN
market_NN
share_NN
by_PIN
value_NN
of_PIN
Avandia_NN
Avandamet_NN
in_PIN
the_DT
USA_NN
Seretide_NN
Advair_NN
in_PIN
Europe_NN
increase_NN
of_PIN
6_CD
percentage_NN
increase_NN
of_PIN
2_CD
percentage_NN
points_NN
over_IN
2004_CD
points_NN
over_IN
2004_CD
380m_CD
136m_JJ
value_NN
of_PIN
community_NOMZ
albendazole_NN
tablets_NN
donated_VBD
investment_NOMZ
in_PIN
2005_CD
to_TO
help_VB
eliminate_VB
lymphatic_JJ
lariasis_NN
equivalent_NN
to_PIN
5.6_CD
%_NN
of_PIN
profit_NN
before_IN
tax_NN
GSK_NN
Annual_JJ
Review_NN
2005_CD
14_CD
Business_NOMZ
operating_GER
review_NN
for_PIN
the_DT
year_NN
to_PIN
31st_CD
December_NN
2005_CD
Excellent_JJ
2005_CD
performance_NN
for_PIN
GSK_NN
Pharmaceuticals_NN
Within_PIN
Anti-virals_NN
,_,
HIV_NN
product_NN
sales_NN
grew_VBD
5_CD
%_NN
to_PIN
1.6_CD
GSK_NN
continues_VPRT
to_TO
be_VB [BEMA]
the_DT
global_JJ
leader_NN
in_PIN
respiratory_JJ
billion_CD
,_,
with_PIN
sales_NN
from_PIN
new_JJ
products_NN
Epzicom_NN
Kivexa_NN
and_PHC
pharmaceuticals_NN
with_PIN
sales_NN
of_PIN
its_PIT
three_CD
key_JJ
products_NN
,_,
Lexiva_NN
together_RB
more_EMPH
than_PIN
doubling_VBG
to_PIN
226_CD
million_CD
Seretide_NN
Advair_NN
,_,
Flixotide_NN
Flovent_NN
and_PHC
Serevent_NN
,_,
amounting_VBG
offsetting_VBG
the_DT
performance_NN
of_PIN
Trizivir_NN
down_IN
6_CD
%_NN
to_PIN
303_CD
to_PIN
4.0_CD
billion_CD
,_,
up_RB
15_CD
%_NN
._.
Sales_NN
of_PIN
Seretide_NN
Advair_NN
,_,
the_DT
million_CD
and_CC
Epivir_NN
down_IN
12_CD
%_NN
to_PIN
261_CD
million_CD
._.
Sales_NN
of_PIN
Groups_NN
largest_JJ
product_NN
grew_VBD
22_CD
%_NN
to_PIN
3.0_CD
billion_CD
._.
the_DT
herpes_NN
treatment_NOMZ
Valtrex_NN
grew_VBD
21_CD
%_NN
to_PIN
695_CD
million_CD
._.
Performance_NN
is_VPRT
being_VBG [BYPA]
driven_VBN
by_PIN
the_DT
USA_NN
up_IN
26_CD
%_NN
to_PIN
470_CD
In_PIN
the_DT
USA_NN
,_,
Advair_NN
sales_NN
rose_VBD
26_CD
%_NN
to_PIN
1.7_CD
billion_CD
,_,
with_PIN
million_CD
where_RB
the_DT
product_NN
is_VPRT [BEMA]
the_DT
clear_JJ
market_NN
leader_NN
in_PIN
continued_JJ
gains_NN
in_PIN
market_NN
share_NN
throughout_PIN
the_DT
year_NN
._.
Sales_NN
were_VBD [BEMA]
strong_PRED
in_PIN
both_DT
European_JJ
and_PHC
International_JJ
markets_NN
both_DT
up_RB
16_CD
%_NN
to_PIN
1_CD
billion_CD
and_CC
0.3_CD
billion_CD
Anti-bacterial_JJ
anti-malarial_JJ
sales_NN
declined_VBD
3_CD
%_NN
worldwide_JJ
respectively_RB
._.
and_ANDC
27_CD
%_NN
in_PIN
the_DT
USA_NN
reecting_VBG [WZPRES]
generic_JJ
competition_NOMZ
._.
Pharmaceutical_NN
turnover_NN
by_PIN
therapeutic_JJ
area_NN
:_:
GSK_NN
turnover_NN
in_PIN
2005_CD
grew_VBD
7_CD
%_NN
,_,
driven_VBN [PASTP]
by_PIN
2005_CD
2004_CD
Growth_NN
m_NN
m_NN
CER_NN
%_NN
the_DT
growth_NN
of_PIN
key_JJ
products_NN
Respiratory_NN
5,054_CD
4,394_CD
14_CD
Central_NN
nervous_JJ
system_NN
3,219_CD
3,462_CD
8_CD
Central_NN
nervous_JJ
system_NN
CNS_NN
sales_NN
declined_VBD
8_CD
%_NN
to_PIN
3.2_CD
Anti-virals_NN
2,598_CD
2,359_CD
9_CD
billion_CD
._.
Total_JJ
Paxil_NN
sales_NN
fell_VBD
42_CD
%_NN
to_PIN
615_CD
million_CD
,_,
due_JJ
to_PIN
Anti-bacterials_JJ
generic_JJ
competition_NOMZ
and_CC
the_DT
interruption_NOMZ
in_PIN
supply_NN
to_PIN
Paxil_NN
anti-malarials_NN
1,519_CD
1,547_CD
3_CD
CR_NN
during_PIN
the_DT
year_NN
._.
Partially_DWNT
mitigating_VBG
this_DEMO
decline_NN
was_VBD
Metabolic_NN
1,495_CD
1,251_CD
18_CD
the_DT
strong_JJ
performance_NN
of_PIN
the_DT
product_NN
in_PIN
Japan_NN
,_,
up_IN
17_CD
%_NN
Vaccines_NN
1,389_CD
1,194_CD
15_CD
to_PIN
197_CD
million_CD
._.
Oncology_NN
and_PHC
emesis_NN
1,016_CD
934_CD
8_CD
Total_JJ
Wellbutrin_NN
product_NN
sales_NN
fell_VBD
2_CD
%_NN
to_PIN
739_CD
million_CD
._.
Cardiovascular_NN
and_PHC
Wellbutrin_NN
IR_NN
and_PHC
SR_NN
sales_NN
fell_VBD
68_CD
%_NN
to_PIN
92_CD
million_CD
due_JJ
to_PIN
urogenital_JJ
1,331_CD
932_CD
41_CD
generic_JJ
competition_NOMZ
but_CC
this_DEMP
was_VBD [SPAU] [BYPA]
largely_RB
offset_VBN
by_PIN
the_DT
Other_JJ
1,040_CD
1,027_CD
very_AMP
strong_JJ
performance_NN
of_PIN
Wellbutrin_NN
XL_NN
up_IN
38_CD
%_NN
to_PIN
647_CD
million_CD
._.
18,661_CD
17,100_CD
8_CD
In_PIN
Metabolic_NN
,_,
the_DT
diabetes_NN
treatments_NOMZ
Avandia_NN
Avandamet_NN
GSKs_NN
underlying_VBG [WZPRES]
growth_NN
was_VBD [BYPA]
driven_VBN
by_PIN
continue_VPRT
to_TO
perform_VB
very_AMP
strongly_AMP
,_,
with_PIN
overall_JJ
sales_NN
of_PIN
strong_JJ
sales_NN
performance_NN
of_PIN
key_JJ
products_NN
:_:
1.3_CD
billion_CD
up_IN
18_CD
%_NN
._.
In_PIN
the_DT
USA_NN
,_,
sales_NN
grew_VBD
14_CD
%_NN
to_PIN
977_CD
million_CD
._.
Avandia_NN
Avandamet_NN
is_VPRT [SPAU]
also_RB
establishing_VBG [PRIV]
a_DT
Seretide_NN
Advair_NN
3.0_CD
billion_CD
up_IN
22_CD
%_NN
strong_JJ
position_NOMZ
in_PIN
Europe_NN
,_,
with_PIN
sales_NN
rising_VBG [WZPRES]
52_CD
%_NN
to_PIN
157_CD
Vaccines_NN
1.4_CD
billion_CD
up_IN
15_CD
%_NN
million_CD
helped_VBN
by_PIN
the_DT
launch_NN
of_PIN
Avandamet_NN
throughout_PIN
the_DT
region_NN
._.
Sales_NN
in_PIN
International_JJ
markets_NN
rose_VBD
13_CD
%_NN
to_PIN
Avandia_NN
Avandamet_NN
1.3_CD
billion_CD
up_IN
18_CD
%_NN
195_CD
million_CD
._.
Lamictal_JJ
0.8_CD
billion_CD
up_IN
24_CD
%_NN
Boniva_NN
Bonviva_NN
,_,
a_DT
new_JJ
once-monthly_JJ
oral_JJ
bisphosphonate_NN
Valtrex_NN
0.7_CD
billion_CD
up_IN
21_CD
%_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
osteoporosis_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
developed_VBN
Coreg_NN
0.6_CD
billion_CD
up_IN
32_CD
%_NN
with_PIN
Roche_NN
,_,
had_VBD
a_DT
strong_JJ
launch_NN
in_PIN
the_DT
USA_NN
and_CC
now_TIME
has_VPRT
a_DT
10_CD
%_NN
share_NN
of_PIN
new_JJ
prescriptions_NOMZ
for_PIN
oral_JJ
bisphosphonates_NN
._.
Boniva_NN
injection_NOMZ
,_,
the_DT
first-ever_JJ
quarterly_JJ
The_DT
strong_JJ
growth_NN
of_PIN
GSKs_NN
epilepsy_NN
and_CC
bi-polar_JJ
disorder_NN
treatment_NOMZ
for_PIN
osteoporosis_NN
,_,
was_VBD [PASS]
approved_VBN
in_PIN
the_DT
USA_NN
in_PIN
treatment_NOMZ
Lamictal_NN
continued_VBD
,_,
with_PIN
sales_NN
up_IN
24_CD
%_NN
to_PIN
849_CD
January_NN
2006_CD
and_CC
received_VBD
a_DT
positive_JJ
opinion_NN
from_PIN
the_DT
million_CD
,_,
driven_VBN [PASTP]
by_PIN
the_DT
indication_NOMZ
for_PIN
the_DT
maintenance_NN
CHMP_NN
in_PIN
Europe_NN
on_PIN
27th_JJ
January_NN
2006_CD
._.
treatment_NOMZ
of_PIN
bi-polar_JJ
disorder_NN
._.
The_DT
vaccines_NN
business_NOMZ
performed_VBD
well_RB
with_PIN
total_JJ
sales_NN
Requip_NN
sales_NN
rose_VBD
34_CD
%_NN
to_PIN
156_CD
million_CD
following_VBG
its_PIT
launch_NN
rising_VBG [WZPRES]
15_CD
%_NN
to_PIN
1.4_CD
billion_CD
,_,
led_VBN [PASTP]
by_PIN
Infanrix_NN
._.
Vaccine_NN
sales_NN
in_PIN
the_DT
USA_NN
for_PIN
Restless_NN
Legs_NN
Syndrome_NN
RLS_NN
in_PIN
Q2_NN
2005_CD
._.
were_VBD [BEMA]
particularly_RB
strong_PRED
in_PIN
the_DT
USA_NN
,_,
where_RB
turnover_NN
rose_VBD
In_PIN
Europe_NN
,_,
final_JJ
approval_NN
of_PIN
Requip_NN
Adartrel_NN
for_PIN
RLS_NN
is_VPRT [BEMA]
26_CD
%_NN
to_PIN
338_CD
million_CD
,_,
helped_VBN [PASTP]
by_PIN
the_DT
launch_NN
of_PIN
two_CD
new_JJ
expected_VBN [PRIV]
in_PIN
the_DT
first_JJ
half_NN
of_PIN
2006_CD
._.
products_NN
Fluarix_NN
and_PHC
Boostrix_NN
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
15_CD
Business_NOMZ
operating_GER
review_NN
continued_VBD
In_PIN
Oncology_NN
and_PHC
emesis_NN
,_,
sales_NN
of_PIN
Zofran_NN
grew_VBD
9_CD
%_NN
to_PIN
837_CD
Operating_GER
profit_NN
million_CD
,_,
driven_VBN [PASTP]
by_PIN
the_DT
US_FPP1
performance_NN
,_,
which_WDT [SERE]
was_VBD [BEMA]
up_RB
12_CD
%_NN
The_DT
operating_GER
profit_NN
margin_NN
increased_VBD
2.9_CD
percentage_NN
to_PIN
639_CD
million_CD
._.
points_NN
as_IN
operating_GER
profit_NN
of_PIN
6,874_CD
million_CD
increased_VBD
19_CD
%_NN
in_PIN
sterling_GER
terms_NN
._.
At_PIN
constant_JJ
exchange_NN
rates_NN
In_PIN
Cardiovascular_NN
and_CC
urogenital_JJ
,_,
Coreg_NN
for_PIN
heart_NN
disease_NN
operating_GER
profit_NN
increased_VBD
16_CD
%_NN
and_CC
the_DT
margin_NN
increased_VBD
sales_NN
grew_VBD
32_CD
%_NN
to_PIN
573_CD
million_CD
._.
Avodart_NN
for_PIN
benign_JJ
2.5_CD
percentage_NN
points_NN
._.
prostatic_JJ
hyperplasia_NN
enlarging_VBG [WZPRES]
prostate_NN
had_VBD
a_DT
very_AMP
strong_JJ
year_NN
with_PIN
sales_NN
more_EMPH
than_PIN
doubling_VBG
to_PIN
129_CD
million_CD
._.
By_PIN
This_DEMP
reected_VBD
lower_JJ
charges_NN
relating_VBG [WZPRES]
to_PIN
legal_JJ
matters_NN
and_PHC
January_NN
2006_CD
the_DT
product_NN
accounted_VBD
for_PIN
42_CD
%_NN
of_PIN
new_JJ
share-based_JJ
payments_NOMZ
,_,
higher_JJ
product_NN
and_PHC
asset_NN
disposals_NN
prescriptions_NOMZ
in_PIN
the_DT
US_FPP1
5-Alpha_NN
Reductase_NN
Inhibitor_NN
market_NN
._.
and_ANDC
increases_NN
in_PIN
advertising_GER
,_,
promotion_NOMZ
and_PHC
selling_GER
that_TSUB
were_VBD
below_PLACE
the_DT
rate_NN
of_PIN
turnover_NN
growth_NN
._.
Partially_DWNT
offsetting_VBG
these_DEMO
items_NN
were_VBD [BEMA]
higher_JJ
costs_NN
related_VBN [WZPAST]
to_PIN
GSKs_NN
submissions_NN
to_PIN
the_DT
regulatory_JJ
authorities_NOMZ
programs_NN
to_TO
deliver_VB
future_JJ
cost_NN
savings_GER
and_CC
increased_VBN
in_PIN
the_DT
USA_NN
and_PHC
EU_NN
for_PIN
the_DT
first_JJ
time_NN
and_PHC
R&D_NN
expenditure_NN
._.
approvals_NN
during_PIN
2005_CD
were_VBD
:_:
Taxation_NOMZ
USA_NN
Europe_NN
The_DT
charge_NN
for_PIN
taxation_NOMZ
on_PIN
profit_NN
,_,
amounting_VBG [PRESP]
to_PIN
1,916_CD
Submission_NN
5_CD
7_CD
million_CD
,_,
represents_VPRT
an_DT
effective_JJ
tax_NN
rate_NN
of_PIN
28.5_CD
%_NN
2004_CD
Approval_NN
6_CD
6_CD
30.4_CD
%_NN
._.
The_DT
tax_NN
rate_NN
in_PIN
2005_CD
of_PIN
28.5_CD
%_NN
benefited_VBD
from_PIN
11_CD
13_CD
higher_JJ
tax_NN
relief_NN
on_PIN
actual_JJ
or_CC
potential_JJ
exercise_NN
of_PIN
share_NN
options_NOMZ
by_PIN
employees_NN
,_,
arising_VBG [PRESP]
from_PIN
the_DT
increase_NN
in_PIN
the_DT
share_NN
price_NN
in_PIN
the_DT
year_NN
._.
Product_NN
supply_NN
Following_VBG [WZPRES]
FDA_NN
inspections_NOMZ
in_PIN
2003_CD
and_CC
2004_CD
,_,
which_WDT [SERE]
identied_VBD
possible_JJ
deficiencies_NN
in_PIN
manufacturing_VBG
practices_NN
EPS_NN
82.6_CD
pence_NN
,_,
growth_NN
of_PIN
18_CD
%_NN
at_PIN
the_DT
Groups_NN
facility_NOMZ
at_PIN
Cidra_NN
in_PIN
Puerto_NN
Rico_NN
,_,
the_DT
FDA_NN
halted_VBD
distribution_NOMZ
of_PIN
supplies_NN
of_PIN
Paxil_NN
CR_NN
and_PHC
Avandamet_NN
Earnings_GER
per_PIN
share_NN
in_PIN
March_NN
2005_CD
._.
This_DEMO
site_NN
is_VPRT [PASS]
engaged_VBN
in_PIN
tableting_VBG
and_CC
Full_NN
year_NN
earnings_GER
per_PIN
share_NN
EPS_NN
of_PIN
82.6_CD
pence_NN
increased_VBD
packaging_GER
for_PIN
a_DT
range_NN
of_PIN
GSK_NN
products_NN
primarily_RB
for_PIN
18_CD
%_NN
._.
At_PIN
actual_JJ
rates_NN
of_PIN
exchange_NN
,_,
earnings_GER
per_PIN
share_NN
the_DT
US_FPP1
market_NN
._.
In_PIN
April_NN
2005_CD
,_,
the_DT
Group_NN
reached_VBD
increased_VBN
21_CD
%_NN
._.
The_DT
favourable_JJ
currency_NN
impact_NN
on_PIN
EPS_NN
agreement_NOMZ
with_PIN
the_DT
FDA_NN
on_PIN
a_DT
Consent_NN
Decree_NN
,_,
which_WDT [SERE]
of_PIN
three_CD
percentage_NN
points_NN
reects_VPRT
a_DT
strengthening_GER
of_PIN
provides_VPRT
for_PIN
an_DT
independent_JJ
review_NN
of_PIN
manufacturing_VBG
at_PIN
the_DT
US_FPP1
dollar_NN
and_PHC
Euro_NN
relative_JJ
to_PIN
2004_CD
and_CC
compares_VPRT
the_DT
site_NN
for_PIN
compliance_NN
with_PIN
FDA_NN
requirements_NOMZ
._.
The_DT
Decree_NN
with_PIN
a_DT
1_CD
%_NN
favourable_JJ
currency_NN
impact_NN
on_PIN
turnover_NN
._.
This_DEMO
also_RB
allows_VPRT [SUAV]
for_PIN
potential_JJ
future_JJ
penalties_NN
if_COND
GSK_NN
fails_VPRT
to_PIN
difference_NN
principally_RB
arises_VPRT
from_PIN
a_DT
different_JJ
mix_NN
of_PIN
meet_VB
its_PIT
terms_NN
._.
In_PIN
June_NN
2005_CD
,_,
the_DT
Group_NN
began_VBD
recurrencies_NN
in_PIN
profits_NN
compared_VBN [WZPAST]
with_PIN
turnover_NN
._.
supplying_VBG [PRESP]
the_DT
US_FPP1
and_CC
other_JJ
markets_NN
with_PIN
both_DT
Paxil_NN
CR_NN
and_PHC
Avandamet_NN
._.
The_DT
sales_NN
of_PIN
these_DEMO
products_NN
were_VBD [SPAU] [PASS]
signicantly_RB
impacted_VBN
in_PIN
2005_CD
by_PIN
this_DEMO
interruption_NOMZ
in_PIN
supply_NN
._.
Presentation_NOMZ
The_DT
impact_NN
upon_PIN
Avandamet_NN
was_VBD [BYPA]
mitigated_VBN
by_PIN
the_DT
With_PIN
effect_NN
from_PIN
1st_CD
January_NN
2005_CD
,_,
GSK_NN
has_VPRT [PEAS]
moved_VBN [SUAV]
switching_GER
of_PIN
patients_NN
to_PIN
Avandia_NN
._.
For_PIN
further_JJ
details_NN
see_VPRT [PRIV]
to_TO
reporting_VBG [PUBV]
its_PIT
financial_JJ
results_NN
in_PIN
accordance_NN
with_PIN
Note_NN
41_CD
to_PIN
the_DT
financial_JJ
statements_NOMZ
,_,
Legal_NN
proceedings_GER
,_,
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
as_IN
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
._.
adopted_VBN [PASTP]
for_PIN
use_NN
in_PIN
the_DT
European_NN
Union_NN
._.
Consumer_NN
Healthcare_NN
sales_NN
All_QUAN
comparative_JJ
gures_NN
are_VPRT [PASS]
presented_VBN
on_PIN
this_DEMO
basis_NN
,_,
The_DT
growth_NN
in_PIN
Consumer_NN
Healthcare_NN
sales_NN
of_PIN
2_CD
%_NN
to_PIN
except_PIN
that_DEMO
GSK_NN
has_VPRT [PEAS]
taken_VBN
advantage_NN
of_PIN
an_DT
2,999_CD
million_CD
comprised_VBD
an_DT
OTC_NN
medicines_NN
sales_NN
increase_NN
exemption_NOMZ
which_WDT [WHSUB]
permits_VPRT
financial_JJ
instruments_NOMZ
to_TO
be_VB [BEMA]
of_PIN
1_CD
%_NN
to_PIN
1,437_CD
million_CD
,_,
a_DT
Nutritional_NN
healthcare_NN
sales_NN
accounted_VBD
for_PIN
and_CC
presented_VBN
on_PIN
a_DT
UK_NN
GAAP_NN
basis_NN
in_PIN
increase_NN
of_PIN
7_CD
%_NN
to_PIN
619_CD
million_CD
and_CC
an_DT
Oral_JJ
care_NN
sales_NN
2004_CD
and_CC
2003_CD
and_CC
only_DWNT
in_PIN
accordance_NN
with_PIN
IAS_NN
32_CD
increase_NN
of_PIN
2_CD
%_NN
to_PIN
943_CD
million_CD
._.
Full_JJ
details_NN
of_PIN
the_DT
major_JJ
differences_NN
from_PIN
UK_NN
GAAP_NN
as_IN
they_TPP3
apply_VPRT
to_PIN
GSK_NN
In_PIN
OTC_NN
,_,
growth_NN
from_PIN
analgesics_NN
,_,
up_RB
6_CD
%_NN
,_,
and_ANDC
respiratory_JJ
are_VPRT [PASS]
given_VBN
in_PIN
Note_NN
40_CD
to_PIN
the_DT
financial_JJ
statements_NOMZ
f_LS
tract_NN
,_,
up_IN
5_CD
%_NN
,_,
helped_VBD
offset_VB
the_DT
loss_NN
of_PIN
sales_NN
from_PIN
the_DT
Transition_NOMZ
to_PIN
IFRS_NN
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
._.
dermatological_JJ
products_NN
divested_VBN [WZPAST]
in_PIN
2004_CD
._.
In_PIN
Oral_JJ
care_NN
,_,
sales_NN
of_PIN
Sensodyne_NN
and_CC
the_DT
denture_NN
care_NN
In_PIN
order_NN
to_TO
illustrate_VB
underlying_VBG
performance_NN
,_,
it_PIT
is_VPRT [BEMA]
the_DT
brands_NN
Polident_NN
,_,
Poligrip_NN
and_PHC
Corega_NN
grew_VBD
by_PIN
12_CD
%_NN
and_PHC
Groups_NN
practice_NN
to_TO
discuss_VB
its_PIT
results_NN
in_PIN
terms_NN
of_PIN
6_CD
%_NN
,_,
respectively_RB
,_,
helping_VBG
to_TO
offset_VB
lower_JJ
sales_NN
of_PIN
other_JJ
constant_JJ
exchange_NN
rate_NN
CER_NN
growth_NN
._.
growth_NN
calculated_VBN [PRIV]
as_IN
if_COND
the_DT
exchange_NN
rates_NN
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
results_NN
of_PIN
overseas_PLACE
companies_NN
in_PIN
sterling_GER
Within_PIN
Nutritional_NN
,_,
Lucozade_NN
,_,
up_RB
11_CD
%_NN
,_,
continued_VBD
to_TO
grow_VB
had_VBD [PEAS]
remained_VBN
unchanged_JJ
from_PIN
those_DEMP
used_VBN
in_PIN
the_DT
strongly_AMP
in_PIN
Europe_NN
._.
All_QUAN
commentaries_NN
are_VPRT [PASS]
presented_VBN
in_PIN
terms_NN
of_PIN
CER_NN
unless_COND
otherwise_CONJ
stated_VBN [PUBV]
._.
On_PIN
23rd_JJ
January_NN
2006_CD
,_,
an_DT
FDA_NN
Advisory_NN
Committee_NN
recommended_VBD [SUAV]
that_THVC
Alli_NN
orlistat_NN
be_VB [PASS]
approved_VBN
for_PIN
over-thecounter_JJ
use_NN
in_PIN
the_DT
USA_NN
to_TO
promote_VB
weight_NN
loss_NN
in_PIN
overweight_JJ
adults_NN
,_,
when_RB
used_VBN
along_IN
with_PIN
a_DT
reduced_VBN
calorie_NN
,_,
low-fat_JJ
diet_NN
._.
If_COND
approved_VBN
,_,
Alli_NN
will_PRMD
be_VB [BEMA]
the_DT
only_DWNT
FDAapproved_NN
weight-loss_JJ
drug_NN
available_JJ
over-the-counter_JJ
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
16_CD
Business_NOMZ
operating_GER
review_NN
continued_VBD
Dividend_NN
Tax_NN
issues_NN
The_DT
Board_NN
has_VPRT [PEAS]
declared_VBN [PUBV]
a_DT
fourth_JJ
interim_JJ
dividend_NN
of_PIN
14_CD
The_DT
Group_NN
has_VPRT
open_JJ
issues_NN
with_PIN
the_DT
revenue_NN
authorities_NOMZ
pence_NN
per_PIN
share_NN
,_,
resulting_VBG [PRESP]
in_PIN
a_DT
dividend_NN
for_PIN
the_DT
year_NN
of_PIN
44_CD
in_PIN
the_DT
USA_NN
,_,
UK_NN
,_,
Japan_NN
and_PHC
Canada_NN
:_:
by_PIN
far_PLACE
the_DT
largest_JJ
pence_NN
per_PIN
share_NN
,_,
a_DT
2_CD
pence_NN
increase_NN
over_IN
the_DT
dividend_NN
of_PIN
relates_VPRT
to_PIN
Glaxo_NN
heritage_NN
products_NN
,_,
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
42_CD
pence_NN
per_PIN
share_NN
for_PIN
2004_CD
._.
US_FPP1
Internal_NN
Revenue_NN
Service_NN
IRS_NN
and_PHC
HM_NN
Revenue_NN
&_CC
Customs_NN
HMRC_NN
in_PIN
the_DT
UK_NN
have_VPRT [PEAS]
made_VBN
competing_VBG
and_CC
contradictory_JJ
claims_NN
._.
2_CD
pence_NN
increase_NN
in_PIN
dividend_NN
resulting_VBG [WZPRES]
in_PIN
44_CD
GSK_NN
has_VPRT [PEAS]
attempted_VBN
to_TO
settle_VB
the_DT
US_FPP1
dispute_NN
,_,
first_RB
through_PIN
pence_NN
for_PIN
the_DT
year_NN
direct_JJ
discussion_NN
with_PIN
the_DT
IRS_NN
and_CC
subsequently_TIME
through_PIN
discussions_NN
between_PIN
the_DT
US_FPP1
and_PHC
UK_NN
authorities_NOMZ
under_IN
Cash_NN
ow_VBD
the_DT
terms_NN
of_PIN
the_DT
double_JJ
tax_NN
convention_NOMZ
between_PIN
the_DT
two_CD
The_DT
net_JJ
cash_NN
inow_NN
from_PIN
operating_VBG
activities_NOMZ
after_IN
taxation_NOMZ
countries_NN
:_:
these_DEMO
discussions_NN
were_VBD [PASS]
terminated_VBN
in_PIN
July_NN
2003_CD
._.
paid_VBN
was_VBD [BEMA]
5,958_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
1,014_CD
million_CD
On_PIN
6th_JJ
January_NN
2004_CD
,_,
the_DT
IRS_NN
issued_VBD
a_DT
Notice_NN
of_PIN
over_IN
2004_CD
,_,
arising_VBG [PRESP]
principally_RB
due_JJ
to_PIN
higher_JJ
operating_VBG
deficiency_NN
for_PIN
the_DT
years_NN
1989-1996_CD
claiming_VBG [PUBV]
additional_JJ
profits_NN
._.
The_DT
net_JJ
cash_NN
outow_NN
from_PIN
investing_VBG
activities_NOMZ
was_VBD [BEMA]
1,660_CD
On_PIN
2nd_JJ
April_NN
2004_CD
,_,
the_DT
Group_NN
led_VBD
a_DT
petition_NOMZ
in_PIN
the_DT
US_FPP1
Tax_NN
million_CD
,_,
an_DT
increase_NN
of_PIN
740_CD
million_CD
which_WDT
reected_VBD
the_DT
Court_NN
disputing_VBG [WZPRES]
the_DT
IRS_NN
claim_NN
and_CC
seeking_VBG
a_DT
refund_NN
of_PIN
$_$
1_CD
purchase_NN
of_PIN
Corixa_NN
and_PHC
ID_NN
Biomedical_NN
in_PIN
2005_CD
for_PIN
over_IN
1_CD
billion_CD
in_PIN
taxes_NN
._.
On_PIN
25th_JJ
January_NN
2005_CD
the_DT
IRS_NN
issued_VBD
a_DT
billion_CD
purchases_NN
of_PIN
businesses_NOMZ
in_PIN
2004_CD
were_VBD [BEMA]
0.3_CD
billion_CD
._.
further_RB
Notice_NN
of_PIN
deficiency_NN
for_PIN
the_DT
years_NN
1997-2000_CD
claiming_VBG [PUBV]
additional_JJ
federal_JJ
taxes_NN
of_PIN
$_$
1.9_CD
billion_CD
,_,
which_WDT [SERE]
the_DT
Free_NN
cash_NN
ow_NN
was_VBD [BEMA]
4.7_CD
billion_CD
,_,
an_DT
increase_NN
of_PIN
26_CD
%_NN
over_IN
Group_NN
contested_VBN [WZPAST]
by_PIN
ling_VBG
a_DT
petition_NOMZ
in_PIN
the_DT
US_FPP1
Tax_NN
Court_NN
on_PIN
2004_CD
._.
Free_NN
cash_NN
ow_NN
is_VPRT [BEMA]
the_DT
amount_NN
of_PIN
cash_NN
generated_VBN [WZPAST]
by_PIN
12th_JJ
April_NN
2005_CD
,_,
to_PIN
which_WDT [PIRE]
the_DT
IRS_NN
led_VBD
its_PIT
statutory_JJ
Answer_NN
the_DT
business_NOMZ
after_IN
meeting_VBG
its_PIT
obligations_NOMZ
for_PIN
interest_NN
,_,
tax_NN
on_PIN
7th_JJ
June_NN
2005_CD
._.
In_PIN
September_NN
2005_CD
,_,
the_DT
Court_NN
agreed_VBD [SUAV] [PUBV]
and_CC
dividends_NN
paid_VBN [WZPAST]
to_PIN
minority_NOMZ
interests_NN
,_,
and_ANDC
after_IN
capital_NN
to_TO
consolidate_VB
the_DT
IRS_NN
claims_NN
for_PIN
1997-2000_CD
with_PIN
those_DEMO
for_PIN
expenditure_NN
on_PIN
non-current_JJ
tangible_JJ
and_PHC
intangible_JJ
assets_NN
._.
The_DT
total_JJ
claims_NN
for_PIN
these_DEMO
periods_NN
amount_NN
to_TO
$_$
4.6_CD
billion_CD
of_PIN
additional_JJ
federal_JJ
taxes_NN
Outlook_NN
and_CC
related_JJ
interest_NN
to_PIN
31st_CD
December_NN
2005_CD
of_PIN
$_$
3.7_CD
billion_CD
,_,
Seven_CD
Pharmaceutical_NN
products_NN
expected_VBN [PRIV]
to_TO
be_VB [BEMA]
net_PRED
of_PIN
federal_JJ
tax_NN
relief_NN
,_,
giving_VBG [PRESP]
a_DT
total_NN
of_PIN
$_$
8.3_CD
billion_CD
._.
The_DT
Groups_NN
petitions_NOMZ
against_PIN
the_DT
IRS_NN
claims_NN
include_VPRT
counterapproved_VBN
launched_VBN
in_PIN
2006_CD
:_:
claims_NN
for_PIN
repayment_NOMZ
of_PIN
federal_JJ
taxes_NN
totalling_VBG [WZPRES]
$_$
1.8_CD
billion_CD
,_,
Rotarix_NN
for_PIN
rotavirus_NN
based_VBN [WZPAST]
partly_DWNT
by_PIN
reference_NN
to_PIN
an_DT
Advance_NN
Pricing_GER
Agreement_NOMZ
Entereg_NN
for_PIN
post-operative_JJ
bowel_NN
disorders_NN
APA_NN
between_PIN
SmithKline_NN
Beecham_NN
and_CC
the_DT
IRS_NN
covering_VBG [WZPRES]
the_DT
transfer_NN
pricing_GER
of_PIN
Tagamet_NN
between_PIN
1991_CD
and_CC
1993_CD
._.
Trexima_NN
for_PIN
migraine_NN
On_PIN
23rd_JJ
December_NN
2004_CD
,_,
the_DT
IRS_NN
led_VBD
a_DT
motion_NOMZ
for_PIN
Avandaryl_NN
for_PIN
diabetes_NN
summary_NN
judgement_NOMZ
to_TO
exclude_VB
any_QUAN
evidence_NN
relating_VBG [WZPRES]
to_PIN
Coreg_NN
CR_NN
for_PIN
heart_NN
failure_NN
APAs_NN
from_PIN
the_DT
court_NN
proceedings_GER
._.
On_PIN
31st_CD
March_NN
2005_CD
,_,
Arranon_NN
for_PIN
cancer_NN
the_DT
trial_NN
judge_NN
denied_VBD [PUBV]
the_DT
IRS_NN
motion_NOMZ
and_CC
reserved_VBN
ruling_NN
on_PIN
the_DT
admissibility_NOMZ
of_PIN
APA_NN
evidence_NN
until_IN
full_JJ
trial_NN
,_,
which_WDT [SERE]
Altabax_NN
for_PIN
infections_NOMZ
is_VPRT [PASS]
scheduled_VBN
to_TO
commence_VB
on_PIN
16th_JJ
October_NN
2006_CD
._.
Legal_JJ
proceedings_GER
As_IN
similar_JJ
tax_NN
issues_NN
remain_VPRT
open_JJ
for_PIN
2001_CD
to_PIN
date_NN
,_,
GSK_NN
The_NN
Group_NN
is_VPRT [PASS]
involved_VBN
in_PIN
patent_NN
litigation_NOMZ
with_PIN
expects_VPRT [PRIV]
to_TO
receive_VB
further_JJ
substantial_JJ
claims_NN
by_PIN
the_DT
IRS_NN
for_PIN
manufacturers_NN
seeking_VBG [WZPRES]
to_PIN
market_NN
generic_JJ
versions_NN
of_PIN
these_DEMO
years_NN
._.
GSK_NN
continues_VPRT
to_TO
believe_VB [PRIV]
that_THVC
the_DT
profits_NN
many_QUAN
of_PIN
the_DT
Groups_NN
most_EMPH
important_JJ
products_NN
,_,
including_VBG
reported_VBN [PUBV]
by_PIN
its_PIT
US_FPP1
subsidiaries_NN
for_PIN
the_DT
period_NN
1989_CD
to_PIN
date_NN
,_,
Wellbutrin_NN
,_,
Seretide_NN
,_,
Avandia_NN
,_,
Imitrex_NN
,_,
Valtrex_NN
,_,
Lamictal_NN
on_PIN
which_WDT [PIRE]
it_PIT
has_VPRT [PEAS]
paid_VBN
taxes_NN
in_PIN
the_DT
USA_NN
,_,
are_VPRT [BEMA]
more_EMPH
than_PIN
and_CC
Zofran_NN
,_,
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
._.
sufficient_JJ
to_TO
reect_VB
the_DT
activities_NOMZ
of_PIN
its_PIT
US_FPP1
operations_NOMZ
._.
The_DT
Group_NN
is_VPRT [BEMA]
currently_RB
a_DT
defendant_NN
in_PIN
a_DT
number_NN
of_PIN
product_NN
However_CONJ
,_,
the_DT
Group_NN
tax_NN
creditor_NN
balance_NN
at_PIN
31st_CD
liability_NOMZ
lawsuits_NN
,_,
including_VBG
class_NN
actions_NOMZ
,_,
that_DEMP
involve_VPRT
December_NN
2005_CD
of_PIN
2.3_CD
billion_CD
2004_CD
1.8_CD
billion_CD
substantial_JJ
claims_NN
for_PIN
damages_NN
related_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
includes_VPRT
a_DT
provision_NN
for_PIN
the_DT
estimated_VBN [PRIV]
amount_NN
at_PIN
which_WDT [PIRE]
pharmaceutical_JJ
products_NN
._.
The_DT
Group_NN
is_VPRT [BEMA]
also_RB
a_DT
defendant_NN
the_DT
IRS_NN
dispute_NN
might_POMD [SPAU]
ultimately_RB
be_VB [PASS]
settled_VBN
._.
in_PIN
anti-trust_JJ
actions_NOMZ
led_VBD
following_VBG
adverse_JJ
outcomes_NN
in_PIN
If_COND
the_DT
IRS_NN
were_VBD
to_TO
follow_VB
the_DT
same_JJ
methodology_NN
as_IN
applied_VBN
prosecution_NOMZ
of_PIN
patent_NN
infringement_NOMZ
actions_NOMZ
._.
Further_RB
,_,
the_DT
previously_TIME
in_PIN
respect_NN
of_PIN
these_DEMO
later_TIME
years_NN
,_,
GSK_NN
estimates_VPRT [PRIV] [THATD]
Group_NN
is_VPRT
responding_VBG
to_PIN
federal_JJ
and_CC
state_NN
governmental_JJ
that_THAC
the_DT
potential_JJ
unprovided_JJ
exposure_NN
in_PIN
respect_NN
of_PIN
this_DEMO
investigations_NOMZ
in_PIN
the_DT
USA_NN
into_PIN
pricing_GER
,_,
marketing_GER
and_PHC
dispute_NN
with_PIN
the_DT
IRS_NN
for_PIN
the_DT
years_NN
1989-2005_CD
amounted_VBD
reimbursement_NOMZ
of_PIN
a_DT
number_NN
of_PIN
prescription_NOMZ
drug_NN
to_TO
approximately_RB
$_$
11.5_CD
billion_CD
at_PIN
31st_CD
December_NN
2005_CD
products_NN
._.
See_VB [PRIV]
Note_VB [PRIV]
41_CD
to_PIN
the_DT
financial_JJ
statements_NOMZ
,_,
Legal_NN
2004_CD
$_$
10.1_CD
billion_CD
._.
proceedings_GER
,_,
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
for_PIN
a_DT
discussion_NN
of_PIN
proceedings_GER
and_CC
governmental_JJ
investigations_NOMZ
in_PIN
which_WDT [PIRE]
GSK_NN
is_VPRT [BEMA]
in_PIN
continuing_VBG
discussions_NN
with_PIN
HMRC_NN
in_PIN
respect_NN
of_PIN
the_DT
Group_NN
is_VPRT [SPAU] [PASS]
currently_RB
involved_VBN
._.
UK_NN
transfer_NN
pricing_GER
and_CC
other_JJ
matters_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
in_PIN
dispute_NN
for_PIN
the_DT
years_NN
1995_CD
to_PIN
date_NN
._.
However_CONJ
,_,
little_JJ
progress_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
over_IN
the_DT
past_JJ
year_NN
and_ANDC
consequently_CONJ
these_DEMO
matters_NN
may_POMD
become_VB
subject_JJ
to_PIN
litigation_NOMZ
in_PIN
due_JJ
course_NN
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
17_CD
The_DT
Board_NN
The_NN
Board_NN
of_PIN
Directors_NN
is_VPRT [BEMA]
ultimately_RB
accountable_PRED
for_PIN
the_DT
Groups_NN
activities_NOMZ
,_,
strategy_NN
and_CC
financial_JJ
performance_NN
._.
Sir_NN
Christopher_NN
Gent_NN
Dr_NN
Jean-Pierre_NN
Garnier_NN
Lawrence_NN
Culp_NN
Sir_NN
Crispin_NN
Davis_NN
Julian_NN
Heslop_NN
Sir_NN
Deryck_NN
Maughan_NN
Sir_NN
Ian_NN
Prosser_NN
Dr_NN
Ronaldo_NN
Schmitz_NN
Dr_NN
Lucy_NN
Shapiro_NN
Tom_NN
fide_NN
Swaan_NN
Sir_NN
Robert_NN
Wilson_NN
Dr_NN
Tachi_NN
Yamada_NN
Sir_NN
Christopher_NN
Gent_NN
Aged_VBD
57_CD
Dr_NN
Ronaldo_NN
Schmitz_NN
Aged_VBD
67_CD
Appointed_VBN
on_PIN
1st_CD
June_NN
2004_CD
._.
Sir_NN
Christopher_NN
was_VBD [BEMA]
the_DT
Chief_NN
Appointed_VBN [WZPAST]
on_PIN
23rd_JJ
May_POMD
2000_CD
._.
Dr_NN
Schmitz_NN
was_VBD
Executive_NN
officer_NN
of_PIN
Vodafone_NN
plc_NN
,_,
until_IN
his_TPP3
retirement_NOMZ
in_PIN
July_NN
2003_CD
._.
He_TPP3
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Glaxo_NN
Wellcome_NN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Nonis_NN
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Lehman_NN
Brothers_NN
Holdings_GER
Inc_NN
,_,
a_DT
member_NN
Executive_NN
Director_NN
of_PIN
Legal_NN
&_CC
General_NN
Group_NN
plc_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
of_PIN
the_DT
Financial_NN
Reporting_GER
Council_NN
,_,
a_DT
Senior_JJ
Adviser_NN
at_PIN
Bain_NN
&_CC
Co._NN
and_PHC
Board_NN
of_PIN
Directors_NN
of_PIN
Rohm_NN
and_PHC
Haas_NN
Company_NN
and_PHC
Cabot_NN
Chairman_NN
of_PIN
the_DT
advisory_JJ
board_NN
of_PIN
Reform_NN
._.
Dr_NN
Jean-Pierre_NN
Garnier_NN
Aged_VBD
58_CD
Dr_NN
Lucy_NN
Shapiro_NN
Aged_VBD
65_CD
Appointed_VBN
on_PIN
23rd_JJ
May_POMD
2000_CD
._.
Dr_NN
Garnier_NN
was_VBD [PASS]
Appointed_VBN
on_PIN
23rd_JJ
May_POMD
2000_CD
._.
Dr_NN
Shapiro_NN
was_VBD [PASS]
appointed_VBN
an_DT
Executive_NN
Director_NN
of_PIN
SmithKline_NN
Beecham_NN
plc_NN
in_PIN
1992_CD
,_,
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
She_TPP3
is_VPRT
and_PHC
became_VBD
Chief_NN
Executive_NN
officer_NN
in_PIN
April_NN
2000_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
NonLudwig_NN
Professor_NN
of_PIN
Cancer_NN
Research_NN
in_PIN
the_DT
Department_NOMZ
of_PIN
Executive_NN
Director_NN
of_PIN
United_NN
Technologies_NN
Corporation_NOMZ
and_CC
a_DT
member_NN
Developmental_NN
Biology_NN
and_PHC
Director_NN
of_PIN
the_DT
Beckman_NN
Center_NN
for_PIN
of_PIN
the_DT
Board_NN
of_PIN
Trustees_NN
of_PIN
the_DT
Eisenhower_NN
Exchange_NN
Fellowships_NN
._.
He_TPP3
Molecular_JJ
and_PHC
Genetic_JJ
Medicine_NN
at_PIN
the_DT
Stanford_NN
University_NOMZ
School_NN
of_PIN
holds_VPRT [PRIV]
a_DT
PhD_NN
in_PIN
pharmacology_NN
from_PIN
the_DT
University_NOMZ
of_PIN
Louis_NN
Pasteur_NN
in_PIN
Medicine_NN
and_CC
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Anacor_NN
Pharmaceuticals_NN
,_,
France_NN
and_CC
an_DT
MBA_NN
from_PIN
Stanford_NN
University_NOMZ
in_PIN
the_DT
USA_NN
._.
Inc._NN
._.
She_TPP3
holds_VPRT [PRIV]
a_DT
PhD_NN
in_PIN
molecular_JJ
biology_NN
._.
Lawrence_NN
Culp_NN
Aged_VBD
42_CD
Tom_NN
fide_NN
Swaan_NN
Aged_VBD
59_CD
Appointed_VBN
on_PIN
1st_CD
July_NN
2003_CD
._.
Mr_NN
Culp_NN
is_VPRT [PASS]
Appointed_VBN
on_PIN
1st_CD
January_NN
2006_CD
._.
Mr_NN
fide_VBD
Swaan_NN
President_NN
and_PHC
Chief_NN
Executive_NN
officer_NN
of_PIN
Danaher_NN
Corporation_NOMZ
._.
Prior_RB
to_TO
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Managing_VBG
Board_NN
of_PIN
ABN_NN
AMRO_NN
,_,
of_PIN
which_WDT [PIRE]
he_TPP3
was_VBD
joining_VBG
Danaher_NN
,_,
he_TPP3
held_VBD [PRIV]
positions_NOMZ
in_PIN
Accenture_NN
,_,
previously_TIME
Andersen_NN
Chief_NN
Financial_NN
officer_NN
until_IN
31st_CD
December_NN
2005_CD
._.
He_TPP3
will_PRMD
retire_VB
from_PIN
Consulting_GER
._.
the_DT
Board_NN
of_PIN
ABN_NN
AMRO_NN
on_PIN
1st_CD
May_POMD
2006_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
Director_NN
of_PIN
the_DT
Financial_NN
Services_NN
Authority_NOMZ
,_,
a_DT
member_NN
of_PIN
the_DT
Board_NN
of_PIN
Sir_NN
Crispin_NN
Davis_NN
Aged_VBD
56_CD
the_DT
Institute_NN
of_PIN
International_NN
Finance_NN
,_,
Chairman_NN
of_PIN
the_DT
Board_NN
of_PIN
the_DT
Appointed_VBN
on_PIN
1st_CD
July_NN
2003_CD
._.
Sir_NN
Crispin_NN
is_VPRT
Chief_NN
Netherlands_NN
Opera_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
Board_NN
of_PIN
the_DT
Royal_NN
Executive_NN
of_PIN
Reed_NN
Elsevier_NN
PLC._NN
._.
Prior_RB
to_PIN
that_DEMP
,_,
he_TPP3
was_VBD
Chief_NN
Executive_NN
Concertgebouw_NN
Orchestra_NN
._.
of_PIN
Aegis_NN
Group_NN
plc_NN
,_,
which_WDT [SERE]
he_TPP3
joined_VBD
from_PIN
Guinness_NOMZ
plc_NN
,_,
where_RB
he_TPP3
was_VBD [BEMA]
a_DT
member_NN
of_PIN
the_DT
main_JJ
board_NN
and_PHC
Group_NN
Managing_VBG [WZPRES]
Director_NN
of_PIN
United_NN
Sir_NN
Robert_NN
Wilson_NN
Aged_VBD
62_CD
Distillers_NN
._.
He_TPP3
spent_VBD
his_TPP3
early_TIME
career_NN
with_PIN
Procter_NN
&_CC
Gamble_NN
._.
Sir_NN
Robert_NN
is_VPRT [BEMA]
Non-Executive_JJ
Chairman_NN
of_PIN
BG_NN
Group_NN
plc_NN
and_CC
the_DT
Economist_NN
Group_NN
Julian_NN
Heslop_NN
Aged_VBD
52_CD
and_CC
was_VBD
previously_TIME
Executive_NN
Chairman_NN
of_PIN
Rio_NN
Tinto_NN
._.
Mr_NN
Heslop_NN
joined_VBD
Glaxo_NN
Wellcome_NN
as_IN
Financial_NN
Controller_NN
in_PIN
April_NN
1998_CD
._.
In_PIN
January_NN
2001_CD
,_,
Dr_NN
Tachi_NN
Yamada_NN
Aged_VBD
60_CD
following_VBG
the_DT
merger_NN
,_,
he_TPP3
was_VBD [PASS]
appointed_VBN
Senior_JJ
Vice_NN
President_NN
,_,
Appointed_VBN [PASTP]
on_PIN
1st_CD
January_NN
2004_CD
._.
Prior_RB
to_TO
joining_VBG
Glaxo_NN
Wellcome_NN
,_,
he_TPP3
held_VBD [PRIV]
senior_JJ
Research_NN
&_CC
Development_NOMZ
._.
Dr_NN
Yamada_NN
was_VBD [BEMA]
a_DT
Non-Executive_JJ
Director_NN
,_,
and_ANDC
finance_NN
roles_NN
at_PIN
Grand_NN
Metropolitan_NN
PLC._NN
._.
subsequently_TIME
an_DT
Executive_NN
Director_NN
,_,
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
Prior_RB
to_TO
joining_VBG
SmithKline_NN
Beecham_NN
,_,
he_TPP3
was_VBD
Chairman_NN
of_PIN
the_DT
Department_NOMZ
of_PIN
Sir_NN
Deryck_NN
Maughan_NN
Aged_VBD
58_CD
Internal_NN
Medicine_NN
at_PIN
the_DT
University_NOMZ
of_PIN
Michigan_NN
Medical_NN
School_NN
and_CC
Appointed_VBN
on_PIN
1st_CD
June_NN
2004_CD
._.
Sir_NN
Deryck_NN
is_VPRT [BEMA]
a_DT
Physician-in-Chief_NN
of_PIN
the_DT
University_NOMZ
of_PIN
Michigan_NN
Medical_NN
Center_NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Managing_VBG
Director_NN
of_PIN
Kohlberg_NN
Kravis_NN
Roberts_NN
&_CC
Co._NN
._.
He_TPP3
was_VBD
formerly_TIME
Trustee_NN
of_PIN
the_DT
Rockefeller_NN
Brothers_NN
Fund_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
Advisory_NN
Chairman_NN
and_PHC
CEO_NN
of_PIN
Citigroup_NN
International_NN
and_CC
of_PIN
Salomon_NN
Brothers_NN
Board_NN
of_PIN
Quaker_NN
BioVentures_NN
,_,
Inc._NN
._.
Inc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Reuters_NN
Group_NN
plc_NN
as_RB
well_RB
as_IN
serving_VBG
on_PIN
the_DT
Boards_NN
of_PIN
Directors_NN
of_PIN
Carnegie_NN
Hall_NN
,_,
Lincoln_NN
Center_NN
Dr_NN
Moncef_NN
Slaoui_NN
Aged_VBD
46_CD
and_CC
NYU_NN
Medical_NN
Center_NN
._.
He_TPP3
is_VPRT [BEMA]
also_RB
an_DT
International_NN
Advisory_NN
Board_NN
Chairman_NN
Designate_NN
,_,
Research_NN
&_CC
Development_NOMZ
._.
Dr_NN
Slaoui_NN
,_,
Senior_NN
Vice_NN
member_NN
of_PIN
British_JJ
American_NN
Business_NOMZ
Inc._NN
and_CC
a_DT
Board_NN
member_NN
of_PIN
the_DT
President_NN
,_,
Worldwide_NN
Business_NOMZ
Development_NOMZ
,_,
has_VPRT [PEAS]
been_VBN [PASS]
appointed_VBN
to_PIN
Trilateral_NN
Commission_NN
._.
He_TPP3
served_VBD
as_IN
Vice_NN
Chairman_NN
of_PIN
the_DT
New_NN
York_NN
the_DT
Board_NN
with_PIN
effect_NN
from_PIN
17th_JJ
May_POMD
2006_CD
,_,
and_ANDC
will_PRMD
succeed_VB
Dr_NN
Stock_NN
Exchange_NN
from_PIN
1996_CD
to_PIN
2000_CD
._.
Yamada_NN
as_IN
Chairman_NN
,_,
Research_NN
&_CC
Development_NOMZ
on_PIN
1st_CD
June_NN
2006_CD
._.
Dr_NN
Slaoui_NN
joined_VBD
GSK_NN
Biologicals_NN
in_PIN
1988_CD
where_RB
he_TPP3
engineered_VBD
the_DT
Sir_NN
Ian_NN
Prosser_NN
Aged_VBD
62_CD
development_NOMZ
of_PIN
a_DT
robust_JJ
vaccines_NN
pipeline_NN
._.
He_TPP3
has_VPRT
a_DT
PhD_NN
in_PIN
Molecular_NN
Appointed_VBN [WZPAST]
on_PIN
23rd_JJ
May_POMD
2000_CD
._.
Sir_NN
Ian_NN
Biology_NN
and_PHC
Immunology_NN
from_PIN
Universit_NN
Libre_NN
fide_VBD
Bruxelles_NN
._.
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
He_TPP3
was_VBD
Chairman_NN
and_PHC
Chief_NN
Executive_NN
of_PIN
Bass_NN
plc_NN
and_CC
ultimately_RB
Chairman_NN
Other_JJ
Directors_NN
of_PIN
the_DT
demerged_JJ
InterContinental_NN
Hotels_NN
Group_NN
plc._NN
._.
He_TPP3
was_VBD
Chairman_NN
Mr_NN
John_NN
Coombe_NN
,_,
formerly_TIME
Chief_NN
Financial_NN
officer_NN
,_,
retired_VBN [PASTP]
from_PIN
the_DT
of_PIN
the_DT
World_NN
Travel_NN
and_PHC
Tourism_NN
Council_NN
and_CC
the_DT
London_NN
Stock_NN
Board_NN
on_PIN
31st_CD
March_NN
2005_CD
._.
He_TPP3
is_VPRT [BEMA]
Non-Executive_JJ
Deputy_NN
Chairman_NN
of_PIN
BP_NN
plc_NN
,_,
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Sara_NN
Lee_NN
Corporation_NOMZ
and_CC
a_DT
member_NN
of_PIN
the_DT
CBI_NN
Presidents_NN
Committee_NN
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
18_CD
The_DT
Corporate_JJ
Executive_NN
Team_NN
The_NN
executive_NN
management_NOMZ
of_PIN
the_DT
Group_NN
is_VPRT [BEMA]
through_PIN
the_DT
Corporate_NN
Executive_NN
Team_NN
CET_NN
,_,
comprising_VBG [PRESP]
the_DT
Chief_NN
Executive_NN
officer_NN
,_,
the_DT
Chief_NN
Financial_NN
officer_NN
and_CC
other_JJ
senior_JJ
managers_NN
._.
JP_NN
Garnier_NN
Rupert_NN
Bondy_NN
Ford_NN
Calhoun_NN
John_NN
Clarke_NN
Marc_NN
Dunoyer_NN
Russell_NN
Greig_NN
Julian_NN
Heslop_NN
Dan_NN
Phelan_NN
David_NN
Pulman_NN
David_NN
Stout_NN
Chris_NN
Viehbacher_NN
Andrew_NN
Witty_NN
Tachi_NN
Yamada_NN
Jennie_NN
Younger_NN
JP_NN
Garnier_NN
David_NN
Pulman_NN
Chief_NN
Executive_NN
officer_NN
President_NN
,_,
Global_NN
Manufacturing_GER
and_PHC
Supply_NN
David_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Global_JJ
Manufacturing_GER
and_PHC
Supply_NN
As_IN
Chief_NN
Executive_NN
officer_NN
,_,
JP_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
management_NOMZ
of_PIN
the_DT
Group_NN
._.
He_TPP3
oversees_VPRT
all_QUAN
operational_JJ
aspects_NN
of_PIN
the_DT
Group_NN
,_,
including_VBG
Organisation_NOMZ
and_PHC
Global_NN
Procurement_NOMZ
._.
He_TPP3
joined_VBD
Glaxo_NN
in_PIN
1978_CD
and_CC
establishing_VBG [PRIV]
policies_NN
,_,
objectives_NN
and_PHC
initiatives_NN
,_,
and_ANDC
he_TPP3
directs_VPRT
longwas_NN
responsible_JJ
for_PIN
the_DT
North_PLACE
American_JJ
supply_NN
network_NN
,_,
manufacturing_VBG
term_NN
strategy_NN
._.
He_TPP3
was_VBD
formerly_TIME
Chief_NN
Executive_NN
officer_NN
of_PIN
SmithKline_NN
strategy_NN
and_PHC
logistics_NN
until_IN
his_TPP3
current_JJ
appointment_NOMZ
in_PIN
2002_CD
._.
Beecham_NN
,_,
having_VBG [PEAS]
joined_VBN
the_DT
Group_NN
in_PIN
1990_CD
._.
David_NN
Stout_NN
Rupert_NN
Bondy_NN
President_NN
,_,
Pharmaceutical_NN
Operations_NOMZ
Senior_NN
Vice_NN
President_NN
and_PHC
General_NN
Counsel_NN
David_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
all_QUAN
pharmaceuticals_NN
and_PHC
vaccines_NN
operations_NOMZ
Rupert_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
legal_JJ
matters_NN
across_PLACE
the_DT
Group_NN
,_,
together_RB
with_PIN
worldwide_NN
,_,
including_VBG [PRESP]
the_DT
USA_NN
,_,
Europe_NN
,_,
International_NN
,_,
Japan_NN
and_PHC
Global_NN
Manufacturing_GER
and_PHC
Supply_NN
._.
He_TPP3
joined_VBD
SmithKline_NN
Beecham_NN
in_PIN
1996_CD
environmental_JJ
,_,
health_NN
and_PHC
safety_NN
issues_NN
,_,
insurance_NN
and_PHC
security_NOMZ
._.
He_TPP3
was_VBD [BEMA]
a_DT
lawyer_NN
in_PIN
private_JJ
practice_NN
before_IN
joining_VBG
SmithKline_NN
Beecham_NN
in_PIN
1995_CD
._.
and_ANDC
was_VBD
President_NN
,_,
US_FPP1
Pharmaceuticals_NN
,_,
until_IN
his_TPP3
current_JJ
appointment_NOMZ
in_PIN
2003_CD
._.
Ford_NN
Calhoun_NN
Chief_NN
Information_NOMZ
officer_NN
Chris_NN
Viehbacher_NN
President_NN
,_,
US_FPP1
Pharmaceuticals_NN
Ford_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
information_NOMZ
technology_NN
,_,
a_DT
global_JJ
function_NOMZ
that_TSUB
enables_VPRT
key_JJ
business_NOMZ
processes_VPRT
across_PLACE
all_QUAN
parts_NN
of_PIN
the_DT
Group_NN
._.
With_PIN
doctoral_JJ
Chris_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
US_FPP1
Pharmaceuticals_NN
._.
He_TPP3
joined_VBD
Wellcome_NN
in_PIN
and_CC
post-doctoral_JJ
training_GER
in_PIN
microbiology_NN
,_,
genetics_NN
,_,
biomathematics_NN
and_CC
1988_CD
and_CC
was_VBD [BEMA]
responsible_PRED
for_PIN
GSKs_NN
European_NN
Pharmaceuticals_NN
computer_NN
science_NN
,_,
he_TPP3
joined_VBD
Smith_NN
Kline_NN
&_CC
French_NN
in_PIN
1984_CD
._.
business_NOMZ
before_IN
his_TPP3
current_JJ
appointment_NOMZ
in_PIN
2003_CD
._.
John_NN
Clarke_NN
Andrew_NN
Witty_NN
President_NN
,_,
Consumer_NN
Healthcare_NN
President_NN
,_,
Pharmaceuticals_NN
Europe_NN
John_NN
Clarke_NN
succeeded_VBD
Jack_NN
Ziegler_NN
as_IN
President_NN
,_,
Consumer_NN
Healthcare_NN
Andrew_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Groups_NN
pharmaceuticals_NN
operations_NOMZ
in_PIN
Europe_NN
._.
He_TPP3
joined_VBD
Glaxo_NN
in_PIN
1985_CD
and_CC
was_VBD [BEMA]
Senior_JJ
Vice_NN
President_NN
,_,
Asia_NN
on_PIN
31st_CD
January_NN
2006_CD
._.
He_TPP3
joined_VBD
Beecham_NN
in_PIN
1976_CD
and_CC
progressed_VBN
through_PIN
roles_NN
in_PIN
Australasia_NN
,_,
South_NN
Africa_NN
,_,
The_DT
Far_NN
East_NN
,_,
Japan_NN
,_,
Canada_NN
Pacic_NN
until_IN
his_TPP3
current_JJ
appointment_NOMZ
in_PIN
2003_CD
._.
and_ANDC
the_DT
UK_NN
._.
From_PIN
1998_CD
to_PIN
2003_CD
,_,
John_NN
was_VBD
President_NN
,_,
Consumer_NN
Tachi_NN
Yamada_NN
Healthcare_NN
Europe_NN
,_,
and_ANDC
in_PIN
2004_CD
,_,
appointed_VBN
President_NN
,_,
Futures_NN
Group_NN
._.
Chairman_NN
,_,
Research_NN
&_CC
Development_NOMZ
Tachi_NN
leads_VPRT
the_DT
Groups_NN
complex_JJ
business_NOMZ
of_PIN
drug_NN
discovery_NN
and_PHC
Marc_NN
Dunoyer_NN
President_NN
,_,
Pharmaceuticals_NN
Japan_NN
development_NOMZ
._.
He_TPP3
joined_VBD
SmithKline_NN
Beecham_NN
in_PIN
1994_CD
as_IN
a_DT
Non-Executive_JJ
Marc_NN
was_VBD [PASS]
appointed_VBN
President_NN
,_,
Pharmaceuticals_NN
Japan_NN
in_PIN
March_NN
2003_CD
._.
Director_NN
and_CC
became_VBD
Chairman_NN
,_,
R&D_NN
Pharmaceuticals_NN
in_PIN
1999_CD
._.
He_TPP3
will_PRMD
He_TPP3
joined_VBD
the_DT
Group_NN
in_PIN
1999_CD
and_CC
was_VBD [BEMA]
Senior_JJ
Vice_NN
President_NN
and_CC
retire_VB
on_PIN
1st_CD
June_NN
2006_CD
._.
Regional_NN
Director_NN
,_,
Japan_NN
until_IN
his_TPP3
current_JJ
appointment_NOMZ
._.
Jennie_NN
Younger_NN
Russell_NN
Greig_NN
Senior_NN
Vice_NN
President_NN
,_,
Corporate_NN
Communications_NOMZ
&_CC
President_NN
,_,
Pharmaceuticals_NN
International_NN
Community_NOMZ
Partnerships_NN
Russell_NN
leads_VPRT
the_DT
pharmaceutical_JJ
operations_NOMZ
outside_PLACE
the_DT
USA_NN
,_,
Japan_NN
Jennie_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Groups_NN
internal_JJ
and_PHC
external_JJ
communications_NOMZ
,_,
its_PIT
image_NN
and_PHC
partnerships_NN
with_PIN
global_JJ
communities_NOMZ
._.
and_ANDC
most_EMPH
of_PIN
Europe_NN
,_,
covering_VBG
more_EMPH
than_PIN
100_CD
countries_NN
._.
He_TPP3
joined_VBD
the_DT
Group_NN
in_PIN
1980_CD
and_CC
was_VBD [BEMA]
Senior_JJ
Vice_NN
President_NN
,_,
Worldwide_NN
Business_NOMZ
She_TPP3
joined_VBD
Glaxo_NN
Wellcome_NN
in_PIN
1996_CD
as_IN
Director_NN
of_PIN
Investor_NN
Relations_NOMZ
Development_NOMZ
for_PIN
R&D_NN
prior_RB
to_PIN
his_TPP3
current_JJ
appointment_NOMZ
in_PIN
March_NN
2003_CD
._.
and_ANDC
was_VBD [PASS]
appointed_VBN
to_PIN
her_TPP3
current_JJ
position_NOMZ
in_PIN
2001_CD
._.
Moncef_NN
Slaoui_NN
Julian_NN
Heslop_NN
Chairman_NN
Designate_NN
,_,
Research_NN
&_CC
Development_NOMZ
Chief_NN
Financial_NN
officer_NN
Julian_NN
became_VBD
Chief_NN
Financial_NN
officer_NN
on_PIN
1st_CD
April_NN
2005_CD
._.
As_IN
head_NN
of_PIN
the_DT
Moncef_NN
will_PRMD
succeed_VB
Tachi_NN
Yamada_NN
as_IN
Chairman_NN
,_,
Research_NN
&_CC
finance_NN
function_NOMZ
he_TPP3
is_VPRT [BEMA]
responsible_PRED
for_PIN
activities_NOMZ
such_JJ
as_IN
financial_JJ
Development_NOMZ
on_PIN
1st_CD
June_NN
._.
He_TPP3
will_PRMD
join_VB
the_DT
CET_NN
on_PIN
17th_JJ
May_POMD
._.
He_TPP3
joined_VBD
reporting_VBG [PUBV]
and_CC
control_NN
,_,
tax_NN
and_PHC
treasury_NN
,_,
investor_NN
relations_NOMZ
,_,
finance_VB
the_DT
Group_NN
in_PIN
1988_CD
and_CC
is_VPRT [BEMA]
currently_RB
Senior_JJ
Vice_NN
President_NN
,_,
Worldwide_NN
Business_NOMZ
Development_NOMZ
._.
systems_NN
,_,
internal_JJ
audit_NN
and_CC
real_JJ
estate_NN
._.
He_TPP3
joined_VBD
Glaxo_NN
Wellcome_NN
as_IN
Financial_NN
Controller_NN
in_PIN
April_NN
1998_CD
._.
Other_JJ
members_NN
Dan_NN
Phelan_NN
John_NN
Coombe_NN
retired_VBD
as_IN
Chief_NN
Financial_NN
officer_NN
on_PIN
31st_CD
March_NN
2005_CD
._.
Jack_NN
Ziegler_NN
retired_VBD
as_IN
head_NN
of_PIN
the_DT
Consumer_NN
Healthcare_NN
business_NOMZ
on_PIN
Senior_JJ
Vice_NN
President_NN
,_,
Human_NN
Resources_NN
Dan_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
benets_NN
,_,
compensation_NOMZ
,_,
recruitment_NOMZ
,_,
organization_NOMZ
31st_CD
January_NN
2006_CD
._.
Robert_NN
Ingram_NN
continues_VPRT
to_TO
work_VB
part-time_JJ
as_IN
Vice_NN
development_NOMZ
,_,
leadership_NN
development_NOMZ
and_PHC
succession_NN
planning_GER
,_,
human_JJ
Chairman_NN
of_PIN
Pharmaceuticals_NN
,_,
acting_VBG
as_IN
a_DT
special_JJ
advisor_NN
to_PIN
the_DT
Group_NN
resource_NN
information_NOMZ
systems_NN
and_PHC
employee_NN
health_NN
management_NOMZ
._.
and_ANDC
attending_VBG
CET_NN
meetings_GER
in_PIN
that_DEMO
capacity_NOMZ
._.
He_TPP3
was_VBD [BEMA]
a_DT
lawyer_NN
in_PIN
private_JJ
practice_NN
before_IN
joining_VBG
Smith_NN
Kline_NN
&_CC
French_NN
in_PIN
1981_CD
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
19_CD
Summary_NN
Remuneration_NOMZ
Report_NN
for_PIN
the_DT
year_NN
to_PIN
31st_CD
December_NN
2005_CD
INTRODUCTION_NOMZ
performance_NN
conditions_NOMZ
would_PRMD
be_VB [PASS]
based_VBN
on_PIN
the_DT
The_DT
Summary_NN
Remuneration_NOMZ
Report_NN
sets_VPRT
out_PIN
the_DT
annual_JJ
measurable_JJ
delivery_NN
of_PIN
strong_JJ
financial_JJ
performance_NN
and_PHC
remuneration_NOMZ
of_PIN
the_DT
Board_NN
earned_VBD
in_PIN
2005_CD
,_,
together_RB
with_PIN
the_DT
delivery_NN
of_PIN
superior_JJ
returns_NN
to_PIN
shareholders_NN
as_IN
any_QUAN
gains_NN
under_IN
long-term_JJ
incentive_NN
arrangements_NOMZ
._.
It_PIT
also_RB
compared_VBN
with_PIN
other_JJ
pharmaceutical_JJ
companies_NN
:_:
describes_VPRT
the_DT
background_NN
and_CC
outlines_VPRT
the_DT
Groups_NN
rea_VPRT
high_JJ
proportion_NOMZ
of_PIN
the_DT
total_JJ
remuneration_NOMZ
opportunity_NOMZ
muneration_NOMZ
policy_NN
,_,
together_RB
with_PIN
the_DT
performance_NN
graph_NN
will_PRMD
be_VB [PASS]
based_VBN
on_PIN
performance-related_JJ
remuneration_NOMZ
,_,
required_VBN [SUAV] [PASTP]
by_PIN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
Regwhich_NN
will_PRMD
be_VB [PASS]
delivered_VBN
over_IN
the_DT
medium-term_JJ
to_PIN
longulations_NOMZ
2002_CD
the_DT
Regulations_NOMZ
._.
term_NN
:_:
and_ANDC
The_DT
Remuneration_NOMZ
Committee_NN
the_DT
Committee_NN
is_VPRT [BEMA]
no_SYNE
ex-gratia_NN
payments_NOMZ
will_PRMD
be_VB [PASS]
made_VBN
._.
responsible_JJ
for_PIN
making_VBG
recommendations_NOMZ
to_PIN
the_DT
Board_NN
on_PIN
the_DT
companys_NN
remuneration_VPRT
policy_NN
and_CC
,_,
within_PIN
the_DT
Overall_JJ
,_,
the_DT
policy_NN
is_VPRT [PASS]
intended_VBN [SUAV]
to_TO
provide_VB
median_JJ
total_JJ
terms_NN
of_PIN
the_DT
agreed_JJ
policy_NN
,_,
determining_VBG [SUAV] [PRIV] [PRESP]
the_DT
total_JJ
individual_JJ
remuneration_NOMZ
for_PIN
median_JJ
performance_NN
._.
Poor_NN
performance_NN
remuneration_NOMZ
packages_NN
of_PIN
the_DT
Executive_NN
Directors_NN
and_CC
will_PRMD
result_VB
in_PIN
total_JJ
remuneration_NOMZ
signicantly_RB
below_PLACE
the_DT
members_NN
of_PIN
the_DT
CET_NN
Executives_NN
._.
The_DT
members_NN
of_PIN
the_DT
pay_NN
comparator_NN
group_NN
median_NN
,_,
with_PIN
the_DT
opportunity_NOMZ
to_PIN
Committee_NN
are_VPRT [PASS]
set_VBN
out_PIN
on_PIN
page_NN
23_CD
._.
earn_VB
upper_JJ
quartile_JJ
total_JJ
remuneration_NOMZ
for_PIN
exceptional_JJ
performance_NN
._.
The_DT
Committee_NN
has_VPRT [PEAS]
developed_VBN
the_DT
remuneration_NOMZ
policy_NN
to_TO
align_VB
executive_JJ
remuneration_NOMZ
with_PIN
the_DT
interests_NN
of_PIN
shareThis_NN
strong_JJ
alignment_NOMZ
with_PIN
performance_NN
is_VPRT
demonstrably_RB
holders_NN
whilst_OSUB
meeting_VBG
the_DT
imperative_NN
of_PIN
recruiting_GER
and_CC
in_PIN
the_DT
interests_NN
of_PIN
shareholders_NN
and_CC
provides_VPRT
the_DT
Executives_NN
retaining_VBG [WZPRES]
the_DT
executive_NN
talent_NN
essential_JJ
to_PIN
the_DT
leadership_NN
with_PIN
unambiguous_JJ
signals_NN
about_IN
the_DT
importance_NN
of_PIN
of_PIN
the_DT
company_NN
._.
delivering_VBG
success_NN
to_PIN
the_DT
companys_NN
shareholders_NN
._.
The_DT
remuneration_NOMZ
policy_NN
was_VBD [PASS]
nalised_VBN
after_IN
undertaking_VBG
Commitment_NOMZ
an_DT
extensive_JJ
consultation_NOMZ
process_NN
with_PIN
shareholders_NN
and_CC
The_DT
Committee_NN
will_PRMD
apply_VB
this_DEMO
policy_NN
on_PIN
a_DT
consistent_JJ
and_PHC
institutional_JJ
bodies_NN
during_PIN
the_DT
course_NN
of_PIN
2003_CD
and_CC
2004_CD
._.
transparent_JJ
basis_NN
._.
Any_QUAN
significant_JJ
change_NN
will_PRMD
be_VB [PASS]
discussed_VBN
with_PIN
shareholders_NN
in_PIN
advance_NN
of_PIN
implementation_NOMZ
._.
The_DT
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
continues_VPRT
Pay_VB
and_CC
performance_NN
comparators_NN
to_TO
have_VB
regular_JJ
dialogue_NN
with_PIN
institutional_JJ
investors_NN
The_DT
following_JJ
table_NN
sets_VPRT
out_PIN
the_DT
companies_NN
used_VBN [WZPAST]
for_PIN
pay_NN
regarding_VBG [WZPRES]
GSKs_NN
remuneration_NOMZ
policy_NN
._.
and_ANDC
performance_NN
comparison_NN
:_:
Market_NN
The_NN
remuneration_NOMZ
policy_NN
is_VPRT [PASS]
designed_VBN
to_TO
establish_VB [PRIV]
a_DT
Capitalisation_NOMZ
framework_NN
for_PIN
remuneration_NOMZ
which_WDT [WHSUB]
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
31.12.05_CD
companys_NN
scale_NN
and_PHC
scope_NN
of_PIN
operations_NOMZ
,_,
meets_VPRT
the_DT
Company_NN
Country_NN
m_NN
recruitment_NOMZ
needs_NN
of_PIN
the_DT
business_NOMZ
and_CC
is_VPRT [SPAU] [PASS]
closely_RB
aligned_VBN
Abbott_NN
Laboratories_NN
USA_NN
35,561_CD
with_PIN
shareholder_NN
guidelines_NN
._.
AstraZeneca_NN
UK_NN
44,693_CD
Bristol-Myers_NN
Squibb_NN
USA_NN
26,140_CD
Deloitte_NN
&_CC
Touche_NN
LLP_NN
have_VPRT [PEAS]
been_VBN [BYPA]
appointed_VBN
by_PIN
the_DT
Eli_NN
Lilly_NN
USA_NN
37,396_CD
Committee_NN
to_TO
provide_VB
it_PIT
with_PIN
independent_JJ
advice_NN
on_PIN
GlaxoSmithKline_NN
UK_NN
85,497_CD
executive_JJ
remuneration_NOMZ
._.
Johnson_NN
&_CC
Johnson_NN
USA_NN
103,950_CD
Merck_NN
USA_NN
40,440_CD
REMUNERATION_NOMZ
POLICY_NN
Novartis_NN
Switzerland_NN
80,419_CD
Principles_NN
Pzer_NN
USA_NN
99,942_CD
The_DT
Committee_NN
has_VPRT [PEAS]
established_VBN [PRIV]
four_CD
core_NN
principles_NN
Roche_NN
Holdings_GER
Switzerland_NN
61,334_CD
which_WDT
underpin_VPRT
GSKs_NN
remuneration_JJ
policy_NN
._.
These_DEMP
are_VPRT
:_:
Sano-Aventis_NN
France_NN
70,997_CD
securing_VBG
outstanding_JJ
executive_NN
talent_NN
:_:
Schering-Plough_NN
USA_NN
17,915_CD
Takeda_NN
Pharmaceutical_NN
Company_NN
Japan_NN
27,949_CD
pay_NN
for_PIN
performance_NN
and_CC
only_DWNT
for_PIN
performance_NN
:_:
Wyeth_NN
USA_NN
35,952_CD
robust_JJ
and_PHC
transparent_JJ
governance_NN
structures_NN
:_:
and_ANDC
GSKs_NN
executive_NN
remuneration_NOMZ
consists_VPRT
of_PIN
the_DT
a_DT
commitment_NOMZ
to_TO
be_VB [BEMA]
a_DT
leader_NN
of_PIN
good_JJ
remuneration_NOMZ
following_VBG [WZPRES]
components_NN
:_:
practice_NN
in_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
Base_NN
salary_NN
In_PIN
formulating_VBG
the_DT
policy_NN
,_,
the_DT
Committee_NN
decided_VBD [SUAV] [PRIV] [THATD]
that_DEMP
:_:
Base_NN
salaries_NN
are_VPRT [BYPA]
set_VBN
by_PIN
reference_NN
to_PIN
the_DT
median_NN
for_PIN
the_DT
the_DT
remuneration_NOMZ
structure_NN
must_NEMD
support_VB
the_DT
business_NOMZ
relevant_JJ
market_NN
._.
For_PIN
executives_NN
this_DEMP
is_VPRT [BEMA]
the_DT
pharmaceutical_JJ
in_PIN
a_DT
very_AMP
competitive_JJ
market_NN
place_NN
:_:
pay_VB
comparator_NN
group_NN
._.
Base_NN
salary_NN
is_VPRT [BEMA]
the_DT
only_DWNT
element_NOMZ
of_PIN
remuneration_NOMZ
that_DEMP
is_VPRT [PASS]
xed_VBN
._.
UK_NN
shareholder_NN
guidelines_NN
will_PRMD
be_VB [PASS]
followed_VBN
to_PIN
the_DT
maximum_NN
extent_NN
consistent_JJ
with_PIN
the_DT
needs_NN
of_PIN
the_DT
business_NOMZ
Annual_JJ
bonus_NN
and_CC
the_DT
company_NN
would_PRMD
maintain_VB [PUBV]
a_DT
regular_JJ
dialogue_NN
All_QUAN
bonuses_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
on_PIN
the_DT
basis_NN
of_PIN
a_DT
formal_JJ
review_NN
with_PIN
shareholders_NN
:_:
of_PIN
annual_JJ
performance_NN
against_PIN
stretching_VBG
financial_JJ
targets_NN
based_VBN [WZPAST]
on_PIN
profit_NN
before_IN
interest_NN
and_PHC
tax_NN
and_CC
are_VPRT [BEMA]
subject_PRED
to_PIN
global_JJ
pharmaceutical_JJ
companies_NN
are_VPRT [BEMA]
the_DT
primary_JJ
pay_NN
detailed_VBN
assessment_NOMZ
of_PIN
individual_JJ
,_,
business_NOMZ
unit_NN
and_PHC
group_NN
comparator_NN
group_NN
:_:
achievements_NOMZ
against_PIN
objectives_NN
._.
In_PIN
determining_VBG [SUAV] [PRIV]
the_DT
bonus_NN
awards_NN
for_PIN
2005_CD
,_,
the_DT
Committee_NN
took_VBD
into_PIN
account_NN
the_DT
excellent_JJ
financial_JJ
performance_NN
during_PIN
the_DT
year_NN
and_CC
the_DT
encouraging_JJ
progress_NN
in_PIN
building_VBG
the_DT
pipeline_NN
of_PIN
new_JJ
products_NN
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
20_CD
Summary_NN
Remuneration_NOMZ
Report_NN
continued_VBD
Long-term_JJ
incentives_NN
The_DT
Committee_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
that_THVC
for_PIN
the_DT
awards_NN
granted_VBN [SUAV]
The_DT
remuneration_NOMZ
policy_NN
provides_VPRT
that_DEMO
annual_JJ
long-term_JJ
since_OSUB
2004_CD
,_,
there_EX
will_PRMD
be_VB
no_SYNE
performance_NN
retesting_GER
,_,
so_RB
if_COND
incentive_NN
awards_NN
will_PRMD [SPAU]
normally_RB
be_VB [PASS]
made_VBN
up_IN
of_PIN
a_DT
perforthe_JJ
performance_NN
condition_NOMZ
is_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
three-year_JJ
mance_NN
share_NN
award_NN
and_CC
a_DT
share_NN
option_NOMZ
award_NN
._.
The_DT
period_NN
,_,
the_DT
option_NOMZ
will_PRMD
lapse_NN
._.
remuneration_NOMZ
policy_NN
places_NN
greater_JJ
emphasis_NN
on_PIN
the_DT
use_NN
The_DT
performance_NN
criteria_NN
relating_VBG [WZPRES]
to_PIN
performance_NN
shares_NN
of_PIN
performance_NN
shares_NN
rather_RB
than_PIN
share_NN
options_NOMZ
._.
and_ANDC
share_NN
options_NOMZ
awarded_VBN
and_PHC
granted_VBN [SUAV]
prior_RB
to_PIN
2006_CD
are_VPRT [BEMA]
The_DT
Committee_NN
has_VPRT [PEAS]
considered_VBN [PRIV]
which_WDT [WHCL]
performance_NN
given_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
._.
conditions_NOMZ
should_NEMD
be_VB [PASS]
applied_VBN
to_PIN
the_DT
long-term_JJ
incentives_NN
._.
Pensions_NN
The_DT
Committee_NN
concluded_VBD [PRIV]
that_THVC
it_PIT
was_VBD [BEMA]
appropriate_PRED
to_PIN
The_DT
Executives_NN
participate_VB
in_PIN
GSK_NN
senior_JJ
executive_NN
pension_NN
measure_NN
performance_NN
using_VBG [WZPRES]
a_DT
combination_NOMZ
of_PIN
absolute_JJ
plans_NN
._.
The_DT
pension_NN
arrangements_NOMZ
are_VPRT [PASS]
structured_VBN
in_PIN
financial_JJ
results_NN
based_VBN [WZPAST]
on_PIN
earnings_GER
per_PIN
share_NN
EPS_NN
and_PHC
accordance_NN
with_PIN
the_DT
plans_NN
operated_VBN [WZPAST]
for_PIN
executives_NN
in_PIN
the_DT
the_DT
delivery_NN
of_PIN
superior_JJ
value_NN
to_PIN
shareholders_NN
based_VBN [WZPAST]
on_PIN
country_NN
in_PIN
which_WDT [PIRE]
the_DT
executives_NN
are_VPRT [BEMA]
likely_PRED
to_TO
retire_VB
._.
Benets_NN
Total_NN
Shareholder_NN
Return_NN
TSR_NN
measured_VBN [WZPAST]
against_PIN
the_DT
are_VPRT [BEMA]
normally_RB
payable_PRED
at_PIN
age_NN
60_CD
,_,
although_CONC
it_PIT
was_VBD [PASS]
agreed_VBN [SUAV] [PUBV]
comparator_NN
group_NN
._.
that_THVC
Dr_NN
Yamada_NN
could_POMD
retire_VB
at_PIN
age_NN
62_CD
,_,
he_TPP3
will_PRMD
retire_VB
from_PIN
For_PIN
the_DT
Executives_NN
,_,
the_DT
level_NN
of_PIN
performance_NN
shares_NN
vesting_VBG [WZPRES]
the_DT
company_NN
on_PIN
1st_CD
June_NN
2006_CD
._.
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
companys_NN
TSR_NN
relative_JJ
to_PIN
the_DT
performance_NN
comparator_NN
group_NN
over_IN
a_DT
three-year_JJ
measurement_NOMZ
period_NN
._.
EXECUTIVE_NN
DIRECTOR_NN
TERMS_NN
AND_PHC
CONDITIONS_NOMZ
If_COND
GSK_NN
is_VPRT [PASS]
ranked_VBN
at_PIN
position_NOMZ
seven_CD
the_DT
mid-point_NN
of_PIN
the_DT
The_DT
policy_NN
regarding_VBG [WZPRES]
the_DT
Executive_NN
Directors_NN
contracts_NN
performance_NN
comparator_NN
group_NN
,_,
35_CD
%_NN
of_PIN
the_DT
shares_NN
will_PRMD
was_VBD [BEMA]
the_DT
subject_NN
of_PIN
extensive_JJ
review_NN
and_PHC
change_NN
during_PIN
vest_NN
and_ANDC
if_COND
it_PIT
is_VPRT
below_PLACE
that_DEMO
position_NOMZ
then_RB
none_INPR
of_PIN
the_DT
shares_NN
2003_CD
._.
This_DEMP
resulted_VBD
in_PIN
a_DT
new_JJ
framework_NN
for_PIN
contracts_NN
for_PIN
will_PRMD
vest_NN
._.
Only_DWNT
if_COND
GSK_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
top_JJ
two_CD
companies_NN
will_PRMD
Executive_NN
Directors_NN
appointed_VBN [WZPAST]
in_PIN
the_DT
future_NN
._.
When_RB
determining_VBG [SUAV] [PRIV]
vesting_GER
levels_NN
,_,
Dr_NN
Garnier_NN
and_PHC
Dr_NN
Yamada_NN
agreed_VBD [SUAV] [PUBV]
to_PIN
changes_NN
in_PIN
their_TPP3
the_DT
Committee_NN
will_PRMD
have_VB
regard_NN
to_PIN
the_DT
companys_NN
contractual_JJ
terms_NN
without_PIN
compensation_NOMZ
to_TO
bring_VB
their_TPP3
underlying_VBG
financial_JJ
performance_NN
._.
contractual_JJ
terms_NN
broadly_RB
in_PIN
line_NN
with_PIN
the_DT
new_JJ
contractual_JJ
The_DT
performance_NN
conditions_NOMZ
applying_VBG [WZPRES]
to_PIN
the_DT
share_NN
options_NOMZ
framework_NN
,_,
including_VBG [PRESP]
the_DT
reduction_NOMZ
of_PIN
contractual_JJ
notice_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
the_DT
Executives_NN
are_VPRT [PASS]
linked_VBN
to_PIN
the_DT
achievement_NOMZ
period_NN
from_PIN
24_CD
to_PIN
12_CD
calendar_NN
months_NN
._.
However_CONJ
,_,
to_PIN
of_PIN
compound_NN
annual_JJ
EPS_NN
growth_NN
in_PIN
excess_NN
of_PIN
the_DT
Retail_NN
honor_NN
certain_JJ
aspects_NN
of_PIN
their_TPP3
old_JJ
contractual_JJ
terms_NN
,_,
Prices_NN
Index_NN
RPI_NN
over_IN
three_CD
year_NN
performance_NN
periods_NN
._.
there_EX
are_VPRT
a_DT
number_NN
of_PIN
individual_JJ
features_NN
which_WDT [WHSUB]
will_PRMD
be_VB [PASS]
retained_VBN
._.
In_PIN
the_DT
event_NN
of_PIN
early_TIME
termination_NOMZ
by_PIN
the_DT
When_RB
setting_VBG
EPS_NN
targets_NN
,_,
the_DT
Committee_NN
considers_VPRT [PRIV]
the_DT
company_NN
,_,
Dr_NN
Garnier_NN
and_PHC
Dr_NN
Yamada_NN
would_PRMD
receive_VB
a_DT
cash_NN
companys_VPRT
internal_JJ
projections_NOMZ
and_PHC
analysts_NN
forecasts_NN
for_PIN
sum_NN
equivalent_NN
to_PIN
the_DT
total_NN
of_PIN
their_TPP3
annual_JJ
salary_NN
,_,
on_PIN
target_NN
GSKs_NN
EPS_NN
performance_NN
,_,
as_RB
well_RB
as_IN
analysts_NN
forecasts_NN
for_PIN
bonus_NN
and_PHC
pension_NN
contributions_NOMZ
for_PIN
the_DT
12_CD
months_NN
notice_VPRT [PRIV]
the_DT
pharmaceutical_JJ
industry_NN
._.
Vesting_VBG [PRESP]
of_PIN
share_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
February_NN
2006_CD
Mr_NN
Heslops_NN
contract_NN
follows_VPRT
the_DT
new_JJ
framework_NN
._.
increases_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
for_PIN
EPS_NN
performance_NN
between_PIN
the_DT
hurdles_NN
as_IN
set_VBN
out_PIN
in_PIN
the_DT
graph_NN
below_PLACE
._.
TSR_NN
performance_NN
graph_NN
The_DT
graph_NN
below_PLACE
sets_NN
out_PIN
the_DT
performance_NN
of_PIN
the_DT
company_NN
relative_JJ
to_PIN
the_DT
FTSE_NN
100_CD
index_NN
of_PIN
which_WDT [PIRE]
the_DT
company_NN
is_VPRT [BEMA]
a_DT
Exceptional_JJ
100_CD
%_NN
constituent_NN
and_CC
to_PIN
the_DT
performance_NN
comparator_NN
group_NN
._.
It_PIT
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
Regulations_NOMZ
and_PHC
Superior_NN
is_VPRT [BEMA]
not_XX0
an_DT
indication_NOMZ
of_PIN
the_DT
likely_JJ
vesting_GER
of_PIN
awards_NN
granted_VBN [SUAV]
Baseline_NN
under_IN
any_QUAN
of_PIN
the_DT
incentive_NN
plans_NN
._.
Threshold_NN
50_CD
%_NN
110_CD
100_CD
0_CD
%_NN
90_CD
RPI_NN
3_CD
%_NN
RPI_NN
4_CD
%_NN
RPI_NN
5_CD
%_NN
RPI_NN
6_CD
%_NN
p._FW
a._FW
p._FW
a._FW
p._FW
a._FW
p._FW
a._FW
EPS_NN
Target_NN
80_CD
This_DEMO
performance_NN
condition_NOMZ
is_VPRT [BEMA]
substantially_RB
consistent_PRED
with_PIN
UK_NN
shareholder_NN
guidelines_NN
and_PHC
expectations_NOMZ
and_CC
is_VPRT [BEMA]
70_CD
demanding_VBG [SUAV]
when_RB [WHCL]
compared_VBN
with_PIN
those_DEMP
operated_VBN
by_PIN
other_JJ
global_JJ
pharmaceutical_JJ
companies_NN
._.
This_DEMP
is_VPRT [BEMA]
consistent_PRED
with_PIN
60_CD
the_DT
policy_NN
of_PIN
providing_VBG
pay_NN
for_PIN
performance_NN
and_CC
only_DWNT
for_PIN
31_CD
12_CD
00_CD
31_CD
12_CD
01_CD
31_CD
12_CD
02_CD
31_CD
12_CD
03_CD
31_CD
12_CD
04_CD
31_CD
12_CD
05_CD
performance_NN
._.
GlaxoSmithKline_NN
Total_NN
Return_NN
Index_NN
GlaxoSmithKline_NN
Pharma_NN
Peers_NN
Return_NN
Index_NN
FTSE_NN
100_CD
Total_JJ
Return_NN
Index_NN
GSK_NN
Annual_JJ
Review_NN
2005_CD
21_CD
Vesting_JJ
percentage_NN
Summary_NN
Remuneration_NOMZ
Report_NN
continued_VBD
ANNUAL_NN
REMUNERATION_NOMZ
2005_CD
2004_CD
Fees_NN
and_CC
Other_JJ
Annual_JJ
Deferred_JJ
Total_JJ
annual_JJ
Total_JJ
annual_JJ
salary_NN
benets_NN
bonus_NN
bonus_NN
remuneration_NOMZ
remuneration_NOMZ
Directors_NN
of_PIN
GSK_NN
000 000 000 000_CD
000_CD
000_CD
Executive_NN
Directors_NN
Dr_VPRT
JP_NN
Garnier_NN
$_$
1,582_CD
$_$
641_CD
$_$
2,812_CD
$_$
1,556_CD
$_$
6,591_CD
$_$
4,559_CD
Mr_NN
J_NN
Heslop_NN
240_CD
9_CD
280_CD
529_CD
Dr_NN
T_NN
Yamada_NN
$_$
763_CD
$_$
739_CD
$_$
1,110_CD
$_$
698_CD
$_$
3,310_CD
$_$
2,303_CD
Former_NN
Executive_NN
Director_NN
Mr_NN
J_NN
Coombe_NN
139 32 171 515_CD
Total_NN
Executive_NN
Directors_NN
1,667_CD
799_CD
2,436_CD
1,238_CD
6,140_CD
4,265_CD
Current_JJ
Non-Executive_JJ
Directors_NN
Mr_NN
L_NN
Culp_NN
$_$
136_CD
$_$
136_CD
$_$
97_CD
Sir_NN
Crispin_NN
Davis_NN
70_CD
70_CD
57_CD
Sir_NN
Christopher_NN
Gent_NN
500 500 175_CD
Sir_NN
Deryck_NN
Maughan_NN
$_$
146_CD
$_$
146_CD
$_$
57_CD
Sir_NN
Ian_NN
Prosser_NN
100_CD
100_CD
65_CD
Dr_NN
R_NN
Schmitz_NN
95_CD
95_CD
72_CD
Dr_NN
L_NN
Shapiro_NN
$_$
230_CD
$_$
230_CD
$_$
182_CD
Sir_NN
Robert_NN
Wilson_NN
90_CD
90_CD
66_CD
Former_JJ
Non-Executive_JJ
Directors_NN
Dr_VPRT
M_NN
Barzach_NN
58_CD
58_CD
78_CD
Sir_NN
Christopher_NN
Hogg_NN
370_CD
Sir_NN
Roger_NN
Hurn_NN
5_CD
5_CD
Sir_NN
Peter_NN
Job_NN
5_CD
5_CD
57_CD
Mr_NN
J_NN
McArthur_NN
$_$
60_CD
Mr_NN
D_NN
McHenry_NN
$_$
42_CD
Sir_NN
Richard_NN
Sykes_NN
1_CD
1_CD
1_CD
Total_JJ
Non-Executive_JJ
Directors_NN
1,195_CD
11_CD
1,206_CD
1,180_CD
Total_JJ
remuneration_NOMZ
2,862_CD
810_CD
2,436_CD
1,238_CD
7,346_CD
5,445_CD
Remuneration_NOMZ
for_PIN
Directors_NN
on_PIN
the_DT
US_FPP1
payroll_NN
is_VPRT [PASS]
reported_VBN [PUBV]
in_PIN
Dollars_NN
._.
Amounts_NN
have_VPRT [PEAS]
been_VBN [PASS]
converted_VBN
to_PIN
Sterling_GER
at_PIN
the_DT
average_JJ
exchange_NN
rates_NN
for_PIN
each_QUAN
year_NN
._.
Following_VBG [PRESP]
the_DT
merger_NN
,_,
those_DEMO
participants_NN
in_PIN
the_DT
legacy_NN
schemes_NN
who_WP [WHSUB]
elected_VBD
to_TO
exchange_VB
their_TPP3
legacy_NN
options_NOMZ
for_PIN
options_NOMZ
over_IN
GSK_NN
shares_NN
were_VBD [PASS]
granted_VBN [SUAV]
an_DT
additional_JJ
cash_NN
benefit_NN
equal_JJ
to_PIN
10_CD
%_NN
of_PIN
the_DT
grant_NN
price_NN
of_PIN
the_DT
original_JJ
option_NOMZ
._.
This_DEMO
additional_JJ
benefit_NN
known_VBN [PRIV]
as_IN
the_DT
Exchange_NN
Offer_NN
Incentive_NN
EOI_NN
is_VPRT [BEMA]
only_DWNT
payable_PRED
when_RB
the_DT
new_JJ
option_NOMZ
is_VPRT [PASS]
exercised_VBN
or_CC
lapses_NN
above_PLACE
market_NN
value_NN
._.
During_PIN
the_DT
year_NN
Dr_NN
Garnier_NN
received_VBD
$_$
174,472_CD
2004_CD
$_$
335,730_CD
and_CC
Dr_NN
Yamada_NN
received_VBD
$_$
167,405_CD
2004_CD
nil_NN
relating_VBG [WZPRES]
to_PIN
options_NOMZ
exercised_VBN
under_IN
the_DT
EOI_NN
._.
Those_DEMO
amounts_NN
are_VPRT [PASS]
included_VBN
in_PIN
other_JJ
benets_NN
in_PIN
the_DT
table_NN
above_PLACE
._.
Non-Executive_JJ
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
receive_VB
a_DT
significant_JJ
part_NN
of_PIN
their_TPP3
fees_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
or_CC
ADSs_NN
and_CC
from_PIN
1st_CD
October_NN
2004_CD
,_,
all_QUAN
Non-Executive_JJ
Directors_NN
,_,
except_PIN
the_DT
Chairman_NN
,_,
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
take_VB
at_PIN
least_JJ
25_CD
%_NN
of_PIN
fees_NN
under_IN
the_DT
fee_NN
allocation_NOMZ
arrangement_NOMZ
._.
They_TPP3
can_POMD [SPAU]
also_RB
elect_VB
to_TO
invest_VB
part_NN
or_CC
all_QUAN
of_PIN
the_DT
remaining_VBG
balance_NN
of_PIN
their_TPP3
fees_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
or_CC
ADSs_NN
._.
The_DT
value_NN
of_PIN
these_DEMO
shares_NN
and_PHC
ADSs_NN
at_PIN
the_DT
dates_NN
of_PIN
award_NN
are_VPRT [PASS]
included_VBN
in_PIN
fees_NN
and_PHC
salary_NN
above_PLACE
._.
These_DEMO
shares_NN
and_PHC
ADSs_NN
are_VPRT [PASS]
not_XX0
paid_VBN
out_PIN
until_IN
the_DT
Director_NN
leaves_VPRT
the_DT
Board_NN
._.
In_CONJ
addition_NULL
to_PIN
annual_JJ
compensation_NOMZ
,_,
GSK_NN
operates_VPRT
share_NN
plans_NN
to_TO
provide_VB
incentives_NN
to_PIN
Executive_NN
Directors_NN
to_TO
achieve_VB
longer-term_JJ
growth_NN
in_PIN
shareholder_NN
value_NN
._.
Gains_NN
under_IN
such_JJ
plans_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
exercise_NN
or_CC
maturity_NOMZ
of_PIN
the_DT
award_NN
,_,
but_CC
reect_JJ
value_NN
earned_VBN
over_IN
a_DT
period_NN
of_PIN
years_NN
._.
The_DT
timing_NN
of_PIN
exercise_NN
is_VPRT [BEMA]
normally_RB
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Director_NN
._.
Full_JJ
details_NN
relating_VBG [WZPRES]
to_PIN
the_DT
operation_NOMZ
of_PIN
the_DT
companys_NN
share_NN
plans_NN
may_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
2005_CD
Annual_JJ
Report_NN
._.
In_PIN
2001_CD
,_,
following_VBG [PRESP]
the_DT
merger_NN
,_,
Dr_NN
Garnier_NN
,_,
Mr_NN
Coombe_NN
and_PHC
Dr_NN
Yamada_NN
were_VBD [PASS]
awarded_VBN
a_DT
one-off_PIN
special_JJ
deferred_VBN
bonus_NN
as_IN
members_NN
of_PIN
the_DT
CET_NN
._.
Each_QUAN
was_VBD [PASS]
awarded_VBN
an_DT
amount_NN
equivalent_NN
to_PIN
his_TPP3
salary_NN
on_PIN
31st_CD
December_NN
2001_CD
and_CC
this_DEMP
was_VBD [SPAU] [PASS]
notionally_RB
invested_VBN
in_PIN
GSK_NN
shares_NN
or_CC
ADSs_NN
on_PIN
15th_JJ
February_NN
2002_CD
._.
The_DT
amount_NN
of_PIN
the_DT
bonus_NN
vesting_VBG [WZPRES]
on_PIN
15th_JJ
February_NN
2005_CD
was_VBD [BEMA]
equivalent_PRED
to_PIN
the_DT
then_RB
value_NN
of_PIN
shares_NN
or_CC
ADSs_NN
notionally_RB
acquired_VBN
in_PIN
February_NN
2002_CD
plus_PIN
dividends_NN
reinvested_VBN
over_IN
the_DT
period_NN
._.
These_DEMO
amounts_NN
were_VBD [PASS]
paid_VBN
in_PIN
February_NN
2005_CD
and_CC
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
table_NN
above_PLACE
._.
Mr_NN
Coombe_NN
waived_VBD
his_TPP3
entitlements_NOMZ
to_PIN
the_DT
2001_CD
special_JJ
deferred_VBN
bonus_NN
of_PIN
383,924_CD
,_,
2004_CD
annual_JJ
bonus_NN
of_PIN
650,370_CD
and_CC
prorated_VBD
2005_CD
bonus_NN
of_PIN
106,870_CD
._.
The_DT
company_NN
made_VBD
a_DT
contribution_NOMZ
in_PIN
2005_CD
to_PIN
the_DT
pension_NN
plan_NN
of_PIN
1,141,164_CD
to_TO
enhance_VB
his_TPP3
pension_NN
entitlement_NOMZ
._.
Mr_NN
fide_NN
Swaan_NN
joined_VBD
the_DT
Board_NN
as_IN
a_DT
non-executive_JJ
Director_NN
on_PIN
1st_CD
January_NN
2006_CD
._.
No_SYNE
remuneration_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
for_PIN
him_TPP3
in_PIN
the_DT
table_NN
above_PLACE
._.
The_DT
accrued_VBN
annual_JJ
benets_NN
under_IN
the_DT
dened_VBN
benefit_NN
pension_NN
schemes_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
were_VBD
:_:
Dr_NN
Garnier_NN
$_$
1,092,697_CD
:_:
Mr_NN
Heslop_NN
74,505_CD
:_:
and_ANDC
Dr_NN
Yamada_NN
$_$
209,631_CD
._.
In_CONJ
addition_NULL
,_,
Dr_NN
Garnier_NN
and_PHC
Dr_NN
Yamada_NN
are_VPRT
members_NN
of_PIN
a_DT
money_NN
purchase_NN
scheme_NN
into_PIN
which_WDT [PIRE]
contributions_NOMZ
of_PIN
$_$
154,172_CD
and_CC
$_$
73,679_CD
,_,
respectively_RB
,_,
were_VBD [PASS]
paid_VBN
during_PIN
2005_CD
._.
None_INPR
of_PIN
the_DT
above_PLACE
Directors_NN
received_VBD
expenses_NN
during_PIN
the_DT
year_NN
requiring_VBG [SUAV] [WZPRES]
separate_JJ
disclosure_NN
as_IN
dened_VBN
by_PIN
the_DT
Regulations_NOMZ
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
22_CD
Corporate_JJ
governance_NN
GOVERNANCE_NN
AND_PHC
POLICY_NN
Audit_NN
Committee_NN
The_NN
Board_NN
and_PHC
Corporate_NN
Executive_NN
Team_NN
The_NN
Audit_NN
Committee_NN
reviews_VPRT
the_DT
financial_JJ
and_PHC
internal_JJ
The_DT
Directors_NN
are_VPRT [PASS]
listed_VBN
under_IN
The_DT
Board_NN
on_PIN
page_NN
18_CD
._.
reporting_VBG [PUBV]
process_NN
,_,
the_DT
system_NN
of_PIN
internal_JJ
control_NN
and_PHC
management_NOMZ
of_PIN
risks_NN
and_CC
the_DT
external_JJ
and_PHC
internal_JJ
audit_NN
The_DT
Board_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Groups_NN
system_NN
of_PIN
process_NN
._.
The_DT
Committee_NN
also_RB
proposes_VPRT [SUAV]
to_PIN
shareholders_NN
corporate_JJ
governance_NN
and_CC
is_VPRT [BEMA]
ultimately_RB
accountable_PRED
for_PIN
the_DT
appointment_NOMZ
of_PIN
the_DT
external_JJ
auditors_NN
and_CC
is_VPRT [BEMA]
directly_RB
the_DT
Groups_NN
activities_NOMZ
,_,
strategy_NN
and_CC
financial_JJ
performance_NN
._.
responsible_JJ
for_PIN
their_TPP3
remuneration_NOMZ
and_PHC
oversight_NN
of_PIN
their_TPP3
The_DT
CEO_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
executive_JJ
management_NOMZ
of_PIN
the_DT
work_NN
._.
The_DT
Committee_NN
consists_VPRT
entirely_AMP
of_PIN
independent_JJ
Group_NN
and_CC
is_VPRT [PASS]
assisted_VBN
in_PIN
this_DEMO
by_PIN
the_DT
CET_NN
._.
The_DT
CET_NN
meets_VPRT
Non-Executive_JJ
Directors_NN
._.
It_PIT
meets_VPRT
at_PIN
least_JJ
four_CD
times_NN
a_DT
year_NN
._.
11_CD
times_NN
per_PIN
year_NN
and_ANDC
otherwise_CONJ
as_RB
necessary_JJ
._.
The_DT
Remuneration_NOMZ
Committee_NN
members_NN
and_CC
their_TPP3
responsibilities_NOMZ
are_VPRT [PASS]
listed_VBN
under_IN
The_DT
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
the_DT
terms_NN
of_PIN
Corporate_NN
Executive_NN
Team_NN
on_PIN
page_NN
19_CD
._.
service_NN
and_PHC
remuneration_NOMZ
of_PIN
the_DT
Executive_NN
Directors_NN
and_CC
The_DT
Board_NN
comprises_VPRT
three_CD
Executive_NN
and_CC
nine_CD
Nonmembers_NN
of_PIN
the_DT
CET_NN
and_CC
,_,
with_PIN
the_DT
assistance_NN
of_PIN
external_JJ
Executive_NN
Directors_NN
._.
Whilst_OSUB
the_DT
Board_NN
considers_VPRT [PRIV]
all_QUAN
of_PIN
its_PIT
independent_JJ
advisors_NN
,_,
it_PIT
evaluates_VPRT
and_PHC
makes_VPRT
Non-Executive_JJ
Directors_NN
to_TO
be_VB [BEMA]
independent_PRED
in_PIN
character_NN
recommendations_NOMZ
to_PIN
the_DT
Board_NN
on_PIN
overall_JJ
executive_NN
and_PHC
judgement_NOMZ
,_,
it_PIT
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
Dr_NN
Shapiro_NN
should_NEMD
remuneration_VB
policy_NN
._.
The_DT
Committee_NN
consists_VPRT
entirely_AMP
of_PIN
not_XX0
be_VB [PASS]
considered_VBN [PRIV]
as_IN
independent_JJ
under_IN
the_DT
Combined_VBN
independent_JJ
Non-Executive_JJ
Directors_NN
._.
It_PIT
meets_VPRT
at_PIN
least_JJ
Code_NN
on_PIN
Corporate_NN
Governance_NN
Combined_NN
Code_NN
._.
This_DEMO
four_CD
times_NN
a_DT
year_NN
and_ANDC
otherwise_CONJ
as_RB
necessary_JJ
._.
is_VPRT [BEMA]
due_PRED
to_PIN
the_DT
remuneration_NOMZ
that_TOBJ
she_TPP3
receives_VPRT
from_PIN
the_DT
Nominations_NOMZ
Committee_NN
Group_NN
as_IN
a_DT
member_NN
of_PIN
the_DT
GSK_NN
scientific_JJ
Advisory_NN
Board_NN
._.
The_DT
Nominations_NOMZ
Committee_NN
reviews_VPRT
the_DT
structure_NN
,_,
size_NN
The_NN
Board_NN
considers_VPRT [PRIV]
that_THVC
Mr_NN
Culp_NN
,_,
Sir_NN
Crispin_NN
Davis_NN
,_,
Sir_NN
and_PHC
composition_NOMZ
of_PIN
the_DT
Board_NN
and_CC
the_DT
appointment_NOMZ
of_PIN
Deryck_NN
Maughan_NN
,_,
Sir_NN
Ian_NN
Prosser_NN
,_,
Dr_NN
Schmitz_NN
,_,
Mr_NN
fide_VBD
Swaan_JJ
members_NN
of_PIN
the_DT
Board_NN
and_CC
the_DT
CET_NN
,_,
and_ANDC
makes_VPRT
and_CC
Sir_NN
Robert_NN
Wilson_NN
are_VPRT [BEMA]
independent_PRED
under_IN
the_DT
Combined_JJ
recommendations_NOMZ
to_PIN
the_DT
Board_NN
as_IN
appropriate_JJ
._.
Sir_NN
Ian_NN
Prosser_NN
is_VPRT [BEMA]
the_DT
Senior_JJ
Independent_NN
Director_NN
._.
Committee_NN
also_RB
monitors_VPRT
the_DT
planning_GER
of_PIN
succession_NN
to_PIN
the_DT
Board_NN
and_PHC
Senior_NN
Management_NOMZ
._.
The_DT
Committee_NN
Throughout_PIN
2005_CD
and_CC
up_RB
to_PIN
the_DT
date_NN
of_PIN
this_DEMO
publication_NOMZ
,_,
consists_VPRT
entirely_AMP
of_PIN
Non-Executive_JJ
Directors_NN
,_,
of_PIN
whom_WP [PIRE]
a_DT
a_DT
majority_NOMZ
of_PIN
the_DT
Board_NN
members_NN
,_,
excluding_VBG [PRESP]
the_DT
Chairman_NN
,_,
majority_NOMZ
are_VPRT [BEMA]
independent_PRED
,_,
and_ANDC
meets_VPRT
at_PIN
least_JJ
once_TIME
a_DT
year_NN
were_VBD [BEMA]
independent_JJ
Non-Executive_JJ
Directors_NN
,_,
in_PIN
accordance_NN
and_ANDC
otherwise_CONJ
as_RB
necessary_JJ
._.
with_PIN
the_DT
recommendations_NOMZ
of_PIN
the_DT
Combined_NN
Code_NN
._.
Corporate_JJ
Responsibility_NOMZ
Committee_NN
Board_NN
process_NN
The_DT
Corporate_JJ
Responsibility_NOMZ
Committee_NN
consists_VPRT
entirely_AMP
The_DT
Board_NN
meets_VPRT
at_PIN
least_JJ
six_CD
times_NN
a_DT
year_NN
._.
It_PIT
has_VPRT
a_DT
formal_JJ
of_PIN
Non-Executive_JJ
Directors_NN
and_CC
provides_VPRT
a_DT
Board_NN
level_NN
schedule_NN
of_PIN
matters_NN
reserved_VBN [WZPAST]
to_PIN
it_PIT
for_PIN
decision_NN
but_CC
forum_NN
for_PIN
the_DT
regular_JJ
review_NN
of_PIN
external_JJ
issues_NN
that_TSUB
have_VPRT
otherwise_CONJ
delegates_NN
specic_JJ
responsibilities_NOMZ
to_PIN
Board_NN
the_DT
potential_NN
for_PIN
serious_JJ
impact_NN
upon_PIN
the_DT
Groups_NN
business_NOMZ
committees_NN
,_,
as_IN
described_VBN
below_PLACE
._.
The_DT
Board_NN
works_VPRT
to_PIN
an_DT
and_CC
reputation_NOMZ
and_CC
for_PIN
the_DT
oversight_NN
of_PIN
reputation_NOMZ
agreed_VBD [SUAV] [PUBV]
business_NOMZ
agenda_NN
in_PIN
reviewing_VBG
the_DT
key_JJ
activities_NOMZ
of_PIN
management_NOMZ
._.
The_DT
Committee_NN
is_VPRT [BEMA]
also_RB
responsible_PRED
for_PIN
the_DT
business_NOMZ
,_,
and_ANDC
receives_VPRT
papers_NN
and_PHC
presentations_NOMZ
to_PIN
annual_JJ
governance_NN
oversight_NN
of_PIN
the_DT
Groups_NN
worldwide_VPRT
enable_VB
it_PIT
to_TO
do_VB
so_RB
effectively_RB
._.
The_DT
Board_NN
considers_VPRT [PRIV]
and_CC
donations_NOMZ
and_PHC
community_NOMZ
support_NN
._.
The_DT
Committee_NN
meets_VPRT
reviews_VPRT
the_DT
work_NN
undertaken_VBN [WZPAST]
by_PIN
its_PIT
Committees_NN
._.
formally_RB
three_CD
times_NN
a_DT
year_NN
and_ANDC
otherwise_CONJ
as_RB
necessary_JJ
._.
The_DT
Company_NN
Secretary_NN
is_VPRT [BEMA]
responsible_PRED
to_PIN
the_DT
Board_NN
and_CC
is_VPRT [BEMA]
Financial_JJ
Results_NN
Committee_NN
available_JJ
to_PIN
individual_JJ
Directors_NN
in_PIN
respect_NN
of_PIN
Board_NN
The_NN
Financial_NN
Results_NN
Committee_NN
reviews_VPRT
and_PHC
approves_VPRT
,_,
on_PIN
procedures_NN
._.
The_DT
Company_NN
Secretary_NN
is_VPRT
Mr_NN
Simon_NN
Bicknell_NN
,_,
behalf_NN
of_PIN
the_DT
Board_NN
,_,
the_DT
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_NN
,_,
the_DT
a_DT
barrister_NN
,_,
who_WP
was_VBD [PASS]
appointed_VBN
in_PIN
May_POMD
2000_CD
and_CC
joined_VBD
Annual_JJ
Review_NN
and_CC
the_DT
convening_VBG
of_PIN
the_DT
AGM_NN
,_,
together_RB
GSK_NN
in_PIN
1984_CD
._.
He_TPP3
is_VPRT
secretary_NN
to_PIN
all_QUAN
the_DT
Board_NN
Committees_NN
._.
with_PIN
the_DT
preliminary_JJ
and_PHC
quarterly_JJ
statements_NOMZ
of_PIN
trading_GER
Board_NN
Committees_NN
results_NN
._.
Each_QUAN
Director_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Committee_NN
and_PHC
The_NN
Board_NN
has_VPRT [PEAS]
established_VBN [PRIV]
a_DT
number_NN
of_PIN
committees_NN
._.
the_DT
quorum_NN
for_PIN
a_DT
meeting_GER
is_VPRT [BEMA]
any_QUAN
three_CD
members_NN
._.
To_TO
be_VB
Executive_NN
Directors_NN
are_VPRT
not_XX0
members_NN
of_PIN
the_DT
Audit_NN
,_,
quorate_NN
,_,
each_QUAN
meeting_GER
must_NEMD
include_VB
the_DT
Chairman_NN
or_CC
the_DT
Remuneration_NOMZ
,_,
Nominations_NOMZ
or_CC
Corporate_NN
Responsibility_NOMZ
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
and_CC
the_DT
CEO_NN
or_CC
the_DT
Committees_NN
,_,
although_CONC
they_TPP3
may_POMD
be_VB [PASS]
invited_VBN
to_TO
attend_VB
CFO_NN
._.
The_DT
Committee_NN
meets_VPRT
as_RB
necessary_JJ
._.
Each_QUAN
Director_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Corporate_JJ
Corporate_JJ
Administration_NOMZ
&_CC
Transactions_NOMZ
Administration_NOMZ
&_CC
Transactions_NOMZ
and_CC
Financial_JJ
Results_NN
Committee_NN
Committees_NN
._.
Membership_NN
of_PIN
these_DEMO
Committees_NN
is_VPRT [PASS]
shown_VBN [PRIV]
The_DT
Corporate_JJ
Administration_NOMZ
&_CC
Transactions_NOMZ
Committee_NN
in_PIN
the_DT
table_NN
below_PLACE
._.
reviews_NN
and_CC
approves_VPRT
matters_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
Corporate_JJ
administration_NOMZ
of_PIN
the_DT
Groups_NN
business_NOMZ
,_,
and_ANDC
certain_JJ
Audit_NN
Remuneration_NOMZ
Nominations_NOMZ
Responsibility_NOMZ
corporate_JJ
transactions_NOMZ
._.
The_DT
Committee_NN
consists_VPRT
of_PIN
the_DT
Sir_NN
Christopher_NN
Gent_NN
C_NN
C_NN
Directors_NN
,_,
CET_NN
members_NN
and_CC
the_DT
Company_NN
Secretary_NN
._.
The_DT
Mr_NN
L_NN
Culp_NN
M_NN
Committee_NN
meets_VPRT
as_RB
necessary_JJ
._.
Sir_NN
Crispin_NN
Davis_NN
M_NN
Sir_NN
Deryck_NN
Maughan_NN
M_NN
Remuneration_NOMZ
of_PIN
Directors_NN
Sir_NN
Ian_NN
Prosser_NN
M_NN
M_NN
M_NN
Information_NOMZ
on_PIN
the_DT
remuneration_NOMZ
of_PIN
Directors_NN
is_VPRT [PASS]
given_VBN
in_PIN
Dr_NN
R_NN
Schmitz_NN
C_NN
M_NN
M_NN
Dr_NN
L_NN
Shapiro_NN
M_NN [BEMA]
the_DT
Summary_NN
Remuneration_NOMZ
Report_NN
on_PIN
pages_NN
20_CD
to_PIN
22_CD
._.
Mr_NN
fide_NN
Swaan_NN
M_NN
Sir_NN
Robert_NN
Wilson_NN
M_NN
C_NN
Mr_NN
fide_NN
Swaan_NN
will_PRMD
succeed_VB
Dr_NN
Schmitz_NN
as_IN
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
from_PIN
September_NN
2006_CD
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
23_CD
Responsibility_NOMZ
statements_NOMZ
ANNUAL_NN
REVIEW_NN
INDEPENDENT_NN
AUDITORS_NN
STATEMENT_NOMZ
TO_PIN
THE_DT
The_DT
Annual_JJ
Review_NN
is_VPRT [BEMA]
a_DT
summary_NN
report_NN
and_CC
does_VPRT
not_XX0
MEMBERS_NN
OF_PIN
GLAXOSMITHKLINE_NN
PLC_NN
contain_VPRT
sufficient_JJ
information_NOMZ
to_TO
allow_VB [SUAV]
as_IN
full_JJ
an_DT
underWe_NN
have_VPRT [PEAS]
examined_VBN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
standing_VBG [WZPRES]
of_PIN
the_DT
results_NN
and_PHC
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Group_NN
which_WDT [WHSUB]
comprise_VPRT
the_DT
Summary_NN
consolidated_JJ
income_NN
as_IN
is_VPRT [BYPA]
provided_VBN
by_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
._.
Shareholders_NN
statement_NOMZ
,_,
Summary_NN
consolidated_JJ
balance_NN
sheet_NN
and_CC
requiring_VBG [SUAV]
more_EMPH
detailed_JJ
information_NOMZ
may_POMD
obtain_VB
,_,
free_JJ
of_PIN
Summary_NN
consolidated_JJ
cash_NN
ow_NN
statement_NOMZ
and_CC
the_DT
charge_NN
,_,
a_DT
copy_NN
of_PIN
the_DT
Annual_JJ
Report_NN
and_CC
may_POMD [SPAU]
also_RB
elect_VB
Summary_NN
Report_NN
of_PIN
the_DT
Directors_NN
including_VBG [WZPRES]
the_DT
Summary_NN
to_TO
receive_VB
a_DT
copy_NN
of_PIN
the_DT
Annual_JJ
Report_NN
in_PIN
future_JJ
years_NN
Remuneration_NOMZ
Report_NN
._.
Respective_JJ
responsibilities_NOMZ
of_PIN
Directors_NN
and_PHC
auditors_NN
The_DT
Independent_NN
Auditors_NN
report_VPRT [PUBV]
on_PIN
the_DT
full_JJ
financial_JJ
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
the_DT
Annual_JJ
statements_NOMZ
of_PIN
the_DT
Group_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
Review_NN
in_PIN
accordance_NN
with_PIN
applicable_JJ
law_NN
._.
Our_FPP1
responDecember_NN
2005_CD
is_VPRT [BEMA]
unqualied_PRED
and_CC
does_VPRT
not_XX0
contain_VB
any_QUAN
sibility_NOMZ
is_VPRT
to_TO
report_VB [PUBV]
to_PIN
you_SPP2
our_FPP1
opinion_NN
on_PIN
the_DT
consistency_NN
statement_NOMZ
concerning_VBG [WZPRES]
inadequate_JJ
accounting_GER
records_NN
or_CC
of_PIN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
within_PIN
the_DT
Annual_JJ
failure_NN
to_TO
obtain_VB
necessary_JJ
information_NOMZ
and_PHC
explanations_NOMZ
._.
Review_NN
with_PIN
the_DT
Annual_JJ
financial_JJ
statements_NOMZ
,_,
the_DT
Report_NN
of_PIN
the_DT
Directors_NN
and_CC
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
,_,
STATEMENT_NOMZ
BY_PIN
THE_DT
DIRECTORS_NN
and_CC
its_PIT
compliance_NN
with_PIN
the_DT
relevant_JJ
requirements_NOMZ
of_PIN
The_DT
Annual_JJ
Review_NN
2005_CD
is_VPRT [BEMA]
the_DT
Summary_NN
Directors_NN
report_VPRT [PUBV]
Section_NOMZ
251_CD
of_PIN
the_DT
United_NN
Kingdom_NN
Companies_NN
Act_NN
1985_CD
and_CC
includes_VPRT
the_DT
Summary_NN
financial_JJ
statements_NOMZ
of_PIN
Glaxoand_NN
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
We_FPP1
also_RB
read_VBD
the_DT
SmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2005_CD
,_,
other_JJ
information_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Review_NN
and_ANDC
which_WDT
is_VPRT [PASS]
published_VBN
in_PIN
hard-copy_JJ
printed_VBN
form_NN
and_CC
on_PIN
the_DT
consider_VB [PRIV]
the_DT
implications_NOMZ
for_PIN
our_FPP1
report_NN
if_COND
we_FPP1
become_VPRT
website_JJ
._.
The_DT
Business_NOMZ
operating_VBG [WZPRES]
review_NN
,_,
the_DT
Summary_NN
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
material_NN
inconfinancial_JJ
statements_NOMZ
,_,
the_DT
Summary_NN
Remuneration_NOMZ
Report_NN
sistencies_NN
with_PIN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
._.
and_ANDC
the_DT
Statement_NOMZ
on_PIN
corporate_JJ
governance_NN
are_VPRT
summaries_NN
These_DEMO
statements_NOMZ
,_,
including_VBG [PRESP]
the_DT
opinion_NN
,_,
have_VPRT [PEAS]
been_VBN [BEMA]
preof_JJ
information_NOMZ
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
._.
pared_VBN [PASTP]
for_PIN
and_CC
only_DWNT
for_PIN
the_DT
companys_NN
members_NN
as_IN
a_DT
body_NN
profit_NN
attributable_JJ
to_PIN
shareholders_NN
and_CC
total_JJ
equity_NOMZ
are_VPRT [BEMA]
also_RB
in_PIN
accordance_NN
with_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
restated_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
as_IN
additional_JJ
1985_CD
and_CC
for_PIN
no_SYNE
other_JJ
purpose_NN
._.
We_FPP1
do_VPRT
not_XX0
,_,
in_PIN
giving_VBG
this_DEMO
information_NOMZ
provided_VBN [WZPAST]
to_PIN
US_FPP1
shareholders_NN
._.
opinion_NN
,_,
accept_VB [PRIV]
or_CC
assume_VB [PRIV]
responsibility_NOMZ
for_PIN
any_QUAN
other_JJ
purpose_NN
or_CC
to_PIN
any_QUAN
other_JJ
person_NN
to_PIN
whom_WP [PIRE]
this_DEMO
statement_NOMZ
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
maintenance_NN
and_CC
is_VPRT [PASS]
shown_VBN [PRIV]
or_CC
into_PIN
whose_WPS [PIRE]
hands_NN
it_PIT
may_POMD
come_VB
save_IN
where_RB
integrity_NOMZ
of_PIN
the_DT
Annual_JJ
Review_NN
on_PIN
the_DT
website_NN
in_PIN
accordance_NN
expressly_RB
agreed_VBN [SUAV] [PUBV]
by_PIN
our_FPP1
prior_JJ
consent_NN
in_PIN
writing_VBG [PUBV]
._.
with_PIN
the_DT
UK_NN
legislation_NOMZ
governing_VBG [WZPRES]
the_DT
preparation_NOMZ
and_PHC
dissemination_NOMZ
of_PIN
financial_JJ
statements_NOMZ
._.
Access_NN
to_PIN
the_DT
website_JJ
Basis_NN
of_PIN
opinion_NN
is_VPRT [BEMA]
available_PRED
from_PIN
outside_PLACE
the_DT
UK_NN
,_,
where_RB
comparable_JJ
We_FPP1
conducted_VBD
our_FPP1
work_NN
in_PIN
accordance_NN
with_PIN
Bulletin_NN
legislation_NOMZ
may_POMD
be_VB [BEMA]
different_PRED
._.
1999_CD
6_CD
,_,
The_DT
auditors_NN
statement_NOMZ
on_PIN
the_DT
Summary_NN
financial_JJ
statement_NOMZ
issued_VBN [WZPAST]
by_PIN
the_DT
Auditing_GER
Practices_NN
Board_NN
for_PIN
use_NN
CORPORATE_JJ
GOVERNANCE_NN
in_PIN
the_DT
United_NN
Kingdom_NN
._.
The_DT
Combined_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
is_VPRT [PASS]
specified_VBN
Opinion_NN
by_PIN
the_DT
Listing_GER
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
Authority_NOMZ
for_PIN
In_PIN
our_FPP1
opinion_NN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
are_VPRT [BEMA]
conthe_JJ
guidance_NN
of_PIN
listed_VBN
companies_NN
Combined_NN
Code_NN
._.
The_DT
sistent_NN
with_PIN
the_DT
Annual_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
,_,
Board_NN
considers_VPRT [PRIV]
that_THVC
throughout_PIN
2005_CD
and_CC
up_RB
to_PIN
the_DT
date_NN
the_DT
Report_NN
of_PIN
the_DT
Directors_NN
and_CC
the_DT
Remuneration_NOMZ
Report_NN
of_PIN
approval_NN
of_PIN
this_DEMO
review_NN
,_,
GlaxoSmithKline_NN
plc_NN
applied_VBD
of_PIN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
the_DT
principles_NN
of_PIN
the_DT
Combined_NN
Code_NN
and_CC
,_,
with_PIN
the_DT
2005_CD
and_CC
comply_VB
with_PIN
the_DT
applicable_JJ
requirements_NOMZ
of_PIN
exception_NOMZ
of_PIN
matters_NN
where_RB
the_DT
companys_NN
position_NOMZ
is_VPRT
Section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
described_VBN
in_PIN
the_DT
Annual_JJ
Report_NN
,_,
complied_VBN [PASTP]
with_PIN
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
provisions_NN
of_PIN
the_DT
Combined_NN
Code_NN
,_,
and_ANDC
the_DT
guidance_NN
on_PIN
internal_JJ
control_NN
issued_VBN [WZPAST]
by_PIN
the_DT
1998_CD
Turnbull_NN
Committee_NN
._.
The_DT
Annual_JJ
Review_NN
,_,
including_VBG
Summary_NN
financial_JJ
statements_NOMZ
,_,
has_VPRT [PEAS]
been_VBN [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
and_CC
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
Sir_NN
Christopher_NN
Gent_NN
LLP_NN
Chairman_NN
Chartered_NN
Accountants_NN
and_PHC
Registered_NN
Auditors_NN
1st_CD
March_NN
2006_CD
London_NN
1st_CD
March_NN
2006_CD
GSK_NN
Annual_JJ
Review_NN
2005_CD
24_CD
Summary_NN
financial_JJ
statements_NOMZ
SUMMARY_NN
CONSOLIDATED_NN
INCOME_NN
STATEMENT_NOMZ
2005_CD
Growth_NN
2004_CD
m_NN [BEMA]
CER_CD
%_NN
m_NN
Turnover_NN
Pharmaceutical_NN
18,661_CD
8_CD
17,100_CD
Consumer_NN
Healthcare_NN
2,999_CD
2_CD
2,886_CD
Total_JJ
turnover_NN
21,660_CD
7_CD
19,986_CD
Cost_NN
of_PIN
sales_NN
4,764_CD
8_CD
4,360_CD
Gross_NN
profit_NN
16,896_CD
7_CD
15,626_CD
Selling_GER
,_,
general_JJ
and_CC
administration_NOMZ
7,250_CD
7,201_CD
Research_NN
and_PHC
development_NOMZ
3,136_CD
8_CD
2,904_CD
Other_JJ
operating_GER
income_NN
364_CD
235_CD
Operating_GER
profit_NN
6,874_CD
16_CD
5,756_CD
Finance_NN
income_NN
257_CD
176_CD
Finance_NN
costs_NN
451_CD
362_CD
Share_NN
of_PIN
after_IN
tax_NN
profits_NN
of_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
52_CD
60_CD
profit_NN
on_PIN
disposal_NN
of_PIN
interest_NN
in_PIN
associates_NN
149_CD
profit_NN
before_IN
taxation_NOMZ
6,732_CD
13_CD
5,779_CD
Taxation_NOMZ
1,916_CD
1,757_CD
profit_NN
after_IN
taxation_NOMZ
for_PIN
the_DT
year_NN
4,816_CD
17_CD
4,022_CD
profit_NN
attributable_JJ
to_PIN
minority_NOMZ
interests_NN
127_CD
114_CD
profit_NN
attributable_JJ
to_PIN
shareholders_NN
4,689_CD
3,908_CD
4,816_CD
4,022_CD
Basic_JJ
earnings_GER
per_PIN
share_NN
pence_NN
82.6_CD
p_NN
18_CD
68.1_CD
p_NN
Diluted_VBN
earnings_GER
per_PIN
share_NN
pence_NN
82.0_CD
p_VPRT
68.0_CD
p_JJ
SUMMARY_NN
CONSOLIDATED_NN
BALANCE_NN
SHEET_NN
2005_CD
2004_CD
m_NN
m_NN [BEMA]
Total_JJ
non-current_JJ
assets_NN
14,021_CD
12,164_CD
Total_JJ
current_JJ
assets_NN
13,177_CD
10,780_CD
Total_JJ
assets_NN
27,198_CD
22,944_CD
Total_JJ
current_JJ
liabilities_NOMZ
9,511_CD
8,564_CD
Total_JJ
non-current_JJ
liabilities_NOMZ
10,117_CD
8,443_CD
Total_JJ
liabilities_NOMZ
19,628_CD
17,007_CD
Net_JJ
assets_NN
7,570_CD
5,937_CD
Shareholders_NN
equity_NOMZ
7,311_CD
5,724_CD
Minority_NOMZ
interests_NN
259_CD
213_CD
Total_JJ
equity_NOMZ
7,570_CD
5,937_CD
SUMMARY_NN
CONSOLIDATED_NN
CASH_NN
FLOW_NN
STATEMENT_NOMZ
2005_CD
2004_CD
m_NN
m_NN [BEMA]
Net_JJ
cash_NN
inow_NN
from_PIN
operating_VBG
activities_NOMZ
5,958_CD
4,944_CD
Net_JJ
cash_NN
outow_NN
from_PIN
investing_VBG
activities_NOMZ
1,660_CD
920_CD
Net_JJ
cash_NN
outow_NN
from_PIN
nancing_VBG
activities_NOMZ
2,914_CD
3,407_CD
Increase_VPRT
in_PIN
cash_NN
in_PIN
the_DT
year_NN
1,384_CD
617_CD
Exchange_NN
adjustments_NOMZ
233_CD
93_CD
Cash_NN
and_PHC
bank_NN
overdrafts_NN
at_PIN
beginning_GER
of_PIN
year_NN
2,355_CD
1,831_CD
Cash_NN
and_PHC
bank_NN
overdrafts_NN
at_PIN
end_NN
of_PIN
year_NN
3,972_CD
2,355_CD
Cash_NN
and_PHC
bank_NN
overdrafts_NN
at_PIN
end_NN
of_PIN
year_NN
comprise_VPRT
:_:
Cash_NN
and_PHC
cash_NN
equivalents_NN
4,209_CD
2,467_CD
Overdrafts_NN
237_CD
112_CD
3,972_CD
2,355_CD
GSK_NN
Annual_JJ
Review_NN
2005_CD
25_CD
Summary_NN
information_NOMZ
under_IN
US_FPP1
GAAP_NN
The_NN
following_VBG [WZPRES]
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
material_NN
adjustments_NOMZ
to_TO
profit_VB
and_CC
shareholders_NN
funds_NN
which_WDT [WHSUB]
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
IFRS_NN
._.
PROFIT_NN
2005_CD
2004_CD
m_NN
m_NN
profit_NN
after_IN
taxation_NOMZ
for_PIN
the_DT
year_NN
under_IN
IFRS_NN
4,816_CD
4,022_CD
profit_NN
attribtable_JJ
to_PIN
minority_NOMZ
interests_NN
127_CD
114_CD
profit_NN
attributable_JJ
to_PIN
shareholders_NN
under_IN
IFRS_NN
4,689_CD
3,908_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Product_NN
rights_NN
1,682_CD
1,651_CD
Capitalised_VBN
interest_NN
1_CD
17_CD
Disposal_NN
of_PIN
interests_NN
in_PIN
associates_NN
and_PHC
subsidiaries_NN
97_CD
Equity_NOMZ
investments_NOMZ
2_CD
30_CD
Employee_NN
costs_NN
121_CD
113_CD
Derivative_JJ
instruments_NOMZ
and_CC
hedging_VBG
30_CD
50_CD
Restructuring_GER
1_CD
12_CD
Taxation_NOMZ
538_CD
747_CD
Other_JJ
56_CD
53_CD
Net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
3,336_CD
2,732_CD
Basic_JJ
income_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
58.8_CD
p_NN
47.6_CD
p_VPRT
Diluted_JJ
income_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
58.3_CD
p_NN
47.5_CD
p_NN
EQUITY_NOMZ
SHAREHOLDERS_NN
FUNDS_NN
2005_CD
2004_CD
m_NN
m_NN [BEMA]
Total_JJ
equity_NOMZ
under_IN
IFRS_NN
7,570_CD
5,937_CD
Minority_NOMZ
interests_NN
259_CD
213_CD
Shareholders_NN
equity_NOMZ
under_IN
IFRS_NN
7,311_CD
5,724_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Product_NN
rights_NN
and_PHC
goodwill_NN
30,041_CD
31,573_CD
Fixed_VBN
assets_NN
212_CD
223_CD
Marketable_JJ
securities_NOMZ
49_CD
Other_JJ
investments_NOMZ
576_CD
532_CD
Employee_NN
costs_NN
1,249_CD
1,230_CD
Restructuring_GER
65_CD
80_CD
Derivative_JJ
instruments_NOMZ
and_CC
hedging_VBG
33_CD
2_CD
Dividends_NN
568_CD
571_CD
Deferred_JJ
taxation_NOMZ
4,531_CD
4,840_CD
Other_JJ
40_CD
40_CD
Shareholders_NN
equity_NOMZ
under_IN
US_FPP1
GAAP_NN
34,282_CD
34,042_CD
A_DT
summary_NN
of_PIN
the_DT
material_NN
differences_NN
between_PIN
IFRS_NN
and_PHC
US_FPP1
GAAP_NN
that_TSUB
apply_VB
to_PIN
the_DT
Group_NN
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
26_CD
Shareholder_NN
information_NOMZ
FINANCIAL_NN
REPORTING_GER
DIVIDENDS_NN
Financial_NN
reporting_VBG [PUBV] [WZPRES]
calendar_NN
2006_CD
GSK_NN
pays_VPRT
dividends_NN
quarterly_RB
._.
Announcement_NOMZ
of_PIN
1st_CD
Quarter_NN
Results_NN
The_DT
Board_NN
has_VPRT [PEAS]
declared_VBN [PUBV]
dividends_NN
for_PIN
2005_CD
as_IN
follows_VPRT
:_:
April_NN
2006 2005 2004_CD
Announcement_NOMZ
of_PIN
2nd_CD
Quarter_NN
Results_NN
Dividends_NN
per_PIN
share_NN
pence_NN
pence_NN
July_NN
2006_CD
First_NN
interim_JJ
paid_VBN
7th_JJ
July_NN
2005_CD
10_CD
10_CD
Announcement_NOMZ
of_PIN
3rd_CD
Quarter_NN
Results_NN
Second_JJ
interim_NN
paid_VBD
6th_JJ
October_NN
2005_CD
10_CD
10_CD
October_NN
2006_CD
Third_NN
interim_JJ
paid_VBN
5th_JJ
January_NN
2006_CD
10_CD
10_CD
Fourth_JJ
interim_JJ
payable_JJ
6th_JJ
April_NN
2006_CD
14_CD
12_CD
Preliminary_JJ
Announcement_NOMZ
of_PIN
Annual_JJ
Results_NN
February_NN
2007_CD
Total_JJ
44_CD
42_CD
Publication_NOMZ
of_PIN
Annual_JJ
Report_NN
Review_NN
As_IN
a_DT
guide_NN
to_PIN
holders_NN
of_PIN
ADRs_NN
,_,
the_DT
table_NN
below_PLACE
sets_NN
out_PIN
March_NN
2007_CD
the_DT
dividends_NN
paid_VBD
per_PIN
ADS_NN
in_PIN
US_FPP1
dollars_NN
in_PIN
the_DT
last_JJ
five_CD
years_NN
translated_VBN [WZPAST]
into_PIN
US_FPP1
dollars_NN
at_PIN
applicable_JJ
exchange_NN
Results_NN
Announcements_NOMZ
rates_NN
._.
Results_NN
Announcements_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
and_CC
are_VPRT [BEMA]
available_PRED
on_PIN
its_PIT
news_NN
service_NN
._.
Shortly_TIME
Year_NN
US$_$
afterwards_TIME
,_,
they_TPP3
are_VPRT [PASS]
issued_VBN
to_PIN
the_DT
media_NN
,_,
are_VPRT [PASS]
made_VBN
2005_CD
1.57_CD
available_JJ
on_PIN
the_DT
website_NN
and_CC
are_VPRT [PASS]
submitted_VBN [PUBV]
to_PIN
the_DT
US_FPP1
2004_CD
1.53_CD
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
and_CC
the_DT
New_NN
York_NN
2003_CD
1.39_CD
Stock_NN
Exchange_NN
._.
2002_CD
1.24_CD
2001_CD
1.11_CD
Financial_JJ
reports_NN
The_DT
company_NN
publishes_VPRT
an_DT
Annual_JJ
Report_NN
and_CC
,_,
for_PIN
the_DT
Dividend_NN
calendar_NN
investor_NN
not_XX0
needing_VBG
the_DT
full_JJ
detail_NN
of_PIN
the_DT
Report_NN
,_,
an_DT
Fourth_JJ
quarter_NN
2005_CD
Annual_JJ
Review_NN
._.
These_DEMP
are_VPRT [BEMA]
available_PRED
on_PIN
the_DT
website_NN
._.
The_DT
Ex-dividend_NN
date_NN
15th_JJ
February_NN
2006_CD
Annual_JJ
Review_NN
is_VPRT [PASS]
sent_VBN
to_PIN
all_QUAN
shareholders_NN
on_PIN
the_DT
date_NN
of_PIN
Record_NN
date_NN
17th_JJ
February_NN
2006_CD
publication_NOMZ
._.
Shareholders_NN
may_POMD [SPAU]
also_RB
elect_VB
to_TO
receive_VB
the_DT
Payable_JJ
6th_JJ
April_NN
2006_CD
Annual_JJ
Report_NN
by_PIN
writing_VBG [PUBV]
to_PIN
the_DT
companys_NN
registrars_NN
._.
Alternatively_CONJ
,_,
shareholders_NN
may_POMD
elect_VB
to_TO
receive_VB
notication_NOMZ
First_JJ
quarter_NN
2006_CD
by_PIN
email_NN
of_PIN
the_DT
publication_NOMZ
of_PIN
financial_JJ
reports_NN
by_PIN
Ex-dividend_NN
date_NN
10th_JJ
May_POMD
2006_CD
registering_VBG
on_PIN
www_NN
._.
Copies_NN
of_PIN
previous_JJ
Record_NN
date_NN
12th_JJ
May_POMD
2006_CD
financial_JJ
reports_NN
are_VPRT [BEMA]
available_PRED
on_PIN
the_DT
website_NN
._.
Printed_NN
Payable_NN
6th_VPRT
July_NN
2006_CD
copies_NN
can_POMD
be_VB [PASS]
obtained_VBN
from_PIN
the_DT
registrar_NN
in_PIN
the_DT
UK_NN
and_CC
from_PIN
the_DT
Customer_NN
Response_NN
Center_NN
in_PIN
the_DT
USA_NN
._.
Second_JJ
quarter_NN
2006_CD
Publications_NOMZ
Ex-dividend_NN
date_NN
2nd_JJ
August_NN
2006_CD
In_PIN
late_TIME
March_NN
2006_CD
GSK_NN
will_PRMD
publish_VB
on_PIN
the_DT
website_NN
its_PIT
Record_NN
date_NN
4th_JJ
August_NN
2006_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
covering_VBG [WZPRES]
performance_NN
in_PIN
Payable_JJ
5th_JJ
October_NN
2006_CD
areas_NN
including_VBG [WZPRES]
community_NOMZ
investment_NOMZ
,_,
ethics_NN
and_CC
Third_JJ
quarter_NN
2006_CD
integrity_NOMZ
,_,
access_NN
to_PIN
medicines_NN
,_,
R&D_NN
,_,
environment_NOMZ
and_PHC
health_NN
and_PHC
safety_NN
._.
Ex-dividend_NN
date_NN
1st_CD
November_NN
2006_CD
Record_NN
date_NN
3rd_CD
November_NN
2006_CD
SHARE_NN
PRICE_NN
Payable_JJ
4th_JJ
January_NN
2007 2005 2004_CD
ANNUAL_NN
GENERAL_NN
MEETING_GER
2005_CD
At_PIN
1st_CD
January_NN
12.22_CD
12.80_CD
The_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
will_PRMD
be_VB [PASS]
held_VBN [PRIV]
at_PIN
the_DT
Queen_NN
High_NN
during_PIN
the_DT
year_NN
15.44_CD
12.99_CD
Elizabeth_NN
II_NN
Conference_NN
Centre_NN
,_,
Broad_NN
Sanctuary_NN
,_,
Low_NN
during_PIN
the_DT
year_NN
11.75_CD
10.42_CD
Westminster_NN
,_,
London_NN
SW1P_NN
3EE_NN
on_PIN
17th_JJ
May_POMD
2006_CD
._.
At_PIN
31st_CD
December_NN
14.69_CD
12.22_CD
Increase_VPRT
decrease_NN
20_CD
%_NN
5_CD
%_NN
CAUTIONARY_NN
STATEMENT_NOMZ
The_NN
table_NN
above_PLACE
sets_NN
out_PIN
the_DT
middle_JJ
market_NN
closing_GER
prices_NN
Under_IN
the_DT
safe_JJ
harbor_NN
provisions_NN
of_PIN
the_DT
US_FPP1
Private_NN
derived_VBD
from_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
Daily_NN
Ofcial_NN
Securities_NOMZ
Litigation_NOMZ
Reform_NN
Act_NN
of_PIN
1995_CD
,_,
the_DT
company_NN
List_NN
._.
The_DT
companys_NN
share_VPRT
price_NN
increased_VBN [WZPAST]
by_PIN
20_CD
%_NN
in_PIN
2005_CD
cautions_VPRT
investors_NN
that_TOBJ
any_QUAN
forward_RB
looking_VBG
statements_NOMZ
from_PIN
a_DT
price_NN
of_PIN
12.22_CD
at_PIN
1st_CD
January_NN
2005_CD
to_PIN
14.69_CD
at_PIN
or_CC
projections_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
company_NN
,_,
including_VBG [PRESP]
those_DEMO
31st_CD
December_NN
2005_CD
._.
This_DEMP
compares_VPRT
with_PIN
an_DT
increase_NN
in_PIN
made_VBN
in_PIN
this_DEMO
Annual_JJ
Review_NN
,_,
are_VPRT [BEMA]
subject_PRED
to_PIN
risks_NN
and_CC
the_DT
FTSE_NN
100_CD
index_NN
of_PIN
17_CD
%_NN
during_PIN
the_DT
year_NN
._.
uncertainties_NN
that_TSUB
may_POMD
cause_VB
actual_JJ
results_NN
to_TO
differ_VB
materially_RB
from_PIN
those_DEMP
projected_VBN
._.
Factors_NN
that_TSUB
may_POMD
affect_VB
Market_NN
capitalization_NOMZ
the_DT
Groups_NN
operations_NOMZ
are_VPRT [PASS]
described_VBN
under_IN
Legal_JJ
The_DT
market_NN
capitalization_NOMZ
of_PIN
GSK_NN
at_PIN
31st_CD
December_NN
2005_CD
proceedings_GER
and_PHC
Risk_NN
factors_NN
in_PIN
the_DT
companys_NN
Annual_JJ
was_VBD [BEMA]
85_CD
billion_CD
._.
At_PIN
that_DEMO
date_NN
GSK_NN
was_VBD [BEMA]
the_DT
fourth_JJ
largest_JJ
Report_NN
2005_CD
._.
company_NN
by_PIN
market_NN
capitalization_NOMZ
on_PIN
the_DT
FTSE_NN
index_NN
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
27_CD
Shareholder_NN
information_NOMZ
continued_VBD
SMITHKLINE_NN
BEECHAM_NN
PLC_NN
FLOATING_GER
RATE_NN
ORDINARY_NN
SHARES_NN
UNSECURED_NN
LOAN_NN
STOCK_NN
1990_CD
2010_CD
The_DT
companys_NN
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
London_NN
Stock_NN
The_NN
loan_NN
stock_NN
is_VPRT [PASS]
not_XX0
listed_VBN
on_PIN
any_QUAN
exchange_NN
but_CC
holders_NN
Exchange_NN
LSE_NN
._.
may_POMD
require_VB [SUAV]
SmithKline_NN
Beecham_NN
plc_NN
to_TO
redeem_VB
their_TPP3
loan_NN
stock_NN
at_PIN
par_NN
,_,
i._FW
e._FW
1_CD
for_PIN
every_QUAN
1_CD
of_PIN
loan_NN
stock_NN
held_VBN [PRIV]
,_,
on_PIN
the_DT
Registrar_NN
first_JJ
business_NOMZ
day_NN
of_PIN
March_NN
,_,
June_NN
,_,
September_NN
and_CC
The_DT
companys_NN
registrars_NN
are_VPRT
:_:
December_NN
._.
Holders_NN
wishing_VBG [WZPRES]
to_TO
redeem_VB
all_QUAN
or_CC
part_NN
of_PIN
their_TPP3
Lloyds_NN
TSB_NN
Registrars_NN
loan_NN
stock_NN
should_NEMD
complete_VB
the_DT
notice_NN
on_PIN
the_DT
back_NN
of_PIN
their_TPP3
The_DT
Causeway_NN
,_,
Worthing_GER
,_,
West_NN
Sussex_NN
BN99_NN
6DA_NN
loan_NN
stock_NN
certicate_NN
and_CC
return_VB
it_PIT
to_PIN
the_DT
registrar_NN
,_,
to_TO
arrive_VB
www_NN
._.
co._FW
uk_FW
at_PIN
least_JJ
30_CD
days_NN
before_IN
the_DT
relevant_JJ
redemption_NOMZ
date_NN
._.
Tel_NN
:_:
0870 600 3991_CD
inside_PLACE
the_DT
UK_NN
The_NN
provision_NN
of_PIN
the_DT
details_NN
on_PIN
this_DEMO
page_NN
is_VPRT [PASS]
not_XX0
intended_VBN [SUAV]
Tel_NN
:_:
44_CD
0_CD
121 415 7067_CD
outside_PLACE
the_DT
UK_NN
to_TO
be_VB [BEMA]
an_DT
invitation_NOMZ
or_CC
inducement_NOMZ
to_TO
engage_VB
in_PIN
an_DT
The_DT
registrars_NN
also_RB
provide_VPRT
the_DT
following_JJ
services_NN
:_:
investment_NOMZ
activity_NOMZ
._.
Advice_NN
on_PIN
share_NN
dealing_VBG [WZPRES]
should_NEMD
be_VB [PASS]
obtained_VBN
from_PIN
a_DT
stockbroker_NN
or_CC
independent_JJ
financial_JJ
GlaxoSmithKline_NN
Investment_NOMZ
Plan_NN
adviser_NN
._.
GlaxoSmithKline_NN
Individual_NN
Savings_GER
Account_NN
GlaxoSmithKline_NN
Corporate_NN
Sponsored_NN
Nominee_NN
SHARE_NN
BUY-BACK_NN
PROGRAMME_NN
Shareview_NN
service_NN
A_DT
total_NN
of_PIN
6.5_CD
billion_CD
has_VPRT [PEAS]
been_VBN [BYPA]
spent_VBN
by_PIN
the_DT
company_NN
Shareview_NN
dealing_VBG [WZPRES]
service_NN
since_OSUB
2001_CD
on_PIN
buying_VBG
its_PIT
own_JJ
shares_NN
for_PIN
cancellation_NOMZ
or_CC
Share_NN
dealing_VBG [WZPRES]
service_NN
to_TO
be_VB [PASS]
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
,_,
of_PIN
which_WDT [PIRE]
1_CD
billion_CD
was_VBD [PASS]
spent_VBN
Hoare_NN
Govett_NN
operate_VPRT
a_DT
postal_JJ
dealing_VBG
service_NN
in_PIN
the_DT
in_PIN
2005_CD
._.
The_DT
program_NN
covers_VPRT
purchases_NN
by_PIN
the_DT
companys_NN
ordinary_JJ
shares_NN
._.
It_PIT
enables_VPRT
investors_NN
to_TO
buy_VB
or_CC
company_NN
of_PIN
shares_NN
for_PIN
cancellation_NOMZ
or_CC
to_TO
be_VB [PASS]
held_VBN [PRIV]
as_IN
sell_JJ
shares_NN
at_PIN
competitive_JJ
commission_NN
charges_NN
._.
Further_JJ
Treasury_NN
shares_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
authority_NOMZ
given_VBN
details_NN
may_POMD
be_VB [BYPA]
obtained_VBN
by_PIN
telephoning_VBG
44_CD
0_CD
20_CD
7661_CD
by_PIN
shareholders_NN
at_PIN
the_DT
AGM_NN
in_PIN
2005_CD
._.
In_PIN
May_POMD
2005_CD
the_DT
company_NN
was_VBD [PASS]
authorised_VBN
to_TO
purchase_VB
a_DT
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
maximum_NN
of_PIN
586.4_CD
million_CD
shares_NN
._.
During_PIN
2005_CD
72.8_CD
corporate_JJ
PEPs_NN
million_CD
shares_NN
were_VBD [PASS]
purchased_VBN
and_PHC
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
The_DT
Share_NN
Centre_NN
Limited_NN
see_VPRT [PRIV]
Note_NN
31_CD
to_PIN
the_DT
financial_JJ
statements_NOMZ
,_,
Share_NN
capital_NN
Oxford_NN
House_NN
,_,
Oxford_NN
Road_NN
,_,
Aylesbury_NN
,_,
Bucks_NN
HP21_NN
8SZ_NN
and_PHC
share_NN
premium_NN
account_NN
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
._.
Tel_NN
:_:
44_CD
0_CD
1296 414 141_CD
The_DT
exact_JJ
amount_NN
and_PHC
timing_NN
of_PIN
future_JJ
purchases_NN
,_,
and_ANDC
the_DT
extent_NN
to_PIN
which_WDT [PIRE]
repurchased_VBD
shares_NN
will_PRMD
be_VB [PASS]
held_VBN [PRIV]
as_IN
AMERICAN_NN
DEPOSITARY_NN
SHARES_NN
Treasury_NN
shares_NN
rather_RB
than_PIN
being_VBG [PASS]
canceled_VBN
,_,
will_PRMD
be_VB [BEMA]
The_DT
companys_NN
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
New_NN
York_NN
Stock_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
by_PIN
the_DT
company_NN
and_CC
is_VPRT [BEMA]
dependent_PRED
on_PIN
market_NN
Exchange_NN
NYSE_NN
in_PIN
the_DT
form_NN
of_PIN
American_JJ
Depositary_JJ
conditions_NOMZ
and_CC
other_JJ
factors_NN
._.
Shares_NN
ADSs_NN
and_CC
these_DEMP
are_VPRT [BYPA]
evidenced_VBN
by_PIN
American_JJ
Depositary_NN
Receipts_NN
ADRs_NN
,_,
each_QUAN
one_CD
of_PIN
which_WDT [PIRE]
represents_VPRT
INTERNET_NN
two_CD
ordinary_JJ
shares_NN
._.
Information_NOMZ
about_IN
the_DT
company_NN
,_,
including_VBG
details_NN
of_PIN
the_DT
In_PIN
general_JJ
,_,
the_DT
NYSEs_NN
rules_NN
permit_VPRT
the_DT
company_NN
to_TO
follow_VB
share_NN
price_NN
,_,
is_VPRT [BEMA]
available_PRED
on_PIN
GSKs_NN
website_VPRT
at_PIN
www_NN
._.
com_NN
UK_NN
corporate_JJ
governance_NN
practices_NN
instead_CONJ
of_NULL
those_DEMO
that_DEMO
Information_NOMZ
made_VBD
available_JJ
on_PIN
the_DT
website_NN
does_VPRT
not_XX0
apply_VB
in_PIN
the_DT
US_FPP1
,_,
provided_VBD
that_DEMO
the_DT
company_NN
explains_VPRT [PUBV]
any_QUAN
constitute_VPRT
part_NN
of_PIN
this_DEMO
Annual_JJ
Review_NN
._.
This_DEMO
explanation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
the_DT
companys_NN
website_VPRT
._.
TRADEMARKS_NN
ADR_VPRT
program_NN
administrator_NN
Brand_NN
names_NN
appearing_VBG [SMP] [WZPRES]
in_PIN
italics_NN
throughout_PIN
this_DEMO
The_DT
ADR_NN
program_NN
is_VPRT [BYPA]
administered_VBN
by_PIN
:_:
publication_NOMZ
are_VPRT
trademarks_NN
either_CC
owned_VBN
by_PIN
and_CC
or_CC
licensed_VBN
to_PIN
GSK_NN
or_CC
associated_VBN
companies_NN
,_,
with_PIN
the_DT
The_NN
Bank_NN
of_PIN
New_NN
York_NN
exception_NOMZ
of_PIN
Boniva_NN
Bonviva_NN
,_,
a_DT
trademark_NN
of_PIN
Roche_NN
,_,
Shareholder_NN
Relations_NOMZ
Entereg_NN
,_,
a_DT
trademark_NN
of_PIN
Adolor_NN
Corporation_NOMZ
,_,
and_ANDC
PO_NN
Box_NN
11258_CD
,_,
Church_NN
Street_NN
Station_NOMZ
Nicoderm_NN
,_,
a_DT
trademark_NN
of_PIN
Sano-Aventis_NN
,_,
Elan_NN
,_,
Novartis_NN
New_NN
York_NN
NY_NN
10286-1258_CD
or_CC
GSK_NN
in_PIN
certain_JJ
countries_NN
,_,
all_QUAN
of_PIN
which_WDT [PIRE]
are_VPRT [PASS]
used_VBN
in_PIN
certain_JJ
www_NN
._.
com_NN
countries_NN
under_IN
license_NN
by_PIN
the_DT
Group_NN
._.
Tel_NN
:_:
1_CD
877 353 1154_CD
toll_NN
free_JJ
Tel_NN
:_:
1_CD
212 815 3700_CD
outside_PLACE
the_DT
USA_NN
INVESTOR_NN
RELATIONS_NOMZ
Customer_NN
Response_NN
Center_NN
Investor_NN
Relations_NOMZ
may_POMD
be_VB [PASS]
contacted_VBN
as_IN
follows_VPRT
:_:
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
UK_NN
The_DT
administrators_NN
also_RB
provide_VPRT
Global_JJ
BuyDIRECT_NN
,_,
a_DT
direct_JJ
980_CD
Great_NN
West_NN
Road_NN
,_,
Brentford_NN
,_,
Middlesex_NN
TW8_NN
9GS_NN
ADS_NN
purchase_NN
sale_NN
and_PHC
dividend_NN
reinvestment_NOMZ
plan_NN
for_PIN
Tel_NN
:_:
44_CD
0_CD
20 8047 5557 5558_CD
ADR_NN
holders_NN
._.
Fax_NN
:_:
44_CD
0_CD
20 8047 7807_CD
USA_NN
One_CD
Franklin_NN
Plaza_NN
,_,
PO_NN
Box_NN
7929_CD
,_,
Philadelphia_NN
PA_NN
19101_CD
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
Tel_NN
:_:
1_CD
215 751 4638_CD
outside_PLACE
the_DT
USA_NN
Fax_NN
:_:
1_CD
919 315 3344_CD
GSK_NN
Annual_JJ
Review_NN
2005_CD
28_CD
Chairman_NN
and_PHC
CEOs_NN
closing_VBG [WZPRES]
letter_NN
Dear_RB
shareholder_NN
We_FPP1
value_VPRT
our_FPP1
investors_NN
and_CC
hope_VB [PRIV]
this_DEMO
Annual_JJ
Review_NN
has_VPRT [PEAS]
highlighted_VBN
what_WP
your_SPP2
company_NN
achieved_VBN [WZPAST]
during_PIN
the_DT
year_NN
and_ANDC
what_WP
we_FPP1
are_VPRT
aiming_VBG
to_TO
do_VB [PROD]
in_PIN
the_DT
future_NN
._.
We_FPP1
remain_VPRT
focused_VBN
on_PIN
delivering_VBG
performance_NN
and_CC
making_VBG
your_SPP2
company_NN
one_CD
you_SPP2
can_POMD
be_VB [BEMA]
proud_PRED
of_PIN [STPR]
._.
We_FPP1
continue_VPRT
to_TO
meet_VB
the_DT
challenges_NN
of_PIN
improving_VBG
productivity_NOMZ
in_PIN
R&D_NN
and_CC
ensuring_VBG [SUAV] [PRIV] [THATD]
patients_NN
have_VPRT
access_NN
to_PIN
medicines_NN
,_,
even_RB
in_PIN
the_DT
poorest_JJ
parts_NN
of_PIN
the_DT
world_NN
._.
This_DEMO
review_NN
highlights_VPRT
some_QUAN
of_PIN
the_DT
work_NN
we_FPP1
have_VPRT [PEAS]
done_VBN
to_TO
implement_VB
our_FPP1
strategies_NN
to_TO
meet_VB
these_DEMO
challenges_NN
._.
Behind_PLACE
each_QUAN
one_CD
is_VPRT [BEMA]
a_DT
human_JJ
story_NN
._.
We_FPP1
thank_VPRT
all_QUAN
our_FPP1
employees_NN
for_PIN
their_TPP3
efforts_NN
in_PIN
2005_CD
._.
Their_TPP3
commitment_NOMZ
and_PHC
passion_NN
,_,
both_DT
individually_RB
and_CC
through_PIN
their_TPP3
teamwork_NN
,_,
have_VPRT [PEAS]
helped_VBN
us_FPP1
make_VB
GSK_NN
the_DT
success_NN
it_PIT
is_VPRT
today_TIME
._.
We_FPP1
also_RB
appreciate_VPRT
the_DT
great_JJ
support_NN
our_FPP1
employees_NN
receive_VPRT
from_PIN
their_TPP3
families_NN
for_PIN
the_DT
work_NN
they_TPP3
are_VPRT
doing_VBG [PROD]
at_PIN
GSK_NN
._.
We_FPP1
are_VPRT [BEMA]
grateful_PRED
for_PIN
the_DT
significant_JJ
contribution_NOMZ
of_PIN
Tachi_NN
Yamada_NN
,_,
Chairman_NN
of_PIN
R&D_NN
and_PHC
Executive_NN
Director_NN
,_,
who_WP
is_VPRT
to_TO
retire_VB
in_PIN
June_NN
2006_CD
,_,
and_ANDC
we_FPP1
welcome_VPRT
Moncef_NN
Slaoui_NN
,_,
who_WP
will_PRMD
succeed_VB
Tachi_NN
with_PIN
effect_NN
from_PIN
1st_CD
June_NN
2006_CD
._.
We_FPP1
would_PRMD [SPAU]
also_RB
like_VB
to_TO
thank_VB
Jack_NN
Ziegler_NN
,_,
President_NN
of_PIN
GSK_NN
Consumer_NN
Healthcare_NN
,_,
who_WP
retired_VBD
from_PIN
the_DT
company_NN
in_PIN
January_NN
2006_CD
,_,
and_ANDC
welcome_VB
his_TPP3
successor_NN
,_,
John_NN
Clarke_NN
._.
We_FPP1
also_RB
thank_VPRT
Dr_NN
Lucy_NN
Shapiro_NN
,_,
who_WP
is_VPRT
to_TO
retire_VB
as_IN
a_DT
Non-Executive_JJ
Director_NN
at_PIN
the_DT
companys_NN
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
in_PIN
May_POMD
2006_CD
,_,
and_ANDC
we_FPP1
welcome_VPRT
Tom_NN
fide_NN
Swaan_NN
,_,
who_WP
joined_VBD
the_DT
Board_NN
in_PIN
January_NN
2006_CD
as_IN
a_DT
new_JJ
Non-Executive_NN
Director_NN
._.
As_IN
a_DT
shareholder_NN
,_,
your_SPP2
views_NN
are_VPRT [BEMA]
important_PRED
to_PIN
us_FPP1
._.
We_FPP1
would_PRMD
be_VB [BEMA]
grateful_PRED
if_COND
you_SPP2
would_PRMD
complete_VB
an_DT
online_JJ
survey_NN
to_TO
let_VB
us_FPP1
know_VB [PRIV]
what_WP [WHCL]
you_SPP2
think_VPRT [PRIV]
of_PIN
this_DEMO
Annual_JJ
Review_NN
._.
You_SPP2
can_POMD
nd_VB
the_DT
survey_NN
at_PIN
www_NN
._.
If_COND
you_SPP2
would_PRMD
like_VB
to_TO
know_VB [PRIV]
more_EMPH
about_IN
GSK_NN
,_,
please_VB
contact_NN
us_FPP1
or_CC
go_VB
to_PIN
the_DT
information_NOMZ
sources_NN
listed_VBN [WZPAST]
on_PIN
the_DT
back_JJ
cover_NN
._.
Sir_NN
Christopher_NN
Gent_NN
,_,
Chairman_NN
,_,
and_ANDC
JP_NN
Garnier_NN
,_,
Chief_NN
Executive_NN
officer_NN
GlaxoSmithKline_NN
is_VPRT
addressing_VBG
the_DT
key_JJ
challenges_NN
that_TSUB
face_VPRT
both_DT
the_DT
pharmaceutical_JJ
industry_NN
and_PHC
society_NN
as_IN
a_DT
whole_NN
:_:
Improving_GER
productivity_NOMZ
in_PIN
research_NN
and_PHC
development_NOMZ
Ensuring_GER
patients_NN
have_VPRT
access_NN
to_PIN
medicines_NN
._.
Our_FPP1
strategies_NN
to_TO
meet_VB
these_DEMO
challenges_NN
focus_VB
on_PIN
several_QUAN
business_NOMZ
drivers_NN
:_:
Build_VB
the_DT
best_JJ
product_NN
pipeline_NN
in_PIN
the_DT
industry_NN
to_PIN
the_DT
benefit_NN
of_PIN
patients_NN
,_,
consumers_NN
and_PHC
society_NN
Continuously_RB
improve_VB
performance_NN
through_PIN
commercial_JJ
and_PHC
operational_JJ
excellence_NN
Improve_NN
access_NN
to_PIN
medicines_NN
through_PIN
a_DT
range_NN
of_PIN
extensive_JJ
programs_NN
,_,
both_DT
in_PIN
the_DT
developed_VBN
and_CC
the_DT
developing_VBG
world_NN
Be_VB [BEMA]
the_DT
best_JJ
place_NN
for_PIN
the_DT
best_JJ
people_NN
to_TO
do_VB [PROD]
their_TPP3
best_JJ
work_NN
._.
GSK_NN
Annual_JJ
Review_NN
2005_CD
29_CD
Corporate_JJ
Website_JJ
brochure_NN
About_IN
us_FPP1
Meeting_VBG
global_JJ
challenges_NN
Our_FPP1
products_NN
Commitment_NOMZ
to_PIN
innovation_NOMZ
Your_SPP2
health_NN
Access_NN
to_PIN
medicines_NN
Responsibility_NOMZ
Therapy_NN
areas_NN
In_PIN
the_DT
community_NOMZ
Our_FPP1
mission_NN
Research_NN
&_CC
Development_NOMZ
A_NN
better_RB
future_JJ
What_WP
would_PRMD
Investors_NN
Media_NN
center_NN
you_SPP2
like_VPRT
to_TO
know_VB [PRIV]
Careers_NN
about_IN
GSK_NN
?_.
com_NN
Corporate_JJ
Annual_JJ
responsibility_NOMZ
review_NN
report_NN
Access_NN
to_PIN
medicines_NN
An_DT
interview_NN
with_PIN
the_DT
Chairman_NN
and_PHC
CEO_NN
Research_NN
and_PHC
innovation_NOMZ
Focus_NN
on_PIN
the_DT
patient_JJ
Ethical_JJ
conduct_NN
The_DT
year_NN
of_PIN
the_DT
vaccine_NN
Employees_NN
Annual_JJ
Growing_VBG
brands_NN
Human_JJ
rights_NN
Powering_VBG [WZPRES]
performance_NN
report_NN
Environment_NOMZ
Performance_NN
highlights_VPRT
Community_NOMZ
investment_NOMZ
Business_NOMZ
operating_VBG [WZPRES]
review_NN
Summary_NN
remuneration_NOMZ
report_NN
An_DT
interview_NN
with_PIN
Corporate_JJ
governance_NN
the_DT
Chairman_NN
and_PHC
CEO_NN
Summary_NN
financial_JJ
statements_NOMZ
Financial_JJ
summary_NN
Shareholder_NN
information_NOMZ
Description_NOMZ
of_PIN
business_NOMZ
Chairman_NN
and_PHC
CEOs_NN
Corporate_JJ
governance_NN
closing_VBG [WZPRES]
letter_NN
Remuneration_NOMZ
report_NN
Operating_GER
and_CC
financial_JJ
review_NN
and_PHC
prospects_NN
Financial_JJ
statements_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
Investor_NN
information_NOMZ
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
Head_NN
Ofce_NN
and_PHC
Registered_NN
Ofce_NN
Produced_NN
by_PIN
Corporate_NN
Communications_NOMZ
,_,
GSK_NN
._.
GlaxoSmithKline_NN
plc_NN
980_CD
Great_NN
West_NN
Road_NN
Designed_VBN [WZPAST]
by_PIN
CGI_NN
London_NN
._.
Brentford_NN
,_,
Middlesex_NN
TW8_NN
9GS_NN
Printed_NN
in_PIN
the_DT
UK_NN
by_PIN
St._NN
Ives_NN
Direct_NN
Edenbridge_NN
Ltd._NN
._.
The_DT
paper_NN
United_NN
Kingdom_NN
used_VBD
in_PIN
the_DT
production_NOMZ
of_PIN
this_DEMO
document_NOMZ
is_VPRT [PASS]
made_VBN
from_PIN
pulps_NN
Tel_NN
:_:
44_CD
0_CD
20 8047 5000_CD
harvested_VBN
from_PIN
sustainable_JJ
forests_NN
,_,
also_RB
using_VBG
sawmill_NN
residues_NN
www_NN
._.
